Novel amide derivatives, pharmaceutical compositions containing them, and their use as SOS1 inhibitors
By developing an amide derivative of formula (I), the problem of inhibiting SOS1 protein in existing technologies has been solved, and effective blocking of the RAS signaling pathway has been achieved, which has broad therapeutic potential.
Patent Information
- Application Number
- CN202580022824.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-01-31
- Filing Date
- 2025-01-30
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are unable to effectively inhibit the activity of SOS1 protein, leading to overactivation of the RAS signaling pathway, which promotes tumor initiation and maintenance, and existing SOS1 inhibitors have achieved limited success in clinical practice.
Amide derivatives of formula (I) were developed. These compounds have strong binding affinity and can block the interaction between SOS1 and RAS family members, preventing KRas from recycling to the active GTP-bound form.
Effectively inhibiting the SOS1 protein and blocking the RAS signaling pathway has the potential to treat a variety of cancers, including Ras-related cancers, SOS1-related cancers, and NF-1/NF-2-related cancers, and provides therapeutic benefits in genetic and immune diseases.
Smart Images

Figure CN123125216A_ABST
Abstract
Description
[0001] Invention Field
[0002] This invention relates to novel amide derivatives, methods for their preparation, pharmaceutical compositions containing them, and their use as inhibitors of Son of Sevenless homolog 1 (SOS1). The compounds of this invention inhibit the activity of the SOS1 protein and may be of interest for the treatment of cancer, autoimmune diseases, immune system disorders, and genetic diseases. Background of the Invention
[0004] RAS proteins play an important role in human cancers (Simanshu et al.). Cell 2017, 170, 17-33; Malumbres et al. Nat. Rev.Cancer (2003, 3, 459-465). There are three RAS genes: KRAS, NRAS, and HRAS, which encode four RAS proteins, including two KRAS isoforms (KRAS4A and KRAS4B) generated by variable RNA splicing. These proteins play a crucial role in transmitting growth signals from extracellular growth factors to downstream intracellular pathways. These growth factors can be, among others, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and nerve growth factor (NGF). When they bind to their receptors, they activate the mitogen-activated protein kinase (MAPK) / extracellular regulated kinase (ERK) pathway and the phosphatidylinositol-3-kinase (PI3K) pathway via Ras activation, thereby regulating cell division, survival, and overall function under normal conditions and in abnormal conditions such as cancer.
[0005] The Ras protein functions as a guanosine triphosphatase (GTPases), cycling between an inactive guanosine diphosphate (GDP)-binding state and an active guanosine triphosphate (GTP)-binding state. Mutations in the Ras protein are present in approximately 30% of all tumors (Hobbs et al.). J.Cell Sci., 2016, 129, 1287-1292; Prior et al. Cancer Res,(2020, 80, 2969-2974). These missense gain-of-function mutations in the RAS gene lead to overactivation of signaling pathways, thereby promoting tumor initiation and maintenance. These point mutations are usually located in GTP-binding regions, preventing the hydrolysis of bound GTP, resulting in persistent RAS activation. 98% of these mutations occur at one of three mutation hotspots: G12, G13, and Q61. Over the years, evidence has shown that amino acid substitutions at any of these hotspots can have different biochemical properties, leading to differences in oncogenic potency and functional consequences. Further supporting this is the fact that mutations specific to certain isoforms are known to be cancer type-specific. Recent studies have shown that despite mutations, Ras still requires nucleotide cycling for activation based on its endogenous GTPase activity and sensitivity to exogenous GTPases. Therefore, mutant RAS proteins are sensitive to the inhibition of upstream factors such as SOS1 or SHP2.
[0006] The molecular switch between the active and inactive states is tightly regulated by guanine nucleotide exchange factors (GEFs) and GTPase activators (GAPs). GEFs act as activators of Ras by facilitating the nucleotide exchange from GDP to GTP, while GAPs inactivate Ras-GTP by catalyzing the hydrolysis of bound GTP to GDP. There are three main types of GEFs: two Son of Sevenless proteins (SOS1 and SOS2), four different isoforms of Ras guanine nucleotide releasing proteins (Ras-GRP1-4), and two Ras guanine nucleotide releasing factors (Ras-GRF1 and 2). The most well-studied GEFs are the SOS proteins, as they play a crucial role in cancer. (Hillig et al., Adv. Cancer Res., 2022, 153, 169-203; Kessler et al. Curr. Opin.Chem. Biol., 2021, 62, 109-118).
[0007] The SOS family includes SOS1 and SOS2, which share approximately 70% sequence consistency (Rojas et al., GenesCancer SOS1 has been extensively studied and described as a major regulator of RAS. SOS is a multidomain protein belonging to the GEF family, containing a CDC25 homology domain. The N-terminal region contains two tandem histone folds (HF), a Dbl homology (DH) domain, and a pleckstrin homology (PH) domain. The C-terminal region contains a RAS exchange motif (REM) domain, a CDC25 domain, and a proline-rich (PR) region (Sondermann et al., 2011, 2, 298-305). Cell(2004, 393-405). Importantly, the N-terminal and C-terminal regions of SOS are connected by a helical linker, allowing SOS to adopt both an active membrane-bound conformation and a self-inhibiting cytoplasmic conformation. The SOS protein is recruited to phosphorylated RTKs (receptor tyrosine kinases) through interaction with growth factor receptor-binding protein 2 (GRB2). Recruitment to the plasma membrane causes SOS and RAS to aggregate, thereby activating RAS. The SOS protein exhibits a catalytic site and an allosteric site. SOS promotes nucleotide exchange through the catalytic site, while the allosteric site acts as a positive feedback loop, removing steric hindrance from the catalytic site and is therefore essential for its full activation. Of the two SOS proteins, SOS1 is the most thoroughly studied and characterized to date. Importantly, SOS1 (not SOS2) is a node in the negative feedback regulation of the KRAS pathway. Deactivation of SOS1 autoinhibition subsequently establishes a positive feedback loop from mutant RAS·GTP through SOS1 to wild-type RAS, thereby enhancing the activation of downstream effectors, which is crucial for the proliferation of KRAS mutant pancreatic cancer cells (Sheffels et al.). Genes (2021, 12, 662). Furthermore, SOS1 mutations have been found in Noonan syndrome and various cancers, including lung adenocarcinoma and endometrial cancer (Lepri et al.). Hum. Mutat. 2011, 32, 760-772; Cai et al. Mol. Cancer Res. 2019, 17, 1002-1012).
[0008] Research on Ras as a target for cancer therapy has a long history (Moore et al., Nat. Rev. DrugDiscov., 2020, 19, 533-552). For a considerable period, these proteins were considered "undruggable." This was partly due to the lack of traditional binding pockets on the protein surface and the high flexibility of the proteins themselves. Recently, a class of inhibitors has been discovered that can covalently bind to the cysteine residue of mutant KRAS G12C. The advantage of these mutation-specific inhibitors is that they can achieve good target inhibition in specific patient populations. They also bring a lower risk of wild-type KRAS-mediated toxicity. Other KRAS mutation-specific inhibitors are currently being developed in preclinical studies, but not all mutations can be addressed. In addition, a significant drawback of this approach is the development of acquired resistance in patients (Hofmann et al., Cancer Discov.Therefore, there remains a significant unmet need for the treatment of Ras-dependent tumors, specifically, new therapeutic agents are still required to block Ras signaling. To this end, several SOS1 inhibitors have been developed and published in recent years (He et al., J. Med. Chem., 2022, 65, 13158-13171; Hillig et al., 2022, 12, 924-937). PNAS, 2019, 116, 2551-2560; Liu et al. ACS Med. Chem. Lett. Amide derivatives protected as SOS1 inhibitors are disclosed in patents 2023, 14, 183-190; PCT / EP2018 / 086197, and specifically in PCT / KR2022 / 012254, PCT / US2021 / 063685, or PCT / US2023 / 012307. However, to date, they have achieved limited success in clinical practice. Invention Overview
[0010] This invention provides potent and selective SOS1 inhibitors of formula (I) as defined below. We have demonstrated that compounds of formula (I) possess a strong binding affinity for SOS1 and block the interaction between SOS1 and RAS family members, preventing KRas from cycling back to its active GTP-binding form. Therefore, the compounds of this invention may be significant for a variety of cancers, particularly those associated with Ras family members. Furthermore, the compounds of this invention, as inhibitors of SOS1-Ras protein interactions in cells, offer potential therapeutic benefits for the treatment of various cancers, including Ras-related cancers, SOS1-related cancers, and NF-1 / NF-2-related cancers. Finally, the compounds of this invention may provide therapeutic benefits in genetic and immune diseases.
[0011] In a first aspect of the invention, the invention relates to compounds of formula (I):
[0012] in: Ring A represents a heterocyclic alkyl group. R1 represents a hydrogen atom or a halogen atom. R2 represents a hydrogen atom, a halogen atom, a cyano group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkoxy group, a straight-chain or branched amino(C1-C6) alkyl group, -CH(CH2-OH)CH2-Cl, or... , R3 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a straight-chain or branched di(C1-C6) alkyl phosphoryl group, a cycloalkyl group, an aryl group, or a heterocyclic alkyl group. R4 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy(C1-C6) alkyl group, a straight-chain or branched hydroxy(C1-C6) alkyl group, -CO-CH2-OH, a cycloalkyl group, a heterocyclic alkyl group, or... , or , R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, or a group selected from the following: and , R6 represents a hydrogen atom, a halogen atom, or a straight-chain or branched (C1-C6) alkyl group. W represents a bond, an oxygen atom, -CO-, -O-CH2-, or -CH2-. Cy1 represents aryl or heteroaryl. Cy2 represents aryl, heteroaryl, or heterocyclic alkyl. Cy3 represents cycloalkyl, heterocycloalkyl, or heteroaryl. Their enantiomers and diastereomers, and their addition salts with pharmaceutically acceptable acids or bases.
[0013] In another aspect of the invention, the invention relates to compounds of formula (I):
[0014] in: Ring A represents a heterocyclic alkyl group. R1 represents a hydrogen atom or a halogen atom. R2 represents a hydrogen atom, a halogen atom, a cyano group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkoxy group, a straight-chain or branched amino(C1-C6) alkyl group, -CH(CH2-OH)CH2-Cl, or , R3 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a cycloalkyl group, an aryl group, or a heterocyclic alkyl group. R4 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy(C1-C6) alkyl group, a straight-chain or branched hydroxy(C1-C6) alkyl group, -CO-CH2-OH, a cycloalkyl group, or... , R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, or a group selected from the following: and , R6 represents a hydrogen atom, a halogen atom, or a straight-chain or branched (C1-C6) alkyl group. W represents a bond, an oxygen atom, -CO-, -O-CH2-, or -CH2-. Cy1 represents aryl or heteroaryl. Cy2 represents aryl, heteroaryl, or heterocyclic alkyl. Cy3 represents cycloalkyl, heterocycloalkyl, or heteroaryl. Their enantiomers and diastereomers, and their addition salts with pharmaceutically acceptable acids or bases.
[0015] In another aspect, the present invention provides compounds of formula (I) as described herein for the treatment of cancer, autoimmune diseases and immune system disorders and genetic diseases.
[0016] In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) as described herein and at least one pharmaceutically acceptable excipient.
[0017] definition
[0018] Among pharmaceutically acceptable acids, those that may be mentioned (but without any limitation) include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, mesylic acid, camphoric acid, etc.
[0019] Among pharmaceutically acceptable bases, those that can be mentioned (but without any limitation) include sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine, etc.
[0020] "Halogenated alkyl" or "halogenated (C1-C6) alkyl" refers to a straight-chain or branched, saturated monovalent hydrocarbon group having 1 to 6 carbon atoms and one or more halogen atoms. More preferably, the halogen atom is selected from fluorine, chlorine, and bromine, and more preferably fluorine. Among halogenated alkyl groups, -CH2F (or fluoromethyl), -CHF2 (or difluoromethyl), -CF3, -CH2-CH2F (or 2-fluoroethyl), -CH2-CHF2 (or 2,2-difluoroethyl), -CH2-CF3 (or 3,3,3-trifluoroethyl), -(CH2)2-CF3 (or 3,3,3-trifluoropropyl), -CH(CF3)-CH3, etc.
[0021] "Amino(C1-C6)alkyl" means monovalent -(C1-C6)alkyl-NH2. Among amino(C1-C6)alkyl, -CH2-NH2, -CH2-CH2-NH2, etc. can be mentioned (but are not intended to be limited).
[0022] "Haloalkoxy" or "halo(C1-C6)alkoxy" refers to a straight-chain or branched, saturated monovalent (C1-C6)alkoxy group in which one or more hydrogen atoms are replaced by halogen atoms. More preferably, the halogen atom is selected from fluorine, chlorine, and bromine, more preferably fluorine. Among haloalkoxy groups, -O-CH2F, -O-CF3 (or trifluoromethoxy), -O-CH2-CHF2 (or 2,2-difluoroethoxy), -O-CH2-CF3 (or 2,2,2-trifluoroethoxy), etc., may be mentioned (but are not intended to be limited).
[0023] "Hydroxy(C1-C6)alkyl" means monovalent -(C1-C6)alkyl-OH. Among hydroxy(C1-C6)alkyl, CH2-OH, -CH2-CH2-OH (or hydroxyethyl), -CH2-C(CH3)2-OH, etc. may be mentioned (but are not intended to be limited).
[0024] The term "(C1-C6)alkoxy(C1-C6)alkyl" refers to a monovalent -(C1-C6)alkyl-O-(C1-C6)alkyl, wherein each (C1-C6)alkyl is independent. Among (C1-C6)alkoxy(C1-C6)alkyl, the following may be mentioned (but are not intended to be limited): -CH2-O-CH3 (or methoxymethyl), -(CH2)2-O-CH3 (or methoxyethyl), -(CH2)3-O-CH3 (or methoxypropyl), -CH2-O-CH2CH3, -(CH2)2-O-CH2CH3, -(CH2)2-O-(CH2)2-CH3, etc.
[0025] "Di(C1-C6)alkylphosphoryl" represents a monovalent -P(=O)[(C1-C6)alkyl]2, where each (C1-C6)alkyl group is independent. Among di(C1-C6)alkylphosphoryl groups, -P(=O)(CH3)2, -P(=O)(CH2-CH3)2 (or diethylphosphoryl), -P(=O)(CH3)(CH2-CH3), etc., may be mentioned (but are not intended to be limited).
[0026] "Aryl" refers to a monocyclic or fused bicyclic group consisting of 5 to 10 ring members, having at least one aromatic moiety. Among aryl groups, phenyl, indenyl dihydrogenate, naphthyl, etc., may be mentioned (but are not intended to be limited).
[0027] "Heteroaryl" refers to a monocyclic, fused bicyclic, or bridged bicyclic group consisting of 5 to 12 ring members, having at least one aromatic moiety and containing 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrogen. Among heteroaryl groups, the following may be mentioned (but not limited to): furanyl, thiophene, pyrrole, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, imidazole, pyridazinyl, pyridinyl, pyrazinyl, pyridoneyl, indole, inzolyl, quinolinyl, isoquinolinyl, thiophene-pyridyl, imidazole-pyridyl, furano-pyridyl, oxazole-pyridyl, isoxazole-pyridyl, pyrrolo-pyridyl, pyrano-pyridyl, thiophene-pyrimidinyl, pyrrolo-pyridyl, quinoxalinyl, quinazolinoneyl, benzofuranyl, benzopyranyl, benzodioxacyclopentyl, benzoimidazolyl, benzothiophene, benzotriazolyl, benzothiazolyl, benzoxad (iazolyl), dihydrobenzofuranyl, dihydroindolyl, dihydroquinolinyl, dihydroisoindolyl, dihydropyrrolizinyl, dihydrocyclopentadienthienyl, dihydroquinoxolinyl, dihydrobenzodioxenyl, dihydrothienenodioxenyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydroindolazinyl, tetrahydroquinazolinyl, tetrahydroindazoleyl, tetrahydronaphridyl, tetrahydro-5,8-ethbridgedquinolinyl, tetrahydrobenzothienyl, cyclopentadienpyridyl, cyclopentadienpyrimidinyl, hexahydrocyclopentadienpyridyl, cycloheptadienpyridyl, dioxen[2,3-b]pyridyl, etc.
[0028] “Cycloalkyl” refers to a monocyclic, fused bicyclic, spirobicyclic, or bridged bicyclic non-aromatic carbocyclic group consisting of 3 to 10 ring members. Among cycloalkyl groups, those that may be mentioned (but are not limited to) include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, bicyclo[1.1.1]pentyl, spiro[3.3]heptyl, etc.
[0029] "Heterocyclic alkyl" refers to a monocyclic, fused bicyclic, or spirobicyclic nonaromatic group consisting of 3 to 10 ring members, containing 1 to 3 heteroatoms selected from oxygen, sulfur, and nitrogen, and may contain a double bond. Among heterocyclic alkyl groups, the following may be mentioned (but not limited to): aziridine, aziridine-heptidine, tetrahydropyranyl, dihydropyranyl, tetrahydropyridyl (or dihydro-2H-pyridyl), piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, dioxane, dihydrofuranyl, tetrahydrofuranyl, thiocyclohexane, dioxothiocyclohexane, oxacyclobutane, dioxothiazinyl, thiazinyl (thiazazacyclohexane), azirspiro[3.3]heptane, oxazazaspiro[3.3]heptane, oxazazaspiro[2.5]octane, oxazazaspiro[3.5]nonyl, oxazazaspiro[5.5]undecyl, oxazazaspiro[4.5]decyl, 4-oxo-1,4λ 5 -Oxyphosphazenecyclohexylene, etc.
[0030] As used in this article, the term "cyano" refers to -CN.
[0031] As used in this article, the term "amino" refers to -NH2.
[0032] In the pharmaceutical compositions according to the invention, more specific references may be made to those pharmaceutical compositions suitable for oral, parenteral, nasal, transdermal, rectal, sublingual, ocular or respiratory administration, especially tablets or sugar-coated pills, sublingual tablets, pods, paquets, capsules, sublingual dosage forms, lozenges, suppositories, creams, ointments, skin gels and drinkable or injectable ampoules. The pharmaceutical compositions according to the present invention comprise one or more excipients or carriers selected from the following: diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerin, etc.), lubricants (e.g., silica, talc, stearic acid and its magnesium and calcium salts, polyethylene glycol, etc.), binders (e.g., magnesium aluminum silicate, starch, gelatin, tragacanth gum, methylcellulose, sodium carboxymethyl cellulose and polyvinylpyrrolidone, etc.), disintegrants (e.g., agar, alginate and its sodium salt, effervescent mixtures, etc.), stabilizers, preservatives, absorbents, colorants, sweeteners, flavoring agents, etc. The preferred route of administration is oral or intravenous, and the corresponding pharmaceutical compositions may allow for instantaneous or delayed release of the active ingredient.
[0033] In the combination of compounds of formula (I) according to the invention with anticancer active agents, more specific references may be made to combinations suitable for simultaneous or sequential administration. Combinations according to the invention comprise compounds of formula (I) combined with anticancer active agents selected from: genotoxic agents, mitotic toxins, antimetabolites, proteasome inhibitors, enzyme inhibitors, signaling protein inhibitors, transcription factor inhibitors, epigenetic factor inhibitors, kinase inhibitors, protein-protein interaction inhibitors, immunomodulators, E3 ligase inhibitors, chimeric antigen receptor T-cell therapies, and antibodies. Furthermore, the compounds in the combination may be administered as two separate pharmaceutical compositions, each containing one active ingredient, or the compounds in the combination may be administered as a single pharmaceutical composition in which the active ingredients are mixed together.
[0034] As used herein, the term “treatment” for any disease or disorder, in one embodiment, means improving said disease or disorder (e.g., slowing or halting or reducing the progression of the disease or at least one of its clinical symptoms). In another embodiment, “treatment” means alleviating or improving at least one bodily parameter, including bodily parameters that the patient may not be able to discern. In yet another embodiment, “treatment” means regulating a disease or disorder, whether physical (e.g., stabilizing discernible symptoms), physiological (e.g., stabilizing bodily parameters), or both.
[0035] As used herein, the term "Ras-related cancer" refers to cancer having or associated with dysregulation of the expression, activity, or level of the Ras gene, Ras protein, or any of them (e.g., one or more). Non-limiting examples of Ras-related cancers are described herein. In some embodiments, Ras-related cancer may be KRas-related cancer, HRas-related cancer, NRas-related cancer, or a combination thereof.
[0036] As used herein, the term “SOS1-related cancer” refers to cancer with or associated with dysregulation of the expression, activity, or level of the SOS1 gene, SOS1-GEF (also referred to herein as the SOS1 protein), or any of them (e.g., one or more). Non-limiting examples of SOS1-related cancers are described herein.
[0037] As used herein, “NF-1 / NF-2-associated cancer” refers to cancer associated with or mediated by the neurofibrin (NF-1) and neurofibrin 2 (NF-2) genes, or cancers with loss-of-function mutations in these genes. This article describes non-limiting examples of NF-1 / NF-2-associated cancers.
[0038] In the envisioned cancer treatment and prevention, Ras-related cancers, SOS1-related cancers, and NF-1 / NF-2-related cancers may be mentioned (but not limited to) hematologic malignancies and solid tumors, more specifically, pancreatic cancer, lung cancer, colorectal cancer, bile duct cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial carcinoma, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, kidney cancer, sarcoma, glioma, and malignant peripheral nerve sheath tumor.
[0039] In another aspect, the disease treated or prevented by the compound of formula (I) is RASopathy. The term "RASopathy" refers to a group of rare genetic diseases caused by mutations in certain genes of proteins involved in the Ras / MAPK cell signaling pathway. Preferably, RASopathy is selected from neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple freckles, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardiofaciocutaneous syndrome, Legius syndrome, and hereditary gingival fibromatosis.
[0040] The actual dose level of the active ingredient in the pharmaceutical compositions of the present invention can be varied to obtain an amount of active ingredient that is effective in achieving the desired therapeutic response for a particular patient, composition, and route of administration, and is non-toxic to the patient. The selected dose level depends on a variety of factors, including the activity of the specific compound of the present invention used, the route of administration, the time of administration, the rate of excretion or metabolism of the specific compound used, the rate and extent of absorption, the duration of treatment, other drugs, compounds, and / or materials used in combination with the specific compound used, the age, sex, weight, condition, general health status, and medical history of the patient being treated, and similar factors known in the medical field. The appropriate daily dose of the compounds of the present invention depends on the above factors and can be administered once or in multiple divided doses in the range of 0.01 mg to 2.5 g per day. Invention Details
[0042] Several preferred and advantageous embodiments of the invention are described below. It should be understood that the features specified in each preferred embodiment can be combined with other specified features to provide other preferred embodiments of the invention.
[0043] One advantageous possibility is that it consists of a compound of formula (Ia):
[0044] R1, R2, R3, R4, Cy1, Cy2 and A are as defined with respect to equation (I).
[0045] Preferably, ring A represents a heterocyclic alkyl group selected from the following: and , R4 is defined with respect to equation (I).
[0046] More preferably, ring A represents a heterocyclic alkyl group selected from the following: and , R4 is defined with respect to equation (I).
[0047] Even more preferably, ring A represents a heterocyclic alkyl group, wherein the heterocyclic alkyl group is...
[0048] R4 is defined with respect to equation (I).
[0049] Another favorable possibility is the composition of compounds of formula (Ib):
[0050] R1, R2, R3, R4, Cy1, and Cy2 are as defined with respect to equation (I).
[0051] In one preferred embodiment, R1 represents a hydrogen atom, a chlorine atom, or a fluorine atom. In another preferred embodiment, R1 represents a hydrogen atom or a fluorine atom. More preferably, R1 represents a fluorine atom.
[0052] Advantageously, R2 represents a hydrogen atom, a bromine atom, a cyano group, a methyl group, an ethyl group, an isopropyl group, an isobutyl group, a tert-butyl group, a methoxy group, an ethoxy group, an isopropoxy group, an isobutoxy group, a trifluoromethyl group, a difluoromethyl group, a 2,2,2-trifluoroethyl group, a trifluoromethoxy group, a 2,2-difluoroethoxy group, a -CH2-NH2 group, a -CH(CH2-OH)CH2-Cl group, or a 2-hydroxymethyl group. .
[0053] More advantageously, R2 represents isopropyl or .
[0054] Even more advantageously, R2 represents .
[0055] Preferably, R3 represents a hydrogen atom, methyl, methoxy, cyclopropyl, phenyl, diethylphosphoryl, or dihydrofuranyl. More preferably, R3 represents a hydrogen atom, methyl, methoxy, cyclopropyl, phenyl, or dihydrofuranyl. Even more preferably, R3 represents a hydrogen atom, methyl, or methoxy. Still more preferably, R3 represents a hydrogen atom.
[0056] In a preferred embodiment, R4 represents a hydrogen atom, methyl, ethyl, isopropyl, 2-fluoroethyl, 2,2-difluoroethyl, 3,3,3-trifluoropropyl, methoxyethyl, hydroxyethyl, -CO-CH2-OH, cyclobutyl, tetrahydrofuranyl, oxetaneyl, or... , or .
[0057] In a preferred embodiment, R4 represents a hydrogen atom, methyl, ethyl, isopropyl, 2,2-difluoroethyl, 3,3,3-trifluoropropyl, methoxyethyl, hydroxyethyl, -CO-CH2-OH, cyclobutyl, or .
[0058] In a more preferred embodiment, R4 represents a hydrogen atom, a methyl group, or a hydrogen atom. .
[0059] In a more preferred embodiment, R4 represents a hydrogen atom or a methyl group. Even more preferably, R4 represents a methyl group.
[0060] Advantageously, R5 represents a hydrogen atom, a fluorine atom, a hydroxyl group, a methyl group, a fluoromethyl group, a difluoromethyl group, or a group selected from the following: and .
[0061] More advantageously, R5 represents a hydrogen atom, a fluorine atom, a methyl group, or a group selected from the following: and .
[0062] Even more advantageously, R5 represents a hydrogen atom or a group selected from the following: and .
[0063] Even more advantageously, R5 represents a hydrogen atom.
[0064] Preferably, R6 represents a hydrogen atom, a fluorine atom, or a methyl group. More preferably, R6 represents a hydrogen atom.
[0065] Preferably, W represents a bond, an oxygen atom, or -O-CH2-. More preferably, W represents a bond. In a preferred embodiment, W represents an oxygen atom. In a preferred embodiment, W represents -O-CH2-.
[0066] In a preferred embodiment, Cy1 represents phenyl or pyridyl. In a more preferred embodiment, Cy1 represents phenyl.
[0067] Preferably, Cy2 represents phenyl, pyrazolyl, triazolyl, thiophene, pyridyl, pyrimidinyl, pyrazinyl, pyridoneyl, quinolinyl, isoquinolinyl, thienopyridyl, isoxazolopyridyl, benzoxadiazolyl, or morpholinyl. More preferably, Cy2 represents phenyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridoneyl, quinolinyl, isoquinolinyl, thienopyridyl, isoxazolopyridyl, benzoxadiazolyl, or morpholinyl. Even more preferably, Cy2 represents phenyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, thienopyridyl, isoxazolopyridyl, benzoxadiazolyl, or morpholinyl. In a preferred embodiment, Cy2 represents pyridyl or pyrimidinyl. In a preferred embodiment, Cy2 represents pyridyl. In a preferred embodiment, Cy2 represents pyrimidinyl.
[0068] Advantageously, Cy3 represents cyclopropyl, cyclopentyl, cyclohexyl, spiro[3.3]heptyl, azircyclobutyl, oxacyclobutyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, morpholinyl, piperidinyl, piperazine, tetrahydropyranyl, dihydropyranyl, tetrahydropyridinyl, dioxothiazinyl, dioxothiacyclohexyl, oxazaspiro[3.3]heptyl, oxazaspiro[2.5]octyl, oxazaspiro[3.5]nonyl, oxazaspiro[4.5]decyl, pyrazolyl, pyridinyl, pyridoneyl, or 4-oxo-1,4λ 5-Ozaphosphacyclohexyl. Advantageously, Cy3 represents cyclopropyl, cyclopentyl, cyclohexyl, spiro[3.3]heptyl, aziroxybutyl, oxacyclobutyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, morpholinyl, piperidinyl, piperazine, tetrahydropyranyl, dihydropyranyl, tetrahydropyridinyl, dioxothiazinyl, dioxothiacyclohexyl, oxazaspiro[3.3]heptyl, oxazaspiro[2.5]octyl, oxazaspiro[3.5]nonyl, oxazaspiro[4.5]decyl, pyrazolyl, pyridinyl, or pyridoneyl. More advantageously, Cy3 represents cyclopentyl, cyclohexyl, spiro[3.3]heptyl, aziroxybutyl, oxacyclobutyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, morpholinyl, piperidinyl, piperazine, tetrahydropyranyl, dihydropyranyl, tetrahydropyridinyl, dioxothiazinyl, dioxothiacyclohexyl, oxazaspiro[3.3]heptyl, oxazaspiro[2.5]octyl, oxazaspiro[3.5]nonyl, oxazaspiro[4.5]decyl, pyrazolyl, pyridinyl, or pyridoneyl. Even more advantageously, Cy3 represents oxacyclobutyl, dihydrofuranyl, tetrahydrofuranyl, morpholinyl, piperazine, tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, oxazaspiro[2.5]octyl. In a preferred embodiment, Cy3 represents tetrahydropyranyl or dihydropyranyl. In a preferred embodiment, Cy3 represents tetrahydropyranyl. In a preferred embodiment, Cy3 represents dihydropyranyl.
[0069] Another advantageous possibility is the composition of compounds of formula (Ic):
[0070] R2, R3, R4 and Cy2 are as defined with respect to equation (I).
[0071] Another advantageous possibility is the composition of compounds of formula (Id):
[0072] R4, R5, R6, W, Cy2, and Cy3 are as defined with respect to equation (I).
[0073] The preferred compound according to the present invention is: - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-(oxetane-3-ylmethoxy)nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-3-isopropyl-isooxazolo[5,4-b]pyridine-5-carboxamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-tetrahydropyran-4-yl-nicotinamide; - 5-(2,5-dihydrofuran-3-yl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-[4-(oxecyclobutane-3-carbonyl)piperazinyl]nicotinamide; - N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-[4-(oxecyclobutane-3-carbonyl)piperazinyl]nicotinamide; - 5-[4-(cyclobutanecarbonyl)piperazinyl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - 5-[1-(cyclobutanecarbonyl)-3,6-dihydro-2H-pyridin-4-yl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - 2-[1-[1-(fluoromethyl)cyclopropanecarbonyl]-3,6-dihydro-2H-pyridin-4-yl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]pyrimidine-4-carboxamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide; - 5-(3,6-dihydro-2H-pyran-4-yl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-2-[(3R)-tetrahydrofuran-3-yl]oxy-pyrimidine-4-carboxamide; - 5-[4-(cyclopropanecarbonyl)piperazinyl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-2-tetrahydropyran-4-yl-pyrimidin-4-carboxamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-morpholino-nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(oxacyclobutane-3-ylmethyl)-2-azaspiro[3.3]hept-6-ylidene]methyl]phenyl]ethyl]-2-tetrahydropyran-4-yl-pyrimidine-4-carboxamide.
[0074] Pharmacological studies of the compounds of this invention have demonstrated a strong binding affinity for SOS1 and blocked the interaction between SOS1 and RAS family members, preventing KRas from recycling to its active GTP-bound form. Therefore, the compounds of this invention may have therapeutic value against a variety of cancers, particularly those associated with Ras family members. Furthermore, the compounds of this invention, as inhibitors of intracellular SOS1-Ras protein interactions, have potential therapeutic value for various cancers, including Ras-related cancers, SOS1-related cancers, and NF-1 / NF-2-related cancers. Finally, the compounds of this invention may provide therapeutic benefits in genetic and immune diseases.
[0075] The present invention also relates to pharmaceutical compositions comprising at least one compound of formula (I) or a combination thereof with an addition salt of a pharmaceutically acceptable acid or base and one or more pharmaceutically acceptable excipients. In particular, these pharmaceutical compositions are valuable for use as SOS1 inhibitors, specifically for the treatment of cancers (hematologic malignancies and solid tumors), autoimmune diseases and immune system disorders, and genetic diseases. Preferably, the pharmaceutical compositions are valuable for use as SOS1 inhibitors in the treatment and prevention of Ras-related cancers, SOS1-related cancers, and NF-1 / NF-2 related cancers. Specifically, these pharmaceutical compositions can be used to treat cancers selected from pancreatic cancer, lung cancer, colorectal cancer, bile duct cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial carcinoma, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, sarcoma, glioma, and malignant peripheral nerve sheath tumor. In another embodiment, these pharmaceutical compositions can be used to treat genetic diseases, specifically neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple freckles, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardiofacial skin syndrome, Legius syndrome, and hereditary gingival fibromatosis.
[0076] Furthermore, the present invention relates to combinations of compounds of formula (I) with small molecules, said small molecules including, but not limited to, anticancer agents selected from genotoxic agents, mitotic toxins, antimetabolites, proteasome inhibitors, enzyme inhibitors, signaling protein inhibitors, transcription factor inhibitors, epigenetic factor inhibitors, kinase inhibitors, protein-protein interaction inhibitors, immunomodulators, E3 ligase inhibitors, and chimeric antigen receptor T-cell therapies and antibodies. In one embodiment, the present invention also relates to pharmaceutical compositions comprising such combinations and their use in the preparation of medicaments for treating cancer, particularly pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial carcinoma, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, sarcoma, glioma, and malignant peripheral nerve sheath tumor.
[0077] Example
[0078] The compounds of the present invention can be prepared by a variety of methods well known to those skilled in the art of organic synthesis. For example, the compounds of the present invention can be synthesized using the methods described below, as well as synthetic methods known in the field of synthetic organic chemistry or variations thereof as understood by those skilled in the art. It should be understood that at any point deemed appropriate during the processes described below, some groups (halogens, hydroxyl groups, amino groups, etc.) of the starting reagents or synthetic intermediates may be protected, subsequently deprotected, and functionalized as required for the synthesis. Preferred methods include, but are not limited to, those described below. The compounds of the present invention can be synthesized according to the steps outlined in general schemes 1 and 2, which include the preparation of intermediates III, IV, VII, and VIII. Starting materials I, II, V, and VII are commercially available or prepared by known processes reported in the literature or exemplified in the literature.
[0079] General Solution 1
[0080] R1, Cy1, and A are defined as in equation (I), and PG1 represents the protecting base.
[0081] General Scheme 1 outlines a general method for preparing intermediate IV, which contains a double bond, using intermediate II. Starting material I is converted to the corresponding dialkylphosphonate derivative, which is then reacted with intermediate II under Horner-Wadsworth-Emmons conditions at low temperature using a strong base to yield intermediate III. This is followed by bromination, and finally β-elimination using a strong base to obtain intermediate IV.
[0082] General Solution 2
[0083] R1, R2, R3, Cy1, Cy2 and A are as defined in formula (I), PG1 and PG2 are protecting groups, R' represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, or (R',R') pairs form optionally methylated rings with the oxygen carrying them.
[0084] General Scheme 2 outlines a general method for preparing compounds of formula (I). Intermediate VI is prepared by Suzuki coupling using brominated intermediate IV and boric acid derivative V. After deprotection of group PG2, amidation is carried out using carboxylic acid VII to give intermediate VIII. Then, after deprotection of protecting group PG1, R4 is introduced using the appropriate reactant according to classical chemical reactions to obtain compounds of formula (I).
[0085] Depending on the nature of the separation, mixtures of enantiomers and diastereomers produced in the above methods can be separated into their individual components by chiral salt techniques, normal-phase, reverse-phase, or chiral column chromatography.
[0086] General composition annotations
[0087] All reagents obtained from commercial sources are ready for use without further purification. Anhydrous solvents are obtained from commercial sources and are used directly without further drying.
[0088] The reaction was monitored using an LCMS instrument and / or TLC.
[0089] Merck 60 F is used with a coating. 254 Thin-layer chromatography was performed on 5 cm × 10 cm silica gel plates.
[0090] 1 H-NMR measurements were performed on a Bruker Avance III HD 400 MHz spectrometer using DMSO-d6 or CDCl3 as solvents (purchased from Eurisotop). 1 ¹H NMR data are expressed as delta values in parts per million (ppm), using residual solvent peaks (2.50 ppm for DMSO-d6, 7.26 ppm for CDCl3) as internal standards. Splitting modes are specified as: s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), spt (septet), m (multiplet), br s (broad singlet), br d (broad doublet), br t (broad triplet), br m (broad multiplet), dd (double doublet), br dd (broad double doublet), td (triple doublet), dt (double triplet), qd (double quartet), tt (triple triplet), ddd (double double doublet), dtd (double triple doublet).
[0091] HRMS measurements were performed on an LTQ OrbiTrap Velos Pro mass spectrometer. This system was supported by Orbitrap Technology, ThermoFisherScientific GmbH (Bremen, Germany), and coupled with an ultra-high performance liquid chromatography (UHPLC) system (VANQUISH, ThermoFisher Scientific, Bremen, Germany) using a BEHC18 column (2.1 mm × 100 mm – 1.7 µm). Full scan acquisitions were performed in the m / z range of 115–1500, with a resolution of 30,000 (FWHM). The HESI (heated electrospray ionization) source was operated in positive ion mode. Parameter settings were as follows: electrospray voltage, 3.5 kV; heater temperature, 300 °C; capillary temperature, 300 °C; S-lens RF level, 55%. Nitrogen (N2) was used as the sheath gas and auxiliary gas, and helium (He) as the collision gas.
[0092] ESI was determined on Waters SQD UPLC.
[0093] Use Dassault Systemes' Biovia Draw Version 18.1 to generate chemical names.
[0094] General Method
[0095] General Method 1: Cleavage of tert-Butoxycarbonyl (Boc)
[0096] At room temperature, an aqueous solution of hydrogen chloride (10 eq.) or trifluoroacetic acid (10 eq.) is added to the corresponding tert-butyl-N-carbamate (1.0 eq.) in a stirred solution of dichloromethane or dioxane / water or acetonitrile or 1-methylpyrrolidone-2-one, or under solvent-free conditions. After complete conversion of the starting material, the mixture is concentrated under reduced pressure, and the residue is purified by reversed-phase chromatography or eluted with PoraPak RxnCX (a polymer-based chromatographic product using a strong cation exchange adsorbent) to give the desired amine.
[0097] General Method 2: Peptide Conjugation
[0098] General Method 2A: A stock solution of carboxylic acid (0.18 M N-methyl-2-pyrrolidone) was loaded into a T-mixer and mixed with a stock solution of N-ethyl-N-isopropyl-prop-2-amine (1.2 M dichloromethane). The resulting mixture was continuously pumped and mixed with a stock solution of bis(trichloromethyl) carbonate (0.11 M dichloromethane) in the T-mixer. The resulting mixture was then pumped into a 250 µL PFA (perfluoroalkoxyalkane) reactor coil at 20 °C for a retention time of 0.03 min.
[0099] A vial equipped with an autoinjector and filled with an amine solution (0.40 M dichloromethane solution) was prepared. The solution was pumped and merged with the mains into a T-mixer, and injected into a second PFA spiral reactor (2.00 mL, retention time: 0.03 min) at 20 °C.
[0100] The crude mixture is collected in an automated collector in vials. The mixture is concentrated under reduced pressure to obtain the crude desired amide, which is used in the next step without further purification and is considered in quantitative yield.
[0101] General Method 2B: To a stirred solution of carboxylic acid (1.0 eq.) in N,N-diisopropylethylamine (2.0 eq.), N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)urea hexafluorophosphate (1.3 eq.), and an amine (1 eq.) were added. The mixture was then stirred at room temperature until the reaction was complete. The mixture was dissolved in water and dichloromethane, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography or reversed-phase column chromatography to give the desired amide.
[0102] General Method 2C: N,N-diisopropylethylamine (3.0 eq.) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (2.0 eq.) and an amine (1 eq.) were added to a stirred solution of carboxylic acid (1.0 eq.) in N,N-dimethylformamide (0.05 M) or dichloromethane (0.05 M) or N-methyl-2-pyrrolidone (0.1 M). The mixture was then stirred at room temperature until the reaction was complete. The mixture was dissolved in water and dichloromethane, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography or reversed-phase column chromatography to give the desired amide.
[0103] General Method 3: Phthalimide (phthalimide) Pyrolysis
[0104] At room temperature, to phthalimide- N - Protected amines (1.0 eq.) were added to a stirred solution of hydrazine (5.0 eq.) in ethanol (0.1 M), and the mixture was stirred until the starting material was completely converted. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography or reversed-phase chromatography to obtain the corresponding amine.
[0105] General Method 4: Suzuki Coupling
[0106] General Method 4A: Vinyl bromide (1.0 eq.) was dissolved in a 4:1 toluene / ethanol mixture (0.15 M), degassed with argon for 10 min. Then, borate ester (1.2 eq.), sodium carbonate (3.0 eq.), and triphenylphosphine palladium (2 mol%) were added. The system was purged with argon and heated to 60 °C. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give the desired product.
[0107] General Method 4B: A haloaryl hydrocarbon (1.0 eq.) was dissolved in a 1:4 mixture of water / 1,4-dioxane (0.15 M) degassed with argon for 10 min. Then, boric acid (1.2 eq.), potassium fluoride (3.0 eq.), and [1,1′-bis(diphenylphosphine)ferrocene]palladium(II) dichloride (1:1) (6 mol%) were added. The system was purged with argon and heated to 110 °C. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography to give the desired product.
[0108] General Method 5: Miyaura Boration Reaction
[0109] Aromatic halogens (1.0 eq.) were dissolved in 1,4-dioxane (0.2 M) and degassed with argon for 10 min. Then, 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi-1,3,2-dioxaborhecyclopentane (1.1 eq.), potassium acetate (2.0 eq.), and [1,1′-bis(diphenylphosphine)ferrocene]palladium(II) dichloride (1:1) (2 mol%) were added. The system was purged with argon and heated to 90 °C. The mixture was cooled to room temperature and ground in heptane / ethyl acetate to give the corresponding borate esters.
[0110] General Method 6: Bromine Elimination Reaction
[0111] Add 2 N sodium hydroxide (15 eq.) to a stirred mixture of dibromoalkane in methanol or tetrahydrofuran (0.05 M) and heat the mixture to 45 °C until the reaction is complete. Concentrate the mixture under reduced pressure. Dissolve the residue in ethyl acetate and water, and extract the aqueous layer with ethyl acetate. Wash the combined organic layers with brine, dry over sodium sulfate, filter, and concentrate under reduced pressure to give the desired ethylene bromide, which is used in the next step without further purification, considering quantitative yield.
[0112] General Method 7: Salt Formation Reaction
[0113] Crude amine (1.0 eq.) was dissolved in an acetonitrile / water mixture, and an aqueous solution of 2 N hydrogen chloride or 4 N dioxane hydrogen chloride (1.0–3.5 eq.) was added dropwise. The mixture was then freeze-dried to obtain the corresponding hydrochloride.
[0114] General Method 8: Reductive Amination
[0115] The amine (1.0 eq.) was dissolved in tetrahydrofuran (0.05 M) or a 5:1 dichloromethane / methanol mixture (0.05 M), followed by the addition of 37 wt.% aqueous formaldehyde solution (40 eq.). The mixture was stirred at room temperature for 1 hour, and sodium triacetoxyborohydride (3.0 eq.) was added at 0 °C. The mixture was then allowed to reach room temperature. After the reaction was complete, the mixture was quenched with saturated NaHCO3 and dissolved in dichloromethane. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography or reversed-phase chromatography to give the desired methylated amine.
[0116] General Method 9: Saponification
[0117] General Method 9A: The ester (1.0 eq.) was dissolved in methanol (0.1 M), and 2 N sodium hydroxide (5.0 eq.) was added at room temperature. After the reaction was complete, water was added, and the crude mixture was lyophilized to obtain the corresponding crude sodium carboxylate, which was used in the next step without further purification.
[0118] General Method 9B: The ester (1.0 eq.) was dissolved in a 2:1 mixture of tetrahydrofuran / water, and lithium hydroxide (3.0 eq.) was added at room temperature. After the reaction was complete, water was added, and the crude mixture was lyophilized to obtain the corresponding crude lithium carboxylate, which was used in the next step without further purification.
[0119] General Method 10: Mitsunobu Reaction
[0120] At room temperature, 1.0 eq. of alcohol, 1.5 eq. of triphenylphosphine, and 1.5 eq. of diisopropyl azodicarbonate were added to a stirred solution of phenol (1.0 eq.) in dry tetrahydrofuran (0.2 M). After the reaction was complete, water was added to the mixture, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the desired product.
[0121] General Method 11: Nucleophilic Alkylation
[0122] Add potassium carbonate (0.9 eq.) or [other reagents] to a stirred solution of amine (1.0 eq.) in anhydrous acetonitrile (0.05 M). N , N -Diisopropylamine (2.0 eq.) and an electrophilic reagent (1.1 eq.) were reacted, and the mixture was heated to 80 °C until the reaction was complete. Water was added to the mixture, and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography and lyophilized to give the desired alkylated amine.
[0123] General Method 12: Buchwald Coupling
[0124] A stirred mixture of aryl bromide (1.0 eq.) and amine (1.0 eq.–2.0 eq.) in anhydrous toluene or 1,4-dioxane (0.2 M) was degassed under argon for 10 min. Then, palladium(II) acetate (10 mol%), cesium carbonate (3.0 eq.), and XantPhos (4,5-bis(diphenylphosphine)-9,9-dimethyloxanthracene; 15 mol%) were added, and the mixture was heated to 80 °C until the reaction was complete. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography to give the desired product.
[0125] General Method 13: Diastereomer / Enantiomer Separation
[0126] The desired product was obtained by SFC / reverse phase separation of two diastereomers / enantiomers.
[0127] General Method 14: Hydrogenation
[0128] The olefin (1.0 eq.) was dissolved in methanol (0.1 M), and the system was purged with argon. 10 wt.% Pd / C (20 wt.% / olefin) was added, and the mixture was stirred at room temperature under hydrogen (1 Atm.) until the reaction was complete. The mixture was filtered through a Celite liner and reduced under reduced pressure. The residue was purified by silica gel column chromatography to give the corresponding reduced product.
[0129] General Method 15: Nucleophilic Substitution
[0130] General Method 15A: Under argon atmosphere, sodium hydride (60 wt.%, 3.3 eq.) was added to a stirred mixture of alcohol (3.0 eq.) in tetrahydrofuran (0.1 M) at room temperature, and the mixture was stirred for 20 minutes at room temperature. Then, Ar-X (1.0 eq.) was added, and the mixture was heated to reflux until the reaction was complete. The mixture was cooled to room temperature and acidified with 1 M aqueous hydrogen chloride solution. Ethyl acetate was added, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the desired product. This product was used directly in the next step without further purification, considering quantitative yield.
[0131] General Method 15B: A haloaromatic hydrocarbon (1.0 eq.) was dissolved in an amine (100 eq.), and the mixture was heated to 125 °C until the reaction was complete. The mixture was concentrated under reduced pressure and purified by silica gel column chromatography to obtain the desired product.
[0132] intermediate
[0133] Intermediate 1: 2-[(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl))benzene [ethyl]isoindoline-1,3-quinone
[0134] Step A: Preparation of 2-[(1R)-1-(4-bromophenyl)ethyl]isoindoline-1,3-quinone
[0135] To a solution of (1R)-1-(4-bromophenyl)ethylamine (135 g, 672 mmol, 1.0 eq.) in acetic acid (2.42 L, 18 mL / g), add isobenzofuran-1,3-dione (99.6 g, 672 mmol, 1.0 eq.) and heat the mixture to reflux until the reaction is complete. Partially concentrate the mixture under reduced pressure and add water. Filter the precipitated solid, wash with water, and dry under vacuum to give 2-[(1R)-1-(4-bromophenyl)ethyl]isoindoline-1,3-quinone (204 g, 618 mmol).
[0136] Step B: Preparation of Intermediate 1
[0137] According to General Method 5, intermediate 1 was prepared using 2-[(1R)-1-(4-bromophenyl)ethyl]isoindoline-1,3-quinone (151 g, 0.457 mol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl))-1,3,2-dioxaborhexacyclopentanane (128 g, 0.503 mol) to obtain crude intermediate 1 (101 g, 0.267 mol), which was used in the next step without further purification.
[0138] Intermediate 2: 4-[[4-[(1R)-1-aminoethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert- Butyl acetate
[0139] Step A: Preparation of 1-(diethoxyphosphorylmethyl)-4-fluorobenzene
[0140] 1-(diethoxyphosphorylmethyl)-4-fluorobenzene (500 g, 2.65 mol, 1.0 eq.) was added to triethyl phosphite (571 g, 3.44 mol, 1.3 eq.), and the mixture was heated to 130 °C until the reaction was complete. The mixture was then distilled under reduced pressure to give 1-(diethoxyphosphorylmethyl)-4-fluorobenzene (603 g, 2.45 mol).
[0141] Step B: Preparation of tert-butyl 4-(4-fluorobenzyl)piperidine-1-carboxylate
[0142] At 0 °C, potassium 2-methylprop-2-ol (110 g, 0.979 mol, 1.3 eq.) was slowly added to a stirred solution of 4-oxopiperidinyl-1-carboxylate (150 g, 0.758 mol, 1.0 eq.) and 1-(diethoxyphosphorylmethyl)-4-fluorobenzene (241 g, 0.979 mol, 1.3 eq.) in tetrahydrofuran (3.00 L, 20.0 mL / g). The mixture was stirred at room temperature until the reaction was complete. Ethyl acetate was added, and the organic layer was washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude 4-(4-fluorobenzyl)piperidine-1-carboxylate (358.5 g, 1.230 mol), which was used in the next step without further purification.
[0143] Step C: Preparation of tert-butyl 4-bromo-4-[bromo-(4-fluorophenyl)methyl]piperidine-1-carboxylate
[0144] At 0 °C, a solution of bromine (125.5 g, 40.2 mL, 0.785 mol, 1.1 eq.) in dichloromethane (416 mL, 2 mL / g) was added dropwise to a stirred solution of 208 g (208 g, 0.714 mol, 1.0 eq.) of 4-[(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (44.4 g, 0.312 mol, 0.45 eq.) in dichloromethane (3.57 L, 5 M). The reaction mixture was stirred at room temperature until the reaction was complete. The reaction mixture was cooled to room temperature, quenched with a saturated aqueous solution of thiosulfate, and the mixture was extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized in heptane to give tert-butyl 4-bromo-4-[bromo-(4-fluorophenyl)methyl]piperidine-1-carboxylate (156.7 g, 0.347 mol).
[0145] Step D: Preparation of tert-butyl 4-[bromo-(4-fluorophenyl)methylene]piperidine-1-carboxylate
[0146] According to a modified general method 6, tert-butyl 4-bromo-4-[bromo-(4-fluorophenyl)methyl]piperidine-1-carboxylate (156 g, 0.346 mol) in tetrahydrofuran and 2 N sodium hydroxide (10 eq.) was prepared. The crude residue was ground in hexane and filtered to give tert-butyl 4-[bromo-(4-fluorophenyl)methylene]piperidine-1-carboxylate (102 g, 0.274 mol), which was used in the next step without further purification.
[0147] Step E: 4-[(4-fluorophenyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene]piperidine- Preparation of tert-butyl 1-formate
[0148] According to modified General Method 4A, tert-butyl piperidine-1-carboxylate was prepared using tert-butyl piperidine-1-carboxylate (84.4 g, 0.228 mol, 1.1 eq.) in dioxane (1.56 L, 0.13 M), sodium carbonate (207 mL, 2 M, 2.0 eq.), and intermediate 1 (78.2 g, 0.207 mol, 1.0 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain tert-butyl 4-[(4-fluorophenyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene]piperidine-1-carboxylic acid (60.0 g, 0.111 mol).
[0149] Step F: Preparation of Intermediate 2
[0150] Intermediate 2 was prepared according to General Method 3 using tert-butyl 4-[(4-fluorophenyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene]piperidine-1-carboxylate (60.7 g, 0.109 mol) and hydrazine (26.4 mL, 0.543 mol). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to give intermediate 2 (36.6 g, 0.0892 mol).
[0151] Intermediate 3: 6-[[4-[(1R)-1-aminoethyl]phenyl]-(4-fluorophenyl)methylene]-2-azaspiro[3.3] tert-butyl heptane-2-carboxylate
[0152] Step A: Preparation of tert-butyl 6-(4-fluorobenzyl)-2-azaspiro[3.3]heptane-2-carboxylate
[0153] At 0 °C, butyllithium (1.6 M tetrahydrofuran solution, 6.60 mL, 11.0 mmol, 1.1 eq.) was added dropwise to a stirred solution of (4-fluorophenyl)methyl-triphenyl-chloro(4.20 g, 10.3 mmol, 1.1 eq.) in anhydrous tetrahydrofuran (15.0 mL), and the mixture was stirred at room temperature until the reaction was complete. Then, tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (2.00 g, 9.47 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (15.0 mL) was added dropwise, and the mixture was stirred at 65 °C. After the reaction was completed, the reaction mixture was cooled to room temperature, quenched with ammonium chloride aqueous solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and purified by silica gel column chromatography to obtain tert-butyl 6-(4-fluorobenzyl)-2-azaspiro[3.3]heptane-2-carboxylate (1.10 g, 3.63 mmol).
[0154] Step B: Preparation of tert-butyl 6-bromo-6-[bromo-(4-fluorophenyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate
[0155] At 0 °C, a solution of bromine (1.90 g, 0.620 mL, 12.0 mmol, 2.2 eq.) in dichloromethane (10 mL) was added dropwise to a stirred solution of 6-(4-fluorobenzyl)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (1.70 g, 5.50 mmol, 1.0 eq.) and potassium carbonate (0.840 g, 6.10 mmol, 1.1 eq.) in dichloromethane (10 mL). The reaction mixture was stirred at room temperature until the reaction was complete. The reaction mixture was cooled to room temperature and water was added. The layers were separated, and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (dichloromethane / ethanol / ammonia) to obtain tert-butyl 6-bromo-6-[bromo-(4-fluorophenyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate (1.20 g, 2.591 mmol).
[0156] Step C: Preparation of tert-butyl 6-[bromo-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0157] According to General Method 6, tert-butyl 6-bromo-6-[bromo-(4-fluorophenyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate was prepared using 1.16 g, 2.504 mmol of 6-bromo-6-[bromo-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate in methanol to obtain tert-butyl 6-[bromo-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate (0.89 g, 2.30 mmol), which was used in the next step without further purification.
[0158] Step D: 6-[(4-fluorophenyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene]-2-nitrogen Preparation of tert-butyl heptane-2-carboxylate (3.3)
[0159] According to General Method 4A, tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]-2-azespiro[3.3]heptane-2-carboxylate was prepared using 2.60 g, 6.80 mmol of 6-[bromo-(4-fluorophenyl)methylene]-2-azespiro[3.3]heptane-2-carboxylate (3.10 g, 8.20 mmol) and intermediate 1. The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene]-2-azespiro[3.3]heptane-2-carboxylate (3.00 g, 5.43 mmol). [M+H]+ = 549.2.
[0160] Step E: Preparation of Intermediate 3
[0161] Intermediate 3 was prepared according to modified general method 3 using tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (3.00 g, 5.429 mmol) and hydrazine (0.897 mL, 10.9 mmol, 2.0 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to give intermediate 3 (1.44 g, 3.41 mmol). [M+H]+=350.2.
[0162] Intermediate 4: [(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl] [Phenyl]ethyl]amine
[0163] Step A: Preparation of 6-[bromo-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane
[0164] According to a modified general method 1, 6-[bromo-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (1.00 g, 2.616 mmol) in dichloromethane (0.3 M) and trifluoroacetic acid (1.31 mL, 2.0 eq.) was prepared. The crude residue was eluted with a PoraPakRxnCX to give 6-[bromo-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane (730 mg, 2.587 mmol). [M+H]+ = 283.1.
[0165] Step B: Preparation of 6-[bromo-(4-fluorophenyl)methylene]-2-methyl-2-azaspiro[3.3]heptane
[0166] According to General Method 8, 6-[bromo-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane (700 mg, 2.48 mmol) was prepared in a 5:1 dichloromethane / methanol mixture. The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to 6-[bromo-(4-fluorophenyl)methylene]-2-methyl-2-azaspiro[3.3]heptane (730 mg, 2.47 mmol). [M+H]+ = 297.0.
[0167] Step C: 2-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]benzene Preparation of [ethyl]isoindoline-1,3-quinone
[0168] According to General Method 4A, 2-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]heptane (730 mg, 2.46 mmol)]phenyl]ethyl]isoindoline-1,3-quinone was prepared using 6-[bromo-(4-fluorophenyl)methylene]-2-methyl-2-azaspiro[3.3]hept-6-yenyl)methyl]phenyl]ethyl]isoindoline-1,3-quinone. The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 2-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-yenyl)methyl]phenyl]ethyl]isoindoline-1,3-quinone (750 mg, 1.61 mmol). [M+H]+ = 467.3.
[0169] Step D: Preparation of Intermediate 4
[0170] Intermediate 4 was prepared according to general method 3 using 2-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]isoindoline-1,3-quinone (750 mg, 1.608 mmol) and hydrazine (0.664 mL, 8.04 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to give intermediate 4 (360 mg, 1.070 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 7.31(m, 2H), 7.13(m,4H), 7.02(m, 2H), 3.96(q, 1H), 3.13(s, 4H), 2.94(br d, 4H), 2.15(s, 3H), 2.03(m, 2H), 1.24(d, 3H)| [M+H]+=337.2.
[0171] Intermediate 5: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-methoxy α-Nicotinamide
[0172] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methylene Preparation of tert-butyl piperidine-1-carboxylate
[0173] According to General Method 2B, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (300 mg, 0.731 mmol) and 5-methoxypyridine-3-carboxylic acid (112 mg, 0.731 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (398 mg, 0.730 mmol).
[0174] Step B: Preparation of Intermediate 5
[0175] Intermediate 5 was prepared according to General Method 1 using 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (398 mg, 0.730 mmol) and hydrogen chloride (7.30 mmol) to obtain Intermediate 5 (275 mg, 0.617 mmol). [M+H]+=446.4.
[0176] Intermediate 6: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-isopropyl Oxytonicotinamide
[0177] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene Preparation of tert-butyl piperidine-1-carboxylate
[0178] According to General Method 2B, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (300 mg, 0.731 mmol) and 5-isopropoxypyridine-3-carboxylic acid (133 mg, 0.731 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (350 mg, 0.610 mmol).
[0179] Step B: Preparation of Intermediate 6
[0180] Intermediate 6 was prepared according to General Method 1 using 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (350 mg, 0.610 mmol) and hydrogen chloride (6.10 mmol) to obtain intermediate 6 (280 mg, 0.591 mmol). [M+H]+=474.6.
[0181] Intermediate 7: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl [Base] Nicotinamide
[0182] Step A: 4-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene Preparation of tert-butyl piperidine-1-carboxylate
[0183] According to General Method 2B, tert-butyl 4-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylate was prepared in N,N-dimethylformamide using intermediate 2 (122 mg, 0.731 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give tert-butyl 4-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylate (409 mg, 0.731 mmol).
[0184] Step B: Preparation of Intermediate 7
[0185] Intermediate 7 was prepared according to General Method 1 using 4-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (409 mg, 0.731 mmol) and hydrogen chloride (7.31 mmol) to obtain Intermediate 7 (280 mg, 0.834 mmol). [M+H]+=460.4.
[0186] Intermediate 8: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-tetrahydro pyran-4-yloxy-nicotinamide
[0187] Step A: Preparation of methyl 5-tetrahydropyran-4-yloxynicotinic acid
[0188] 5-Tetrahydropyran-4-yloxynicotinic acid methyl ester was prepared according to General Method 10 using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.26 mmol) and tetrahydropyran-4-ol (0.311 mL, 3.26 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 5-tetrahydropyran-4-yloxynicotinic acid methyl ester (460 mg, 1.938 mmol). [M+H]+=238.1.
[0189] Step B: Preparation of sodium 5-tetrahydropyran-4-yloxynicotinate
[0190] Sodium 5-tetrahydropyran-4-yloxynicotinate was prepared from methyl 5-tetrahydropyran-4-yloxynicotinate (460 mg, 1.93 mmol) according to General Method 9A, yielding sodium 5-tetrahydropyran-4-yloxynicotinate (475 mg, 1.93 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+ = 224.2.
[0191] Step C: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydropyran-4-yloxynicotinyl)amino]ethyl] Preparation of tert-butyl phenyl]methylene]piperidine-1-carboxylate
[0192] According to General Method 2B, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydropyran-4-yloxynicotinamide)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (300 mg, 0.730 mmol) and sodium 5-tetrahydropyran-4-yloxynicotinamide (179 mg, 0.730 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 4-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydropyran-4-yloxynicotinamide)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (333 mg, 0.540 mmol). [M+H]+ = 616.4.
[0193] Step D: Preparation of Intermediate 8
[0194] Intermediate 8 was prepared according to General Method 1 using tert-butyl piperidine-1-carboxylate (333 mg, 0.541 mmol) and aqueous solution of 4N hydrochloric acid (1.35 mL, 5.41 mmol) in dichloromethane (10.0 mL). The residue was eluted with PoraPakRxnCX and purified by reversed-phase chromatography (acetonitrile / water / sodium bicarbonate) to give intermediate 8 (155 mg, 0.301 mmol). [M+H]+ = 516.2.
[0195] Intermediate 9: methyl 5-piperazine nicotinic acid
[0196] Step A: Preparation of tert-butyl 4-(5-methoxycarbonyl-3-pyridyl)piperazine-1-carboxylate
[0197] 4-(5-methoxycarbonyl-3-pyridyl)piperazine-1-carboxylate was prepared in 1,4-dioxane using methyl 5-bromopyridinyl-3-carboxylate (2.00 g, 9.26 mmol) and tert-butyl piperazine-1-carboxylate (2.07 g mL, 11.1 mmol, 1.2 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 4-(5-methoxycarbonyl-3-pyridyl)piperazine-1-carboxylate (2.58 g, 7.22 mmol).
[0198] Step B: Preparation of Intermediate 9
[0199] Intermediate 9 was prepared under solvent-free conditions using tert-butyl 4-(5-methoxycarbonyl-3-pyridyl)piperazine-1-carboxylate (600 mg, 1.87 mmol) and trifluoroacetic acid (1.43 mL, 18.7 mmol). The crude residue was eluted with a PoraPak RxnCX to give intermediate 9 (378 mg, 1.708 mmol), which was used in the next step without further purification.
[0200] Intermediate 11: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[By]phenyl]ethyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)nicotinamide
[0201] Step A: Preparation of lithium 5-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate
[0202] Lithium 5-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate was prepared from methyl 5-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate (1.00 g, 3.14 mmol) to obtain crude lithium 5-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate (974 mg, 3.14 mmol), considering quantitative yield. This compound was used in the next step without further purification.
[0203] Step B: 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl Preparation of tert-butyl 3,6-dihydro-2H-pyridine-1-carboxylate
[0204] According to General Method 2B, tert-butyl 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]-3-pyridyl]-3,6-dihydro-2H-pyridin-1-carboxylic acid was prepared using a solution of 5-(1-tert-butoxycarbonyl-3,6-dihydro-2H-pyridin-4-yl)lithium nicotinate (922 mg, 2.97 mmol) and intermediate 4 (1.00 g, 2.97 mmol) in N,N-dimethylformamide (30.0 mL, 0.1 M). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain tert-butyl 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]-3-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid (1.09 g, 1.75 mmol).
[0205] Step C: Preparation of Intermediate 11
[0206] Intermediate 11 was prepared under solvent-free conditions using tert-butyl 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]-3-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxylate (1.09 g, 1.75 mmol) and trifluoroacetic acid (1.34 mL, 17.5 mmol). After the reaction was complete, the mixture was concentrated under reduced pressure. The crude residue was dissolved in methanol and eluted with a PoraPak RxnCX to give intermediate 11 (915 mg, 1.75 mmol).
[0207] Intermediate 12: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-5-(4-piperidinyl)nicotinamide
[0208] Step A: Preparation of lithium 5-(1-tert-butoxycarbonyl-4-piperidinyl)nicotinate
[0209] Lithium 5-(1-tert-butoxycarbonyl-4-piperidinyl)nicotinate was prepared using methyl 5-(1-tert-butoxycarbonyl-4-piperidinyl)nicotinate (1.10 g, 3.40 mmol) according to General Method 9 B, yielding crude lithium 5-(1-tert-butoxycarbonyl-4-piperidinyl)nicotinate (1.09 g, 3.40 mmol), considering quantitative yield. This compound was used in the next step without further purification.
[0210] Step B: 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl Preparation of tert-butyl [phenyl]ethyl]carbamoyl]-3-pyridyl]piperidine-1-carboxylate
[0211] According to General Method 2B, tert-butyl piperidine-1-carboxylate was prepared using a solution of 5-(1-tert-butoxycarbonyl-4-piperidinyl)nicotinic acid lithium (928 mg, 2.97 mmol) and intermediate 4 (1.00 g, 2.97 mmol) in N,N-dimethylformamide (30.0 mL, 0.1 M) The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain tert-butyl 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]-3-pyridyl]piperidine-1-carboxylate (1.36 g, 2.18 mmol).
[0212] Step C: Preparation of Intermediate 12
[0213] Intermediate 12 was prepared under solvent-free conditions using tert-butyl piperidine-1-carboxylate (1.36 g, 2.18 mmol) and trifluoroacetic acid (1.67 mL, 21.8 mmol) according to General Method 1. After the reaction was complete, the mixture was concentrated under reduced pressure. The crude residue was dissolved in methanol and eluted with a PoraPak RxnCX to give intermediate 12 (1.14 g, 2.17 mmol).
[0214] Intermediate 13: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By][ ...
[0215] Step A: Preparation of lithium 2-(4-tert-butoxycarbonylpiperazinyl)pyrimidine-4-carboxylate
[0216] Lithium 2-(4-tert-butoxycarbonylpiperazinyl)pyrimidine-4-carboxylate was prepared using methyl 2-(4-tert-butoxycarbonylpiperazinyl)pyrimidine-4-carboxylate (951 mg, 2.95 mmol) according to General Method 9B, yielding crude lithium 2-(4-tert-butoxycarbonylpiperazinyl)pyrimidine-4-carboxylate (927 mg, 2.95 mmol), considering quantitative yield. This compound was used in the next step without further purification.
[0217] Step B: 4-[4-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl Preparation of tert-butyl 1-piperazine carbamoyl pyrimidin-2-yl 1-carboxylate
[0218] According to General Method 2B, tert-butyl piperazine-1-pyrimidinium-4-carboxylate was prepared using a solution of 2-(4-tert-butoxycarbonylpiperazinyl)pyrimidinium-4-carboxylate (934 mg, 2.97 mmol) and intermediate 4 (1.00 g, 2.97 mmol) in N,N-dimethylformamide (30.0 mL, 0.1 M) The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain tert-butyl 4-[4-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]pyrimidin-2-yl]piperazine-1-carboxylate (1.22 g, 1.95 mmol).
[0219] Step C: Preparation of Intermediate 13
[0220] Intermediate 13 was prepared under solvent-free conditions using tert-butyl piperazine-1-carboxylate (1.22 g, 1.95 mmol) and trifluoroacetic acid (1.49 mL, 19.5 mmol) according to General Method 1. After the reaction was complete, the mixture was concentrated under reduced pressure. The crude residue was dissolved in methanol and eluted with a PoraPak RxnCX to give intermediate 13 (1.00 g, 1.90 mmol).
[0221] Intermediate 14: 6-[[4-[(1R)-1-aminoethyl]phenyl]-(5-fluoro-2-pyridyl)methylene]-2-aza Spiro[3.3]heptan-2-carboxylic acid tert-butyl ester
[0222] Step A: Preparation of Tributyl-[(5-fluoro-2-pyridyl)methyl]phosphonium bromide
[0223] Tributylphosphine (2.73 mL, 11.1 mmol, 1.0 eq.) was added to a stirred solution of 2-(bromomethyl)-5-fluoropyridine (2.10 g, 11.1 mmol, 1.0 eq.) in acetonitrile (25.0 mL), and the reaction mixture was stirred at 80 °C until the reaction was complete. The reaction mixture was concentrated under reduced pressure to give crude tributyl-[(5-fluoro-2-pyridyl)methyl]phosphonium bromide (4.12 g, 5.29 mmol), which was used in the next step without further purification.
[0224] Step B: Preparation of tert-butyl 6-[(5-fluoro-2-pyridyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0225] To a stirred solution of tributyl-[(5-fluoro-2-pyridyl)methyl]phosphonium bromide (4.12 g, 10.5 mmol, 1.0 eq.) and tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (2.22 g, 10.5 mmol, 1.0 eq.) in acetonitrile (50.0 mL), potassium tert-butoxide (1 M tetrahydrofuran solution, 21.0 mL, 21.0 mmol, 2.0 eq.) was slowly added at 0 °C, and the mixture was stirred at room temperature until the reaction was complete. The reaction mixture was quenched with aqueous ammonium chloride solution and extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude tert-butyl 6-[(5-fluoro-2-pyridyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate (3.20 g, 10.5 mmol), which was used in the next step without further purification.
[0226] Step C: 6-Bromo-6-[bromo-(5-fluoro-2-pyridyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester Preparation
[0227] At 0 °C, potassium carbonate (0.710 g, 5.14 mmol, 0.5 eq.) and bromine (0.580 mL, 11.3 mmol, 1.1 eq.) were added to a stirred solution of 6-[(5-fluoro-2-pyridyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (3.13 g, 10.3 mmol, 1.0 eq.) in dichloromethane (35 mL), and the reaction mixture was stirred at room temperature until the reaction was complete. The reaction mixture was partitioned between water and dichloromethane, and the layers were separated. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude tert-butyl 6-bromo-6-[bromo-(5-fluoro-2-pyridyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylate (4.51 g, 6.32 mmol), which was used in the next step without further purification.
[0228] Step D: Preparation of tert-butyl 6-[bromo-(5-fluoro-2-pyridyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0229] according to Modified General Method 6, using 6-bromo-6-[bromo-(5-fluoro-2-pyridyl)methyl]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (4.50 g, 0.457 mol) in tetrahydrofuran at room temperature, prepared 6-[bromo-(5-fluoro-2-pyridyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (1.54 g, 3.42 mmol). The crude residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether) to obtain 6-[bromo-(5-fluoro-2-pyridyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (1.54 g, 3.42 mmol).
[0230] Step E: 6-[(5-fluoro-2-pyridyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene Preparation of tert-butyl heptane-2-carboxylate [3.3]-2-azaspiro[3.3]-2-carboxylate
[0231] A stirred solution of 6-(bromo(5-fluoropyridin-2-yl)methylene)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (1.54 g, 4.02 mmol) and (R)-2-(1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl))phenyl)ethyl)isoindoline-1,3-dione (1.52 g, 4.02 mmol) and potassium phosphate (2.56 g, 12.1 mmol) in tetrahydrofuran / water (15.0 mL / 3.00 mL) was purged with argon. Add (2-dihexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) chloride (0.316 g, 0.402 mmol), and heat the reaction mixture to 70 °C until the reaction is complete. Cool the mixture to room temperature, add water and ethyl acetate, and filter the mixture through a Celite stub filter. Separate the layers, wash the organic layer with brine, dry it with anhydrous sodium sulfate, and concentrate the mixture under reduced pressure. Purify the crude residue by silica gel column chromatography (petroleum ether / ethyl acetate) to (R)-6-((4-(1-(1,3-dioxoisoindoline-2-yl)ethyl)phenyl)(5-fluoropyridin-2-yl)methylene)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (1.72 g, 2.73 mmol).
[0232] Step F: Preparation of Intermediate 14
[0233] Intermediate 14 was prepared according to modified general method 3 using tert-butyl 6-[(5-fluoro-2-pyridyl)-[4-[(1R)-1-phthaliminoethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (1.72 g, 3.11 mmol, 1.0 eq.) and hydrazine (0.718 g, 9.32 mmol, 3.0 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to give intermediate 14 (1.03 g, 1.97 mmol).
[0234] Example
[0235] Example 1: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-isopropyl β-isoxazolo[5,4-b]pyridine-5-carboxamide; hydrochloride
[0236] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(3-isopropylisoxazolo[5,4-b]pyridine-5-carbonyl) Preparation of tert-butyl [amino]ethyl]phenyl]methylene]piperidine-1-carboxylate
[0237] According to general method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(3-isopropylisooxazolo[5,4-b]pyridine-5-carboxylic acid)-3-isopropylisooxazolo[5,4-b]pyridine-5-carboxylic acid (37.9 mg, 0.184 mmol)]tert-butyl piperidine-1-carboxylic acid was prepared in dichloromethane using intermediate 2 (83.1 mg, 0.202 mmol, 1.1 eq.) and 3-isopropylisooxazolo[5,4-b]pyridine-5-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (110 mg, 0.184 mmol) (mmol), which participates in the next step without further purification, considering quantitative yield.
[0238] Step B: Preparation of Example 1
[0239] Example 1 was prepared according to a modified general method 1 using a dichloromethane solution (0.3 M) of 4-[(4-fluorophenyl)-[4-[(1R)-1-[(3-isopropylisoxazolo[5,4-b]pyridine-5-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (110 mg, 0.184 mmol) and hydrogen chloride (5.0 eq.). The crude residue was purified by SFC (carbon dioxide / methanol / diethylamine). The residue was mixed with an aqueous hydrogen chloride solution (10 eq.) and the mixture was lyophilized to give Example 1 (22.0 mg, 0.0385 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.17(m, 1H),9.12(s, 1H), 8.95(s, 1H), 8.85(m, 2H), 7.4(m, 2H), 7.18(s, 4H), 7.11(s, 1H),5.21(m, 1H), 3.48(m, 1H), 3.12(m, 4H), 2.42(m, 4H), 1.53(m, 3H), 1.44(d, 6H)|[M+H]+=499.2504
[0240] Example 2: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5,6-di Methoxy-nicotinamide
[0241] Step A: 4-[[4-[(1R)-1-[(5,6-dimethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl) Preparation of tert-butyl methylpiperidine-1-carboxylate: Di(imidazol-1-yl) ketone (319 mg, 1.97 mmol, 1.2 eq.) was added to a solution of 5,6-dimethoxypyridine-3-carboxylic acid (300 mg, 1.64 mmol) in tetrahydrofuran (5.0 mL, 4.5 M), and the mixture was stirred at room temperature for 1 hour. Then, intermediate 2 (807 mg, 1.97 mmol, 1.2 eq.) was added, and the mixture was stirred at room temperature until the reaction was complete. Ethyl acetate was added, and the mixture was washed with water and brine. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (ethyl acetate / cyclohexane) to give tert-butyl 4-[[4-[(1R)-1-[(5,6-dimethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid (606 mg, 1.05 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.73(m, 1H), 8.3(m,1H), 7.7(m, 1H), 7.35(m, 2H), 7.15(m, 4H), 7.07(m, 2H), 5.17(m, 1H), 3.87(m,6H), 3.4(m, 4H), 2.23(m, 4H), 1.49(m, 3H), 1.4(s, 9H).
[0242] Step B: Preparation of Example 2
[0243] To a solution of 4-[[4-[(1R)-1-[(5,6-dimethoxypyridin-3-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (300 mg, 0.521 mmol, 1.0 eq.) and 2,6-dimethylpyridine (223 mg, 2.08 mmol, 4.0 eq.) in dichloromethane (10 M), trimethylsilane trifluoromethanesulfonate (347 mg, 0.283 mL, 1.56 mmol, 3.0 eq.) was added dropwise, and the mixture was stirred at room temperature until the reaction was complete. The mixture was quenched with saturated NaHCO3 and dissolved in dichloromethane. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 2 (132 mg, 0.278 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.74 (d, 1H), 8.27 (d, 1H), 7.66 (d, 1H), 7.32 (d, 2H), 7.09 (m, 6H), 5.17 (t, 1H), 3.91 (s, 3H), 3.83 (s, 3H), 2.75 (br s, 4H), 2.15 (s, 1H), 2.15 (m, 4H), 1.47 (d, 3H)| [M+H]+=476.2354
[0244] Example 3: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]quinoline-3- Formamide; hydrochloride
[0245] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-(quinoline-3-carbonylamino)ethyl]phenyl]methylene]piperyl Preparation of tert-butyl 1-pyridine-carboxylate
[0246] According to general method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-(quinoline-3-carbonylamino)ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (326 mg, 0.794 mmol, 1.1 eq.) and quinoline-3-carboxylic acid (125 mg, 0.722 mmol) to give the expected product (408 mg, 0.722 mmol), which was used in the next step without further purification, considering quantitative yield.
[0247] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]quinoline-3-carboxyl Preparation of amines
[0248] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]quinoline-3-carboxamide was prepared according to a modified general method 1 using a 0.3 M solution of 4-[(4-fluorophenyl)-[4-[(1R)-1-(quinoline-3-carbonylamino)ethyl]phenyl]methylene]piperidin-1-carboxylate (7.21 mL, 14.4 mmol, 20 eq.) in dichloromethane and 2 N hydrogen chloride. The crude residue was eluted with a PoraPak RxnCX filter, and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]quinoline-3-carboxamide (33.0 mg, 0.0709 mmol).
[0249] Step C: Preparation of Example 3
[0250] According to General Method 7, Example 3 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]quinoline-3-carboxamide (33 mg, 0.0709 mmol) and hydrogen chloride (0.177 mmol) to obtain Example 3 (34.2 mg, 0.0681 mmol). 1H NMR(500 MHz, dmso-d6) δ ppm 9.36(d, 1H), 9.25(d, 1H), 8.99(br d, 3H), 8.14(m, 2H), 7.92(s, 1H), 7.74(s, 1H), 7.43(d, 2H),7.17(m, 4H), 7.12(d, 2H), 5.08(m, 1H), 3.11(br d, 4H), 2.43(m, 4H), 1.53(d,3H). [M+H]+=466.2295
[0251] Example 4: 5-Bromo-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl] nicotine Amide; hydrochloride
[0252] Step A: 4-[[4-[(1R)-1-[(5-bromonicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperyl Preparation of tert-butyl 1-pyridine-carboxylate
[0253] According to General Method 2A, 4-[[4-[(1R)-1-[(5-bromonicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (324 mg, 0.789 mmol, 1.1 eq.) and 5-bromopyridine-3-carboxylic acid (145 mg, 0.718 mmol) to give crude 4-[[4-[(1R)-1-[(5-bromonicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (427 mg, 0.718 mmol) which was used in the next step without further purification, considering quantitative yield.
[0254] Step B: 5-Bromo-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide Preparation
[0255] According to a modified general method 1, 5-bromo-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide was prepared using a dichloromethane solution (0.3 M) of the product (427 mg, 0.718 mmol) obtained in step 1 above and 2 N hydrogen chloride (7.10 mL, 14.3 mmol, 20 eq.). The crude residue was eluted with a PoraPak RxnCX, and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give 5-bromo-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (33.0 mg, 0.0668 mmol).
[0256] Step C: Preparation of Example 4
[0257] According to General Method 7, Example 4 was prepared using 5-bromo-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (33.0 mg, 0.0668 mmol) and hydrogen chloride (0.167 mmol), yielding Example 4 (34.6 mg, 0.0610 mmol). 1H NMR(500 MHz, dmso-d6) δ ppm 9.12(m, 1H), 9(d,1H), 8.86(br d, 3H), 8.49(s, 1H), 7.37(d, 2H), 7.17(m, 4H), 7.11(d, 2H), 5.11(m, 1H), 3.11(m, 4H), 2.43(m, 4H), 1.48(d, 3H)| [M+H]+=494.1257
[0258] Example 5: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]isoquinoline- 7-Formamide; Hydrochloride
[0259] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-(isoquinoline-7-carbonylamino)ethyl]phenyl]methylene]piperyl Preparation of tert-butyl 1-pyridine-carboxylate
[0260] According to General Method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-(isoquinoline-7-carbonylamino)ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (130 mg, 0.318 mmol, 1.1 eq.) and quinoline-6-carboxylic acid (50.0 mg, 0.289 mmol) to obtain crude 4-[(4-fluorophenyl)-[4-[(1R)-1-(isoquinoline-7-carbonylamino)ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (163 mg, 0.289 mmol), which was used in the next step without further purification, considering quantitative yield.
[0261] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]isoquinoline-7-methyl Preparation of amides
[0262] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]methylene]piperidin-1-carboxylic acid tert-butyl ester (163 mg, 0.289 mmol) was prepared using a dichloromethane solution (0.3 M) and hydrogen chloride according to General Method 1. The crude residue was eluted with a PoraPak RxnCX, and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]isoquinoline-7-carboxamide (100 mg, 0.215 mmol).
[0263] Step C: Preparation of Example 5
[0264] Example 5 was prepared according to General Method 7, using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]isoquinoline-7-carboxamide (100 mg, 0.215 mmol) and hydrogen chloride (0.644 mmol) to obtain Example 5 (114 mg, 0.212 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.19(m, 1H), 9.13(m,3H), 8.79(m, 1H), 8.7(d, 1H), 8.34(dd, 1H), 8.22(d, 1H), 7.82(dd, 1H), 7.42(d, 2H), 7.17(m, 4H), 7.12(d, 2H), 5.25(m, 1H), 3.11(br s, 4H), 2.45(br dd,4H), 1.53(d, 3H)| [M+H]+=466.2290
[0265] Example 6: 3-Cyano-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl] Benzamide; hydrochloride
[0266] Step A: 4-[[4-[(1R)-1-[(3-cyanobenzoyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene Preparation of tert-butyl piperidine-1-carboxylate
[0267] According to General Method 2A, 4-[[4-[(1R)-1-[(3-cyanobenzoyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (154 mg, 0.374 mmol, 1.1 eq.) and 3-cyanobenzoic acid (50.0 mg, 0.339 mmol) to give crude 4-[[4-[(1R)-1-[(3-cyanobenzoyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (183 mg, 0.339 mmol), which was used in the next step without further purification, considering quantitative yield.
[0268] Step B: 3-Cyano-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzyl Preparation of amides
[0269] 3-Cyano-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzamide was prepared according to General Method 1 using a solution of 4-[[4-[(1R)-1-[(3-cyanobenzoyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidin-1-carboxylate (183 mg, 0.339 mmol) in dichloromethane (0.3 M) and hydrogen chloride. The crude residue was eluted with a PoraPak RxnCX, and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give 3-cyano-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzamide (114 mg, 0.259 mmol).
[0270] Step C: Preparation of Example 6
[0271] According to General Method 7, Example 6 was prepared using 3-cyano-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzamide (114 mg, 0.259 mmol) and hydrogen chloride (0.649 mmol) to obtain Example 6 (120 mg, 0.252 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.03(d, 1H), 8.95(m,2H), 8.35(m, 1H), 8.18(m, 1H), 8.01(dt, 1H), 7.69(m, 1H), 7.37(m, 2H), 7.17(s, 4H), 7.09(m, 2H), 5.16(m, 1H), 3.11(m, 4H), 2.42(m, 4H), 1.48(d, 3H)| [M+H]+=440.2123
[0272] Example 7: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzofuran Zan-5-formamide; hydrochloride
[0273] Step A: 4-[[4-[(1R)-1-(benzofuran-5-carbonylamino)ethyl]phenyl]-(4-fluorophenyl)methylene] Preparation of tert-butyl piperidine-1-carboxylate
[0274] According to General Method 2A, 4-[[4-[(1R)-1-(benzofuran-5-carbonylamino)ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylate tert-butyl ester was prepared in dichloromethane using intermediate 2 (183 mg, 0.445 mmol, 1.2 eq.) and 2,1,3-benzoxadiazol-5-carboxylic acid (64.0 mg, 0.371 mmol) to give crude 4-[[4-[(1R)-1-(benzofuran-5-carbonylamino)ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylate tert-butyl ester (206 mg, 0.371 mmol) which was used in the next step without further purification, considering quantitative yield.
[0275] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzofuran-5- Preparation of formamide
[0276] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzofuzan-5-carboxamide was prepared according to General Method 1 using a solution of tert-butyl piperidine-1-carboxylate (206 mg, 0.371 mmol) in dichloromethane (0.3 M) and 2 N hydrogen chloride (20 eq.). The crude residue was eluted with a PoraPak RxnCX and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzofuzan-5-carboxamide (48.7 mg, 0.107 mmol).
[0277] Step C: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzofuran-5- Preparation of formamide and hydrochloride
[0278] According to General Method 7, Example 7 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzofuran-5-carboxamide (48.7 mg, 0.107 mmol) and hydrogen chloride (0.267 mmol) to obtain Example 7 (52.4 mg, 0.106 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.22(d, 1H),8.8(br s, 2H), 8.61(s, 1H), 8.13(dd, 1H), 7.95(dd, 1H), 7.4(d, 2H), 7.16(m,6H), 5.18(t, 1H), 3.12(br s, 4H), 2.43(m, 4H), 1.5(d, 3H)| [M+H]+=457.2045
[0279] Example 8: 5-(2,2-difluoroethoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl] [By]phenyl]ethyl]nicotinamide; hydrochloride
[0280] Step A: 4-[[4-[(1R)-1-[[5-(2,2-difluoroethoxy)nicotinyl]amino]ethyl]phenyl]-(4-fluoro Preparation of tert-butyl phenyl (methylene)piperidine-1-carboxylate
[0281] According to General Method 2A, 4-[[4-[(1R)-1-[[5-(2,2-difluoroethoxy)nicotinyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (183 mg, 0.445 mmol, 1.2 eq.) and 5-(2,2-difluoroethoxy)nicotinyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (220 mg, 0.369 mmol) without further purification and used in the next step, considering quantitative yield.
[0282] Step B: 5-(2,2-difluoroethoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]benzene Preparation of [B-ethyl]nicotinamide
[0283] According to General Method 1, 5-(2,2-difluoroethoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide was prepared using a solution of 4-[[4-[(1R)-1-[[5-(2,2-difluoroethoxy)nicotinyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidin-1-carboxylic acid tert-butyl ester (220 mg, 0.369 mmol) in dichloromethane (0.3 M) and 2 N hydrogen chloride (20 eq.). The crude residue was eluted with a PoraPak RxnCX and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give 5-(2,2-difluoroethoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (43.0 mg, 0.0868 mmol).
[0284] Step C: Preparation of Example 8
[0285] According to General Method 7, Example 8 was prepared using 5-(2,2-difluoroethoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (43.0 mg, 0.0868 mmol) and hydrogen chloride (0.217 mmol), yielding Example 8 (49.0 mg, 0.0862 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.03(m, 3H), 8.72(d, 1H), 8.52(d, 1H), 7.94(m, 1H), 7.38(d, 2H), 7.15(m, 6H),6.44(tt, 1H), 5.18(quin, 1H), 4.5(td, 2H), 3.11(br s, 4H), 2.43(m, 4H), 1.49(d, 3H)
[0286] Example 9: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-5-isopropoxy-nicotinamide
[0287] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene Preparation of tert-butyl heptane-2-carboxylate [3.3]-2-azaspiro[3.3]-2-carboxylate
[0288] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (250 mg, 0.592 mmol) and 5-isopropoxypyridine-3-carboxylic acid (107 mg, 0.592 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (347 mg, 0.593 mmol). [M+H]+=586.3.
[0289] Step B: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 5-isopropoxy-nicotinamide
[0290] N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]isopropoxy-nicotinamide was prepared using a dichloromethane solution (0.3 M) of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isopropoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (347 mg, 0.593 mmol) and trifluoroacetic acid (0.296 mL, 1.19 mmol, 2.0 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide (80.0 mg, 0.165 mmol). [M+H]+=486.4.
[0291] Step C: Preparation of Example 9
[0292] Example 9 was prepared according to General Method 8 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide (80.0 mg, 0.165 mmol) in a 5:1 dichloromethane / methanol mixture. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 9 (45.0 mg, 0.090 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.94(d, 1H), 8.62(d,1H), 8.38(d, 1H), 7.75(m, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.18(t,1H), 4.77(dt, 1H), 3.13(s, 4H), 2.95(br d, 4H), 2.15(s, 3H), 1.49(d, 3H), 1.3(dd, 6H)
[0293] Example 10: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-5-methoxy-nicotinamide
[0294] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methylene Preparation of tert-butyl heptane-2-carboxylate [3.3]-2-azaspiro[3.3]-2-carboxylate
[0295] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (250 mg, 0.592 mmol) and 5-methoxypyridine-3-carboxylic acid (90.6 mg, 0.592 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (250 mg, 0.449 mmol). [M+H]+=558.3.
[0296] Step B: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 5-methoxy-nicotinamide
[0297] N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]nicotinamide was prepared using a dichloromethane solution (0.3 M) of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-methoxynicotinyl)amino]ethyl]phenyl]methyl]trifluoroacetic acid (0.224 mL, 0.897 mmol, 2 eq.) and trifluoroacetic acid (0.224 mL, 0.897 mmol, 2 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-methoxy-nicotinamide (125 mg, 0.273 mmol). [M+H]+=458.4.
[0298] Step C: Preparation of Example 10
[0299] Example 10 was prepared according to General Method 8 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-methoxy-nicotinamide (125.0 mg, 0.273 mmol) in a 5:1 dichloromethane / methanol mixture. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 10 (60.0 mg, 0.127 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.97(d, 1H), 8.66(d,1H), 8.42(d, 1H), 7.77(dd, 1H), 7.35(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.18(quin, 1H), 3.88(s, 3H), 3.15(s, 4H), 2.95(br d, 4H), 2.16(s, 3H), 1.49(d,3H)
[0300] Example 11: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept- 6-Acetyl)methyl]phenyl]ethyl]nicotinamide
[0301] Step A: 6-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene Preparation of tert-butyl heptane-2-carboxylate [3.3]-2-azaspiro[3.3]-2-carboxylate
[0302] According to General Method 2B, 6-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (250 mg, 0.592 mmol) and 5-ethoxypyridine-3-carboxylic acid (98.9 mg, 0.592 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / ethyl acetate) to give 6-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (338 mg, 0.591 mmol). [M+H]+=572.4.
[0303] Step B: 5-ethoxy-N-[(1R)-1-[4-[1-(4-fluorophenyl)-2-oxa-7-azabispirol] Preparation of [2.1.35.13]non-1-yl]phenyl]ethyl]nicotinamide
[0304] According to the modified general method 1, 5-ethoxy-N-[(1R)-1-[4-[1-(4-fluorophenyl)-2-oxa-7-azabispiro[2.1.35.13]non-1-yl]phenyl]ethyl]nicotinamide was prepared using a dichloromethane solution (0.3 M) of 6-[[4-[(1R)-1-[(5-ethoxynicotinyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (338 mg, 0.591 mmol) and trifluoroacetic acid (0.226 mL, 2.96 mmol, 5 eq.). The crude residue was eluted with PoraPak RxnCX to obtain 5-ethoxy-N-[(1R)-1-[4-[1-(4-fluorophenyl)-2-oxa-7-azabispiro[2.1.35.13]non-1-yl]phenyl]ethyl]nicotinamide (150 mg, 0.318 mmol). 1H NMR(400 / 500 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.64(s, 1H), 8.41(s, 1H), 7.75(s,1H), 7.34(d, 1H), 7.14(m, 2H), 7.1(m, 1H), 5.17(m, 1H), 4.16(q, 1H), 3.6(brs, 1H), 3(2br s, 1H), 1.49(d, 1H), 1.36(t, 1H)| [M+H]+=472.2394.
[0305] Step C: Preparation of Example 11
[0306] Example 11 was prepared according to General Method 8 using 5-ethoxy-N-[(1R)-1-[4-[1-(4-fluorophenyl)-2-oxa-7-azabispiro[2.1.35.13]non-1-yl]phenyl]ethyl]nicotinamide (150 mg, 0.318 mmol) in a 5:1 dichloromethane / methanol mixture. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 11 (75.0 mg, 0.154 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.64(d,1H), 8.4(d, 1H), 7.76(dd, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.18(quin, 1H), 4.16(q, 2H), 3.13(s, 4H), 2.95(br d, 4H), 2.15(s, 3H), 1.49(d,3H), 1.36(t, 3H)
[0307] Example 12: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-pyridine 1-Azolium-1-ylbenzamide; hydrochloride
[0308] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(3-pyrazole-1-benzoyl)amino]ethyl]phenyl] Preparation of tert-butyl methylpiperidine-1-carboxylate
[0309] According to General Method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(3-pyrazole-1-benzoyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (184 mg, 0.448 mmol, 1.2 eq.) and 3-pyrazole-1-ylbenzoic acid (74.0 mg, 0.374 mmol) to give crude 4-[(4-fluorophenyl)-[4-[(1R)-1-[(3-pyrazole-1-benzoyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (217 mg, 0.374 mmol) which was used in the next step without further purification, considering quantitative yield.
[0310] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-pyrazole-1- Preparation of β-benzamide
[0311] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]3-pyrazole-1-ylbenzamide was prepared using a 0.3 M solution of 4-[(4-fluorophenyl)-[4-[(1R)-1-[(3-pyrazole-1-benzoyl)amino]ethyl]phenyl]methylene]piperidin-1-carboxylate (217 mg, 0.374 mmol) in dichloromethane and 2 N hydrogen chloride (20 eq.). The crude residue was eluted with a PoraPak RxnCX elution apparatus, and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-pyrazol-1-yl-benzamide (49.0 mg, 0.102 mmol).
[0312] Step C: Preparation of Example 12
[0313] Example 12 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-pyrazole-1-yl-benzamide (49.0 mg, 0.102 mmol) and hydrogen chloride (0.316 mmol) according to General Method 7, yielding Example 12 (55.9 mg, 0.101 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.99(d,1H), 8.81(br s, 2H), 8.57(d, 1H), 8.33(s, 1H), 7.99(br d, 1H), 7.81(d, 1H),7.79(d, 1H), 7.59(t, 1H), 7.39(m, 2H), 7.17(m, 4H), 7.11(m, 2H), 6.58(t, 1H),5.2(t, 1H), 3.12(br s, 4H), 2.43(m, 4H), 1.5(d, 3H)
[0314] Example 13: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(tri- Fluoromethoxynicotinamide; hydrochloride
[0315] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(trifluoromethoxy)nicotinyl]amino]ethyl]phenyl] Preparation of tert-butyl methylenepiperidine-1-carboxylate
[0316] According to General Method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(trifluoromethoxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (183 mg, 0.446 mmol, 1.2 eq.) and 5-(trifluoromethoxy)pyridine-3-carboxylic acid (77.0 mg, 0.372 mmol) to give crude 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(trifluoromethoxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (223 mg, 0.372 mmol) which was used in the next step without further purification, considering quantitative yield.
[0317] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(trifluoromethyl) Preparation of (oxy)nicotinamide
[0318] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(trifluoromethoxy)nicotinamide was prepared using a dichloromethane solution (0.3 M) of 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(trifluoromethoxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidin-1-carboxylic acid tert-butyl ester (223 mg, 0.372 mmol) and 2 N hydrogen chloride (20 eq.). The crude residue was eluted with a PoraPak RxnCX and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(trifluoromethoxy)nicotinamide (58.0 mg, 0.116 mmol).
[0319] Step C: Preparation of Example 13
[0320] According to General Method 7, Example 13 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(trifluoromethoxy)nicotinamide (58.0 mg, 0.116 mmol) and hydrogen chloride (0.290 mmol) to obtain Example 13 (65.9 mg, 0.115 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.19(m,1H), 9.11(s, 1H), 8.98(br s, 2H), 8.84(d, 1H), 8.28(br s, 1H), 7.38(m, 2H),7.17(d, 4H), 7.11(m, 2H), 5.18(t, 1H), 3.11(br s, 4H), 2.43(m, 4H), 1.49(d,3H)
[0321] Example 14: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-piperazine 2,2,2-trifluoroacetic acid
[0322] Step A: 4-[3-[[(1R)-1-[4-[(1-tert-butoxycarbonyl-4-piperidinyl)-(4-fluorophenyl)methyl] Preparation of tert-butyl phenyl]ethyl]carbamoyl]phenyl]piperazine-1-carboxylate
[0323] According to General Method 2A, 4-[3-[[(1R)-1-[4-[(1-tert-butoxycarbonyl-4-piperidinyl)-(4-fluorophenyl)methyl]phenyl]ethyl]carbamoyl]phenyl]piperazine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using intermediate 2 (182 mg, 0.443 mmol, 1.2 eq.) and 3-(4-tert-butoxycarbonyl-4-piperidinyl)-(4-fluorophenyl)methyl]phenyl]ethyl]carbamoyl]phenyl]piperazine-1-carboxylic acid tert-butyl ester (258 mg, 0.369 mmol) without further purification and used in the next step, considering quantitative yield.
[0324] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-piperazinyl- Preparation of benzamide
[0325] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]piperazin-1-carboxylate (258 mg, 0.369 mmol) was prepared using a dichloromethane solution (0.3 M) and 2 N hydrogen chloride (20 eq.). The crude residue was eluted with a PoraPak RxnCX and the mixture was concentrated under reduced pressure. The residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-piperazinyl-benzamide (81.0 mg, 0.163 mmol).
[0326] Step C: Preparation of Example 14
[0327] Crude N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-piperazinyl-benzamide (81.0 mg, 0.163 mmol) was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to obtain Example 14 (71.6 mg, 0.135 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.74 (br d, 4H), 7.37 (m, 5H), 7.15 (m, 7H), 5.17 (m, 1H), 3.34 (m, 12H), 2.41 (s, 1H), 2.41 (m, 4H), 1.47 (d, 3H).
[0328] Example 15: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl [3S]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0329] Step A: Preparation of methyl 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinic acid
[0330] 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinic acid methyl ester was prepared according to general method 10 using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.27 mmol) and (3R)-tetrahydrofuran-3-ol (0.262 mL, 3.27 mmol). The residue was purified by silica gel column chromatography (heptane / ethyl acetate) to give 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinic acid methyl ester (728 mg, 3.26 mmol).
[0331] Step B: Preparation of sodium 5-[(3S)-tetrahydrofuran-3-yl]oxypyridine-3-carboxylate
[0332] Sodium 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinic acid methyl ester (728 mg, 3.26 mmol) was prepared according to General Method 9A to give sodium 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinic acid (750 mg, 3.24 mmol), considering quantitative yield. This compound was used in the next step without further purification.
[0333] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3S)-tetrahydrofuran-3-yl]oxynicotinyl]amino] Preparation of tert-butyl heptane-2-carboxylate [3,3]-ethyl[phenyl]methylene]-2-azaspiro[3,3]heptane-2-carboxylate
[0334] According to general method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3S)-tetrahydrofuran-3-yl]oxynicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (500 mg, 1.18 mmol) and sodium 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate tert-butyl ester. The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3S)-tetrahydrofuran-3-yl]oxynicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (509 mg, 0.829 mmol).
[0335] Step D: Preparation of Example 15
[0336] Example 15 was prepared using a solution of dichloromethane (0.3 M) and trifluoroacetic acid (509 mg, 0.829 mmol) according to General Method 1. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 15 (200 mg, 0.389 mmol). 1H NMR(500 MHz, dmso-d6) δ ppm 8.98(d, 1H), 8.67(br s,1H), 8.41(t, 1H), 7.76(br s, 1H), 7.35(d, 2H), 7.14(m, 2H), 7.13(m, 2H), 7.07(d, 2H), 5.2(m, 1H), 5.17(m, 1H), 3.9(m, 1H), 3.85(m, 2H), 3.83(m, 2H), 3.83(m, 2H), 3.78(m, 1H), 3.08(m, 4H), 2.27(m, 1H), 2(m, 1H), 1.48(d, 3H). [M+H]+=514.2497
[0337] Example 16: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[B]phenyl]ethyl]-5-(oxetane-3-yloxy)nicotinamide
[0338] Step A: Preparation of methyl 5-(oxetane-3-yloxy)nicotinic acid
[0339] 5-(oxetane-3-yloxy)nicotinic acid methyl ester was prepared according to General Method 10 using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.27 mmol) and oxetane-3-ol (242 mg, 3.27 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 5-(oxetane-3-yloxy)nicotinic acid methyl ester (367 mg, 1.75 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.73 (d, 1H), 8.47 (d, 1H), 7.57 (dd, 1H), 5.49 (m, 1H), 4.96 (m, 2H), 4.58 (m, 2H), 3.89 (s, 3H). [M+H]+=210.1.
[0340] Step B: Preparation of sodium 5-(oxetane-3-yloxy)nicotinic acid
[0341] Sodium 5-(oxetane-3-yloxy)nicotinate was prepared from methyl 5-(oxetane-3-yloxy)nicotinate (367 mg, 1.75 mmol) according to General Method 9A, yielding sodium 5-(oxetane-3-yloxy)nicotinate (380 mg, 1.75 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+ = 196.1.
[0342] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-yloxy)nicotinyl]amino] Preparation of tert-butyl ethyl[ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0343] According to general method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxetane-3-yloxy)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (300 mg, 0.710 mmol) and sodium 5-(oxetane-3-yloxy)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate. The crude residue was purified by silica gel column chromatography (dichloromethane / ethyl acetate) to obtain tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-yloxy)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (186 mg, 0.310 mmol).
[0344] Step D: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 5-(oxetane-3-yloxy)nicotinamide
[0345] N-[(1R)-1-[4-[2-azaspiro[3.3]heptane-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-(oxecyclobutane-3-yloxy)nicotinamide was prepared in dichloromethane (10.0 mL) using 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-yloxy)pyridine-3-carbonyl]amino]ethyl]phenyl]ethyl]-5-(oxecyclobutane-3-yloxy)nicotinamide according to General Method 1. The residue was eluted with PoraPak RxnCX and purified by silica gel column chromatography (dichloromethane / methanol-ammonia) to give N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-(oxecyclobutane-3-yloxy)pyridine-3-carboxamide (96.0 mg, 0.192 mmol), which was used in the next step without further purification.
[0346] Step E: Preparation of Example 16
[0347] Example 16 was prepared using (96.0 mg, 0.192 mmol) in a 5:1 dichloromethane / methanol mixture according to General Method 8. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 16 (55.0 mg, 0.107 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.97(d, 1H), 8.7(d, 1H), 8.33(d, 1H), 7.59(m, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.45(m, 1H),5.17(quin, 1H), 4.95(t, 2H), 4.58(m, 2H), 3.13(s, 4H), 2.95(br d, 4H), 2.15(s, 3H), 1.49(d, 3H)
[0348] Example 17: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [3S]-Tetrahydrofuran-3-yl]oxy-nicotinamide
[0349] Example 17 was prepared using Example 15 (145 mg, 0.282 mmol) in a 5:1 dichloromethane / methanol mixture according to General Method 8. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 17 (85.0 mg, 0.161 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.67(d,1H), 8.41(d, 1H), 7.75(dd, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(m, 2H), 3.84(m, 4H), 3.15(s, 4H), 2.95(br d, 4H), 2.27(m, 1H), 2.16(s, 3H),1.99(m, 1H), 1.49(d, 3H)
[0350] Example 18: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[B-5-(oxocyclobutane-3-ylmethoxy)nicotinamide]]phenyl[ethyl]-5-(oxecyclobutane-3-ylmethoxy)nicotinamide
[0351] Step A: Preparation of methyl 5-(oxetane-3-ylmethoxy)nicotinic acid
[0352] According to General Method 10, methyl 5-(oxetane-3-ylmethoxy)nicotinic acid was prepared using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.27 mmol) and oxetane-3-ylmethanol (288 mg, 3.27 mmol) to obtain methyl 5-(oxetane-3-ylmethoxy)nicotinic acid (1.40 g, 3.10 mmol). [M+H]+=224.1.
[0353] Step B: Preparation of sodium 5-(oxetane-3-ylmethoxy)nicotinate
[0354] Sodium 5-(oxetane-3-ylmethoxy)nicotinate was prepared using methyl 5-(oxetane-3-ylmethoxy)nicotinate (1.10 g, 4.90 mmol) to obtain sodium 5-(oxetane-3-ylmethoxy)nicotinate (725 mg, 3.14 mmol), which was used in the next step without further purification. [M+H]+=210.1.
[0355] Step C: Preparation of Example 18
[0356] Example 18 was prepared in N,N-dimethylformamide using intermediate 4 (110 mg, 0.327 mmol) and sodium 5-(oxecyclobutane-3-ylmethoxy)nicotinate (75.6 mg, 0.327 mmol) according to general method 2B. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 18 (34.0 mg, 0.0644 mmol). 1HNMR(400 MHz, dmso-d6) δ ppm 8.96(m, 1H), 8.66(d, 1H), 8.44(d, 1H), 7.83(dd,1H), 7.35(d, 2H), 7.13(m, 5H), 7.07(d, 2H), 5.18(m, 1H), 4.63(m, 4H), 4.35(d,2H), 3.43(m, 1H), 3.27(m, 4H), 2.97(m, 4H), 2.24(m, 3H), 1.47(m, 3H). [M+H]+=528.2668
[0357] Example 19: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl [5-Methoxynicotinamide; Hydrochloride]
[0358] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5- Preparation of methoxy-nicotinamide
[0359] N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-methoxy-nicotinamide was prepared using intermediate 5 (170 mg, 0.382 mmol) in a 5:1 dichloromethane / methanol mixture according to General Method 8. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to give N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-methoxy-nicotinamide (98.0 mg, 0.213 mmol).
[0360] Step B: Preparation of Example 19
[0361] According to General Method 7, Example 19 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-methoxy-nicotinamide (98.0 mg, 0.213 mmol) and hydrogen chloride (0.213 mmol) to obtain Example 19 (100 mg, 0.202 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.51(m,1H), 9.04(m, 1H), 8.68(m, 1H), 8.43(m, 1H), 7.86(m, 1H), 7.39(m, 2H), 7.16(s,4H), 7.1(m, 2H), 5.18(m, 1H), 3.9(s, 3H), 3.42(m, 2H), 3(m, 2H), 2.73(, 3H),2.73(d, 3H), 2.51(m, 4H)| [M+H]+=460.2380.
[0362] Example 20: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl [5-Isopropoxy-nicotinamide; hydrochloride]
[0363] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5- Preparation of isopropoxy-nicotinamide
[0364] N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide was prepared using intermediate 6 (200 mg, 0.422 mmol) in a 5:1 dichloromethane / methanol mixture according to general method 8. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to give N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide (69.0 mg, 0.142 mmol).
[0365] Step B: Preparation of Example 20
[0366] Example 20 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide (69.0 mg, 0.142 mmol) and hydrogen chloride (0.142 mmol) according to General Method 7, yielding Example 20 (60.0 mg, 0.115 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.88(s, 1H), 9.16(d, 1H), 8.72(d, 1H), 8.5(d, 1H), 8(m, 1H), 7.39(d, 2H), 7.15(m,6H), 5.18(quin, 1H), 4.85(spt, 1H), 4.42(br s, 1H), 3.41(br d, 2H), 3(m, 2H),2.72(d, 3H), 2.52(m, 4H), 1.5(d, 3H), 1.31(dd, 6H). [M+H]+=488.2683
[0367] Example 21: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl] [Phenyl]ethyl]nicotinamide; hydrochloride
[0368] Step A: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl] Preparation of ethyl nicotinamide
[0369] 5-Ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]nicotinamide was prepared using intermediate 7 (180 mg, 0.392 mmol) in a 5:1 dichloromethane / methanol mixture according to General Method 8. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to give 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (105 mg, 0.222 mmol).
[0370] Step B: Preparation of Example 21
[0371] Example 21 was prepared using 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (105 mg, 0.222 mmol) and hydrogen chloride (0.222 mmol) according to General Method 7, yielding Example 21 (110 mg, 0.216 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.62(m,1H), 9.06(m, 1H), 8.67(m, 1H), 8.46(m, 1H), 7.84(m, 1H), 7.37(s, 2H), 7.16(m,4H), 7.1(d, 2H), 5.18(m, 1H), 4.18(d, 2H), 3.43(m, 2H), 3(m, 2H), 2.73(d,3H), 2.51(m, 4H), 1.49(d, 3H), 1.36(t, 3H). [M+H]+=474.2563.
[0372] Example 22: 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperyl)-] [Pyridyl]methyl]phenyl]ethyl]nicotinamide; hydrochloride
[0373] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-yloxy)nicotinyl]amino] Preparation of tert-butyl ethyl[phenyl]methylene]piperidine-1-carboxylate
[0374] According to General Method 2B, 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxetane-3-yloxy)nicotinamide]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (300 mg, 0.731 mmol) and sodium 5-(oxetane-3-yloxy)nicotinamide]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid. The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxetane-3-yloxy)nicotinamide]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (275 mg, 0.469 mmol [M+H]+=588.3).
[0375] Step B: 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)] Preparation of [methyl]phenyl]ethyl]nicotinamide
[0376] According to General Method 1, 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide was prepared using a solution of 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-yloxy)nicotinyl]amino]ethyl]nicotinamide in dichloromethane (0.3 M) and hydrogen chloride. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (190 mg, 0.363 mmol).
[0377] Step C: 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)] Preparation of [methyl]phenyl]ethyl]nicotinamide hydrochloride
[0378] Example 22 was prepared according to General Method 7 using 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (75.0 mg, 0.143 mmol) and hydrogen chloride (0.286 mmol) to obtain Example 22 (80.0 mg, 0.134 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.09(m, 1H), 9.03(br s, 2H), 8.7(s, 1H), 8.52(d, 1H), 8(s, 1H),7.38(d, 2H), 7.17(m, 4H), 7.11(d, 2H), 5.18(quin, 1H), 4.77(m, 1H), 3.98(brd, 1H), 3.87(br s, 1H), 3.67(dd, 2H), 3.11(br s, 4H), 2.44(m, 4H), 1.49(d,3H)| [M+H]+=524.2118
[0379] Example 23: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5- [(3R)-Tetrahydrofuran-3-yl]oxy-nicotinamide; hydrochloride
[0380] Step A: Preparation of methyl 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid
[0381] 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid methyl ester was prepared according to General Method 10 using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.27 mmol) and (3S)-tetrahydrofuran-3-ol (288 mg, 3.27 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid methyl ester (1.00 g, 2.69 mmol). [M+H]+ = 224.1.
[0382] Step B: Preparation of sodium 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinate
[0383] Sodium 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid was prepared from methyl 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid (600 mg, 2.69 mmol) according to General Method 9A, yielding sodium 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid (621 mg, 2.69 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+ = 210.1.
[0384] Step C: 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3R)-tetrahydrofuran-3-yl]oxynicotinyl]amino] Preparation of tert-butyl [ethyl]phenyl]methylene]piperidine-1-carboxylate
[0385] According to General Method 2B, tert-butyl 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid sodium salt (169 mg, 0.731 mmol)] in N,N-dimethylformamide was prepared using intermediate 2 (300 mg, 0.731 mmol) and 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid sodium salt (169 mg, 0.731 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give tert-butyl 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid sodium salt (169 mg, 0.731 mmol)] piperidine-1-carboxylate (327 mg, 0.544 mmol). [M+H]+=602.4.
[0386] Step D: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetramethyl] Preparation of hydrofuran-3-yl]oxy-nicotinamide
[0387] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]phenyl]methylene]piperidin-1-carboxylic acid tert-butyl ester (327 mg, 0.544 mmol) was prepared using a dichloromethane solution (0.3 M) and hydrogen chloride according to General Method 1. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide (175 mg, 0.349 mmol).
[0388] Step E: Preparation of Example 23
[0389] According to General Method 7, Example 23 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide (65.0 mg, 0.129 mmol) and hydrogen chloride (0.259 mmol) to obtain Example 23 (70.0 mg, 0.122 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.19(br d, 3H), 8.76(d, 1H), 8.53(d, 1H), 8.01(m, 1H), 7.38(d, 2H),7.17(m, 4H), 7.11(d, 2H), 5.27(dd, 1H), 5.18(quin, 1H), 3.85(m, 4H), 3.1(brs, 4H), 2.44(m, 4H), 2.28(dt, 1H), 2(m, 1H), 1.5(d, 3H)| [M+H]+=502.2507
[0390] Example 24: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5- [(3S)-Tetrahydrofuran-3-yl]oxy-nicotinamide; hydrochloride
[0391] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3S)-tetrahydrofuran-3-yl]oxynicotinyl]amino] Preparation of tert-butyl [ethyl]phenyl]methylene]piperidine-1-carboxylate
[0392] According to General Method 2B, 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3S)-tetrahydrofuran-3-yl]oxynicotinic acid sodium salt (169 mg, 0.731 mmol)] piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (300 mg, 0.731 mmol) and 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinic acidyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (344 mg, 0.572 mmol) was purified by silica gel column chromatography (n-heptane / ethyl acetate). [M+H]+=602.4.
[0393] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3S)-tetramethyl] Preparation of hydrofuran-3-yl]oxy-nicotinamide
[0394] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]phenyl]methylene]piperidin-1-carboxylic acid tert-butyl ester (344 mg, 0.572 mmol) was prepared using a dichloromethane solution (0.3 M) and hydrogen chloride according to General Method 1. The crude residue was purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide (175 mg, 0.349 mmol).
[0395] Step C: Preparation of Example 24
[0396] According to General Method 7, Example 24 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide (75.0 mg, 0.149 mmol) and hydrogen chloride (0.299 mmol) to obtain Example 24 (80.0 mg, 0.139 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.19(br d, 3H), 8.76(d, 1H), 8.53(d, 1H), 8.01(m, 1H), 7.38(d, 2H),7.17(m, 4H), 7.11(d, 2H), 5.27(dd, 1H), 5.18(quin, 1H), 3.85(m, 4H), 3.1(brs, 4H), 2.44(m, 4H), 2.28(m, 1H), 2(m, 1H), 1.5(d, 3H)| [M+H]+=502.2506
[0397] Example 25: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-tetrahydro pyran-4-yloxy-nicotinamide; hydrochloride
[0398] Example 25 was prepared using intermediate 8 (75.0 mg, 0.145 mmol) and hydrogen chloride (0.290 mmol) according to general method 7, resulting in Example 25 (80.0 mg, 0.135 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm9.13(m, 3H), 8.72(d, 1H), 8.55(d, 1H), 8.01(s, 1H), 7.38(d, 2H), 7.15(m, 6H),5.17(quin, 2H), 4.83(br d, 1H), 3.86(m, 2H), 3.51(m, 2H), 3.1(br s, 4H), 2.44(m, 4H), 2(br d, 2H), 1.61(m, 2H), 1.49(d, 3H)| [M+H]+=516.2626
[0399] Example 26: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-methoxy α-Nicotinamide; hydrochloride
[0400] Example 26 was prepared using intermediate 5 (100 mg, 0.225 mmol) and hydrogen chloride (0.112 mL, 0.449 mmol) according to modified general method 7. The residue was purified by SFC (ethanol / diethylamine / carbon dioxide) to obtain Example 26 (45.0 mg, 0.0868 mmol).
[0401] Example 27: 5-[1-(chloromethyl)-2-hydroxyethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl)] [4-piperidinyl]methyl]phenyl]ethyl]nicotinamide; hydrochloride
[0402] Step A: 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl- Preparation of 4-piperidinyl)methyl]phenyl]ethyl]nicotinamide
[0403] According to General Method 8, 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (110 mg, 0.209 mmol) was prepared using a tetrahydrofuran solution (0.05 M) of 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]nicotinamide. The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (71.0 mg, 0.132 mmol).
[0404] Step B: Preparation of Example 27
[0405] According to General Method 7, Example 27 was prepared using 5-[1-(chloromethyl)-2-hydroxy-ethoxy]-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]nicotinamide (71.0 mg, 0.132 mmol) and hydrogen chloride (0.132 mmol) to obtain Example 27 (70.0 mg, 0.121 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 10.47(br s, 1H), 9.07(d, 1H), 8.7(s, 1H), 8.52(d, 1H), 7.99(m,1H), 7.39(d, 2H), 7.16(m, 4H), 7.1(d, 2H), 5.18(quin, 1H), 4.77(quin, 1H),3.95(br dd, 1H), 3.87(m, 1H), 3.67(dd, 2H), 3.42(br d, 2H), 3.01(m, 2H), 2.74(d, 3H), 2.49(br s, 4H), 1.49(d, 3H)| [M+H]+ = 538.2233
[0406] Example 28: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl [3R]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide; hydrochloride
[0407] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5- Preparation of [(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0408] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide (110 mg, 0.219 mmol) was prepared using a tetrahydrofuran solution (0.05 M) of N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide according to General Method 8. The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide (110 mg, 0.213 mmol).
[0409] Step B: Preparation of Example 28
[0410] According to General Method 7, Example 28 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide (72.0 mg, 0.139 mmol) and hydrogen chloride (0.290 mmol), yielding Example 28 (75.0 mg, 0.135 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.48(br s, 1H), 9.06(d, 1H), 8.7(d, 1H), 8.46(d, 1H), 7.86(m, 1H),7.38(d, 2H), 7.16(m, 4H), 7.1(d, 2H), 5.23(m, 1H), 5.18(m, 1H), 3.81(m, 4H),3.42(br d, 2H), 3.01(m, 2H), 2.74(d, 3H), 2.51(br s, 4H), 2.27(m, 1H), 1.99(m, 1H), 1.49(d, 3H)| [M+H]+=516.2663.
[0411] Example 29: 3-(aminomethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]benzene [B-ethyl]benzamide; hydrochloride
[0412] Step A: 4-[[4-[(1R)-1-[[3-[(tert-butoxycarbonylamino)methyl]benzoyl]amino]ethyl] Preparation of tert-butyl [phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylate
[0413] According to the modified general method 2C, 4-[[4-[(1R)-1-[[3-[(tert-butoxycarbonylamino)methyl]benzoic acid (93.0 mg, 0.370 mmol) and intermediate 2 (182.3 mg, 0.444 mmol, 1.2 eq.)]piperidine-1-carboxylic acid tert-butyl ester was prepared in N-methylpyrrolidone using 3-[(1R)-1-[[3-[(tert-butoxycarbonylamino)methyl]benzoyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (238 mg, 0.370 mmol) was used in the next step without further purification, considering quantitative yield.
[0414] Step B: 3-(aminomethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl Preparation of [Benzoamide]
[0415] 3-(aminomethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzamide was prepared according to General Method 1 using tert-butyl piperidine-1-carboxylate (283 mg, 0.440 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to give 3-(aminomethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzamide (45.0 mg, 0.104 mmol).
[0416] Step C: Preparation of Example 29
[0417] Example 29 was prepared using 3-(aminomethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]benzamide (43.0 mg, 0.0969 mmol) and hydrogen chloride (0.139 mmol) according to General Method 7, yielding Example 29 (49.1 mg, 0.0951 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.07(m, 2H), 8.86(m, 1H), 8.36(m, 2H), 8.05(s, 1H), 7.89(m, 1H), 7.62(m, 1H),7.52(m, 1H), 7.38(br d, 2H), 7.16(m, 4H), 7.1(m, 2H), 5.16(m, 1H), 4.07(m,2H), 3.1(m, 4H), 2.4(m, 4H), 1.48(m, 3H)| [M+H]+=444.2453
[0418] Example 30: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-isopropyl Oxytonicotinamide; hydrochloride
[0419] Example 30 was prepared using intermediate 6 (100 mg, 0.211 mmol) and hydrogen chloride (0.422 mmol) according to general method 7, resulting in Example 30 (55.0 mg, 0.100 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm9.04(br d, 1H), 8.97(br s, 2H), 8.66(s, 1H), 8.44(d, 1H), 7.87(br s, 1H),7.37(d, 2H), 7.17(m, 4H), 7.11(d, 2H), 5.17(quin, 1H), 4.8(dt, 1H), 3.11(brs, 4H), 2.43(m, 4H), 1.48(d, 3H), 1.3(dd, 6H)| [M+H]+=474.2565
[0420] Example 31: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl [Base] Nicotinamide; Hydrochloride
[0421] Example 31 was prepared using intermediate 7 (100 mg, 0.217 mmol) and hydrogen chloride (0.435 mmol) according to general method 7, resulting in Example 31 (45.0 mg, 0.0845 mmol). 1H NMR(400 MHz, dmso-d6) δppm 9.09(m, 3H), 8.7(s, 1H), 8.48(d, 1H), 7.93(br s, 1H), 7.38(d, 2H), 7.17(m, 4H), 7.11(d, 2H), 5.18(quin, 1H), 4.2(m, 2H), 3.11(br s, 4H), 2.44(m,4H), 1.49(d, 3H), 1.37(t, 3H)| [M+H]+=460.2404
[0422] Example 32: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl [3S]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide; hydrochloride
[0423] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5- Preparation of [(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0424] N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide (100 mg, 0.199 mmol) was prepared using a tetrahydrofuran solution (0.05 M) of N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide according to General Method 8. The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide (90.0 mg, 0.174 mmol).
[0425] Step B: Preparation of Example 32
[0426] According to General Method 7, Example 32 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide (50.0 mg, 0.0969 mmol) and hydrogen chloride (0.193 mmol) to obtain Example 32 (40.0 mg, 0.0679 mmol). 1H NMR(400MHz, dmso-d6) δ ppm 10.73(br s, 1H), 9.12(d, 1H), 8.73(d, 1H), 8.49(d, 1H),7.93(m, 1H), 7.39(d, 2H), 7.16(m, 4H), 7.1(d, 2H), 5.25(dd, 1H), 5.18(quin,1H), 3.84(m, 4H), 3.42(br d, 2H), 3(m, 2H), 2.73(d, 3H), 2.51(m, 4H), 2.27(m,1H), 2(m, 1H), 1.49(d, 3H)| [M+H]+=516.267.
[0427] Example 33: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl [5-Tetrahydropyran-4-yloxynicotinamide; hydrochloride]
[0428] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5- Preparation of tetrahydropyran-4-yloxy-nicotinamide
[0429] N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide was prepared using a tetrahydrofuran solution (0.05 M) of intermediate 8 (80.0 mg, 0.155 mmol) according to general method 8. The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide (50.0 mg, 0.0944 mmol).
[0430] Step B: Preparation of Example 33
[0431] According to General Method 7, Example 33 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide (50.0 mg, 0.0944 mmol) and hydrogen chloride (0.188 mmol) to obtain Example 33 (50.0 mg, 0.0829 mmol). 1H NMR(400 MHz, dmso-d6) δppm 10.62(br s, 1H), 9.1(d, 1H), 8.7(d, 1H), 8.53(d, 1H), 7.96(s, 1H), 7.39(d, 2H), 7.16(m, 4H), 7.1(d, 2H), 5.18(quin, 1H), 4.8(tt, 1H), 3.86(m, 2H),3.51(m, 2H), 3.42(br d, 2H), 3.01(m, 2H), 2.73(d, 3H), 2.51(m, 4H), 2(br d,2H), 1.61(m, 2H), 1.49(d, 3H)| [M+H]+=530.2820
[0432] Example 34: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(oxygen) Heterocyclic butane-3-yloxy)nicotinamide
[0433] Example 34 was prepared according to General Method 1 using tert-butyl 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-yloxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylate (209 mg, 0.355 mmol) and a dichloromethane solution of hydrogen chloride (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give Example 34 (80.0 mg, 0.164 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d,1H), 8.69(d, 1H), 8.32(d, 1H), 7.59(dd, 1H), 7.32(d, 2H), 7.11(m, 4H), 7.05(d, 2H), 5.44(t, 1H), 5.16(t, 1H), 4.95(t, 2H), 4.57(br t, 2H), 2.71(m, 4H),2.13(m, 5H), 1.47(d, 3H)| [M+H]+=488.2356
[0434] Example 35: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl 1-Methylpyrazole-4-carboxamide
[0435] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(1-methylpyrazole-4-carbonyl)amino]ethyl]phenyl] Preparation of tert-butyl [methyl]-2-azaspiro[3.3]heptane-2-carboxylate
[0436] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(1-methylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (300 mg, 0.71 mmol) and 1-methylpyrazole-4-carboxylic acid (89.5 mg, 0.709 mmol). The crude residue was purified by silica gel column chromatography (ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(1-methylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (377 mg, 0.710 mmol). [M+H]+=530.3.
[0437] Step B: Preparation of Example 35
[0438] Example 35 was prepared according to General Method 1 using tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[(1-methylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (370 mg, 0.697 mmol) and a dichloromethane solution of hydrogen chloride (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 35 (94.0 mg, 0.218 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.33(d, 1H), 8.15(s, 1H), 7.87(s, 1H), 7.3(m, 2H), 7.13(m, 4H), 7.05(m, 2H), 5.11(quin, 1H), 3.79(m, 8H), 3(m, 4H), 1.43(d, 3H). [M+H]+=431.2246
[0439] Example 36: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(oxygen) Heterocyclic butane-3-ylmethoxy)nicotinamide
[0440] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-ylmethoxy)nicotinyl]amino] Preparation of tert-butyl [ethyl]phenyl]methylene]piperidine-1-carboxylate
[0441] According to General Method 2B, 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxetane-3-ylmethoxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (500 mg, 1.21 mmol) and sodium 5-(oxetane-3-ylmethoxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid. The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxetane-3-ylmethoxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (237 mg, 0.393 mmol). [M+H]+=602.4.
[0442] Step B: Preparation of Example 36
[0443] Example 36 was prepared according to General Method 1 using tert-butyl 4-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(oxecyclobutane-3-ylmethoxy)nicotinyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylate (237 mg, 0.393 mmol) and a dichloromethane solution of hydrogen chloride (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 36 (80.0 mg, 0.159 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(d, 1H), 8.44(d, 1H), 7.82(dd, 1H), 7.35(d, 2H), 7.14(d, 4H),7.08(d, 2H), 5.17(t, 1H), 4.72(dd, 2H), 4.44(t, 2H), 4.34(d, 2H), 3.41(m,2H), 2.95(br s, 4H), 2.31(m, 4H), 1.48(d, 3H)| [M+H]+=502.2475
[0444] Example 37: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl 5-(oxetane-3-ylmethoxy)nicotinamide
[0445] Example 37 was prepared according to General Method 8 using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-(oxetane-3-ylmethoxy)nicotinamide (50.0 mg, 0.0996 mmol) in a 5:1 dichloromethane / methanol mixture. The crude residue was purified by SFC (carbon dioxide / methanol / diethylamine) to obtain Example 37 (42.0 mg, 0.0814 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.66(d,1H), 8.44(d, 1H), 7.82(dd, 1H), 7.34(d, 2H), 7.12(m, 4H), 7.06(m, 2H), 5.17(quin, 1H), 4.72(dd, 2H), 4.44(t, 2H), 4.34(d, 2H), 3.41(m, 2H), 2.39(br s,3H), 2.25(m, 4H), 2.21(m, 3H), 1.48(d, 3H)| [M+H]+=516.2657
[0446] Example 38: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By][ ...
[0447] Example 38 was prepared according to General Method 8 using Example 35 (70.0 mg, 0.162 mmol) in a 5:1 dichloromethane / methanol mixture. The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 38 (50.0 mg, 0.112 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.33(d, 1H), 8.15(s,1H), 7.87(s, 1H), 7.3(m, 2H), 7.13(m, 4H), 7.05(m, 2H), 5.11(quin, 1H), 3.84(s, 3H), 3.24(m, 4H), 2.97(br d, 4H), 2.22(s, 3H), 1.43(d, 3H)| [M+H]+=445.2401
[0448] Example 39: 1-Ethyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl] Pyrazole-4-carboxamide; hydrochloride
[0449] Step A: 4-[[4-[(1R)-1-[(1-ethylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)imide Preparation of tert-butyl methylpiperidine-1-carboxylate
[0450] According to the modified general method 2A, 4-[[4-[(1R)-1-[(1-ethylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in 1-methylpyrrolidone using 1-ethylpyrazole-4-carboxylic acid (52.0 mg, 0.371 mmol) and intermediate 2 (183 mg, 0.445 mmol, 1.2 eq.) to give crude 4-[[4-[(1R)-1-[(1-ethylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (197 mg, 0.371 mmol) without further purification for the next step, considering quantitative yield.
[0451] Step B: 1-Ethyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyridine Preparation of azole-4-carboxamide
[0452] 1-Ethyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide was prepared according to General Method 1 using tert-butyl piperidine-1-carboxylate (198 mg, 0.37 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give 1-ethyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (35.0 mg, 0.0809 mmol).
[0453] Step C: Preparation of Example 39
[0454] According to General Method 7, Example 39 was prepared using 1-ethyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (35.0 mg, 0.0809 mmol) and hydrogen chloride (0.242 mmol), yielding Example 39 (40.2 mg, 0.0795 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.9(brs, 2H), 8.35(d, 1H), 8.21(s, 1H), 7.88(s, 1H), 7.32(m, 2H), 7.16(d, 4H), 7.08(m, 2H), 5.1(quin, 1H), 4.13(q, 2H), 3.11(br s, 4H), 2.43(m, 4H), 1.42(d,3H), 1.36(t, 3H). [M+H]+=433.2407
[0455] Example 40: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-isopropyl pyrazole-4-carboxamide; hydrochloride
[0456] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-isopropylpyrazole-4-carbonyl)amino]ethyl]phenyl] Preparation of tert-butyl methylenepiperidine-1-carboxylate
[0457] According to the modified general method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-isopropylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in 1-methylpyrrolidone using 1-isopropylpyrazole-4-carboxylic acid (57.0 mg, 0.369 mmol) and intermediate 2 (182 mg, 0.442 mmol, 1.2 eq.) to give crude 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-isopropylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (202 mg, 0.369 mmol) without further purification for the next step, considering quantitative yield.
[0458] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-isopropyl- Preparation of pyrazole-4-carboxamide
[0459] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]methylene]piperidin-1-carboxylic acid tert-butyl ester (202 mg, 0.37 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M) was prepared according to General Method 1.
[0460] Step C: Preparation of Example 40
[0461] According to General Method 7, Example 40 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-isopropyl-pyrazole-4-carboxamide (32.0 mg, 0.0716 mmol) and hydrogen chloride (0.250 mmol) to obtain Example 40 (35.1 mg, 0.0676 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.91(br s, 2H), 8.34(d, 1H), 8.24(s, 1H), 7.88(s, 1H), 7.33(m, 2H), 7.16(d, 4H),7.08(m, 2H), 5.1(quin, 1H), 4.49(quin, 1H), 3.11(m, 4H), 2.43(m, 4H), 1.41(m,9H)| [M+H]+=447.2563
[0462] Example 41: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-isobutyl pyrazole-4-carboxamide; hydrochloride
[0463] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-isobutylpyrazole-4-carbonyl)amino]ethyl]phenyl] Preparation of tert-butyl methylenepiperidine-1-carboxylate
[0464] according toModified General Method 2A was used to prepare 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-isobutylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester in 1-methylpyrrolidone using 1-isobutylpyrazole-4-carboxylic acid (62.0 mg, 0.368 mmol) and intermediate 2 (181.6 mg, 0.442 mmol, 1.2 eq.) to give crude 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-isobutylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (206 mg, 0.369 mmol), which was used in the next step without further purification, considering quantitative yield.
[0465] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-isobutyl- Preparation of pyrazole-4-carboxamide
[0466] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]methylene]piperidin-1-carboxylic acid tert-butyl ester (207 mg, 0.369 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M) was prepared according to General Method 1.
[0467] Step C: Preparation of Example 41
[0468] According to General Method 7, Example 41 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-isobutyl-pyrazole-4-carboxamide (36.0 mg, 0.0781 mmol) and hydrogen chloride (0.273 mmol) to obtain Example 41 (36.4 mg, 0.0682 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.91(br s, 2H), 8.37(d, 1H), 8.16(s, 1H), 7.9(s, 1H), 7.33(m, 2H), 7.16(m, 4H),7.09(m, 2H), 5.1(quin, 1H), 3.91(d, 2H), 3.49(m, 1H), 3.11(br s, 4H), 2.43(m,4H), 2.09(m, 1H), 1.43(d, 3H), 0.83(d, 6H). [M+H]+=461.2715
[0469] Example 42: 1-(difluoromethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]benzene [B-ethyl]pyrazole-4-carboxamide; hydrochloride
[0470] Step A: 4-[[4-[(1R)-1-[[1-(difluoromethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]-(4-fluorobenzene) Preparation of tert-butyl [methylene]piperidine-1-carboxylate
[0471] According to the modified general method 2A, 4-[[4-[(1R)-1-[[1-(difluoromethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in 1-methylpyrrolidone using 1-(difluoromethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (205 mg, 0.370 mmol) with 1-(difluoromethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester, considering quantitative yield.
[0472] Step B: 1-(difluoromethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl Preparation of pyrazole-4-carboxamide
[0473] According to General Method 1, 1-(difluoromethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide was prepared using tert-butyl piperidine-1-carboxylate (205 mg, 0.369 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give 1-(difluoromethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (47 mg, 0.103 mmol).
[0474] Step C: Preparation of Example 42
[0475] According to General Method 7, Example 42 was prepared using 1-(difluoromethyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (47.0 mg, 0.103 mmol) and hydrogen chloride (0.361 mmol), yielding Example 42 (49.4 mg, 0.0912 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm8.88(br s, 2H), 8.73(s, 1H), 8.68(d, 1H), 8.19(s, 1H), 7.85(m, 1H), 7.34(d,2H), 7.15(m, 6H), 5.11(quin, 1H), 3.11(br s, 4H), 2.43(m, 4H), 1.44(d, 3H)|[M+H]+=455.2058
[0476] Example 43: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-(2, 2,2-Trifluoroethyl)pyrazole-4-carboxamide; hydrochloride
[0477] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino] Preparation of tert-butyl ethyl[phenyl]methylene]piperidine-1-carboxylate
[0478] According to the modified general method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in 1-methylpyrrolidone using 1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (217 mg, 0.370 mmol) to give crude 4-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester, considering quantitative yield.
[0479] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-(2,2,2- Preparation of trifluoroethyl pyrazole-4-carboxamide
[0480] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate was prepared according to General Method 1 using tert-butyl piperidine-1-carboxylate (217 mg, 0.369 mmol) and a dichloromethane solution of hydrogen chloride (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxamide (45.0 mg, 0.0925 mmol).
[0481] Step C: Preparation of Example 43
[0482] According to General Method 7, Example 43 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxamide (45.0 mg, 0.0925 mmol) and hydrogen chloride (0.323 mmol), yielding Example 43 (45.2 mg, 0.0808 mmol). 1H NMR(400 MHz, dmso-d6) δppm 8.97(m, 2H), 8.56(d, 1H), 8.33(s, 1H), 8.03(s, 1H), 7.33(d, 2H), 7.16(m,4H), 7.09(d, 2H), 5.19(quad, 2H), 5.11(quin, 1H), 3.11(m, 4H), 2.43(m, 4H),1.43(d, 3H)| [M+H]+=487.2051
[0483] Example 44: 1-tert-butyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl [By]pyrazole-4-carboxamide; hydrochloride
[0484] Step A: 4-[[4-[(1R)-1-[(1-tert-butylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl) Preparation of tert-butyl methylenepiperidine-1-carboxylate
[0485] According to the modified general method 2A, 4-[[4-[(1R)-1-[(1-tert-butylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in 1-methylpyrrolidone using 1-tert-butylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (210 mg, 0.374 mmol) without further purification for the next step, considering quantitative yield.
[0486] Step B: 1-tert-butyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyridine Preparation of azole-4-carboxamide
[0487] 1-tert-butyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide was prepared according to General Method 1 using tert-butyl 4-[[4-[(1R)-1-[(1-tert-butylpyrazole-4-carbonyl)amino]ethyl]phenyl]ethyl]pyrazole-4-carboxamide (210 mg, 0.374 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give 1-tert-butyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (38.0 mg, 0.0825 mmol).
[0488] Step C: Preparation of Example 44
[0489] According to General Method 7, Example 44 was prepared using 1-tert-butyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (38.0 mg, 0.0825 mmol) and hydrogen chloride (0.288 mmol), yielding Example 44 (36.1 mg, 0.0677 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.01(m,2H), 8.34(s+d, 2H), 7.88(s, 1H), 7.33(d, 2H), 7.16(m, 4H), 7.09(d, 2H), 5.09(quin, 1H), 3.11(m, 4H), 2.42(m, 4H), 1.52(s, 9H), 1.43(m, 3H). [M+H]+=461.2720
[0490] Example 45: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-tetrahydro pyran-4-yl-pyrazole-4-carboxamide; hydrochloride
[0491] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-tetrahydropyran-4-ylpyrazole-4-carbonyl)amino]ethyl Preparation of tert-butyl [phenyl]methylene]piperidine-1-carboxylate
[0492] According to the modified general method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-tetrahydropyran-4-ylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in 1-methylpyrrolidone using 1-tetrahydropyran-4-ylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (219 mg, 0.372 mmol) without further purification for the next step, considering quantitative yield.
[0493] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-tetrahydropyr Preparation of 4-yl-pyrazole-4-carboxamide
[0494] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]tetrahydropyran-4-yl-pyrazole-4-carboxylate was prepared using tert-butyl piperidine-1-carboxylate (219 mg, 0.372 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give 1-tert-butyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxylate (46.0 mg, 0.0941 mmol).
[0495] Step C: Preparation of Example 45
[0496] According to General Method 7, Example 45 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-tetrahydropyran-4-yl-pyrazole-4-carboxamide (46.0 mg, 0.0941 mmol) and hydrogen chloride (0.329 mmol) to obtain Example 45 (43.1 mg, 0.0768 mmol). 1H NMR(400 MHz, dmso-d6) δppm 8.99(m, 2H), 8.36(d, 1H), 8.29(s, 1H), 7.92(s, 1H), 7.33(d, 2H), 7.16(m,4H), 7.09(d, 2H), 5.1(quin, 1H), 4.42(m, 1H), 3.94(m, 2H), 3.43(m, 2H), 3.11(m, 4H), 2.41(m, 4H), 1.93(2m, 4H), 1.43(d, 3H). [M+H]+=489.2672
[0497] Example 46: 1-Cyclopentyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl [By]pyrazole-4-carboxamide; hydrochloride
[0498] Step A: 4-[[4-[(1R)-1-[(1-cyclopentylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl) Preparation of tert-butyl methylenepiperidine-1-carboxylate
[0499] According to the modified general method 2A, 4-[[4-[(1R)-1-[(1-cyclopentylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in 1-methylpyrrolidone using 1-cyclopentylpyrazole-4-carbonyl)amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (213 mg, 0.371 mmol) without further purification for the next step, considering quantitative yield.
[0500] Step B: 1-Cyclopentyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyridine Preparation of azole-4-carboxamide
[0501] 1-Cyclopentyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide was prepared according to General Method 1 using tert-butyl piperidine-1-carboxylate (219 mg, 0.372 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give 1-cyclopentyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (35.0 mg, 0.074 mmol).
[0502] Step C: Preparation of Example 46
[0503] According to General Method 7, Example 46 was prepared using 1-cyclopentyl-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]pyrazole-4-carboxamide (35.0 mg, 0.0740 mmol) and hydrogen chloride (0.259 mmol), yielding Example 46 (35.3 mg, 0.0647 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(m, 2H), 8.34(d, 1H), 8.25(s, 1H), 7.87(s, 1H), 7.33(d, 2H), 7.16(m, 4H),7.08(d, 2H), 5.1(quin, 1H), 4.67(quin, 1H), 3.11(m, 4H), 2.41(m, 4H), 2.1(m,2H), 1.9(m, 2H), 1.77(m, 2H), 1.64(m, 2H), 1.42(d, 3H). [M+H]+=473.2663
[0504] Example 47: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]benzene [Ethyl]-5-methoxy-nicotinamide; hydrochloride
[0505] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl Preparation of 5-methoxynicotinamide
[0506] N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-methoxy-nicotinamide was prepared in acetonitrile using intermediate 5 (75.0 mg, 0.168 mmol, 1.0 eq.) and 2-bromoethanol (23.1 mg, 0.0100 mL, 0.185 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to give N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-methoxy-nicotinamide (70.0 mg, 0.143 mmol).
[0507] Step B: Preparation of Example 47
[0508] Example 47 was prepared according to General Method 7 using N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-methoxy-nicotinamide (70.0 mg, 0.143 mmol) and hydrogen chloride (0.285 mmol), yielding Example 47 (70.0 mg, 0.124 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm10.06(br s, 1H), 9.07(d, 1H), 8.69(d, 1H), 8.47(d, 1H), 7.87(m, 1H), 7.39(d,2H), 7.17(m, 4H), 7.1(d, 2H), 5.18(m, 1H), 3.9(s, 3H), 3.76(br s, 2H), 3.53(br d, 2H), 3.15(br d, 2H), 3.05(m, 2H), 2.54(m, 4H), 1.49(d, 3H)|[M+H]+=490.2513
[0509] Example 48: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl] [Phenyl]ethyl]-5-methoxy-nicotinamide; hydrochloride
[0510] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]benzene Preparation of [ethyl]-5-methoxy-nicotinamide
[0511] N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-methoxy-nicotinamide was prepared in acetonitrile using intermediate 5 (75.0 mg, 0.168 mmol, 1.0 eq.) and 1-bromo-2-methoxy-ethane (25.7 mg, 0.174 mmol, 1.0 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to give N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-methoxy-nicotinamide (70.0 mg, 0.139 mmol).
[0512] Step B: Preparation of Example 48
[0513] According to General Method 7, Example 48 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-methoxy-nicotinamide (70.0 mg, 0.139 mmol) and hydrogen chloride (0.278 mmol), yielding Example 48 (70.0 mg, 0.121 mmol). 1H NMR(400 MHz, dmso-d6) δppm 10.34(br s, 1H), 9.1(d, 1H), 8.7(d, 1H), 8.48(d, 1H), 7.89(br s, 1H),7.39(d, 2H), 7.17(m, 4H), 7.1(d, 2H), 5.18(quin, 1H), 3.91(s, 3H), 3.69(m,2H), 3.5(br d, 2H), 3.29(s, 3H), 3.27(br d, 2H), 3.05(m, 2H), 2.52(m, 4H),1.49(d, 3H)| [M+H]+=504.2666
[0514] Example 49: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl 1-Methylpyrazole-4-carboxamide; hydrochloride
[0515] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-methylpyrazole-4-carbonyl)amino]ethyl]phenyl] Preparation of tert-butyl methylpiperidine-1-carboxylate
[0516] According to General Method 2B, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-methylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (1.00 g, 2.43 mmol) and 1-methylpyrazole-4-carboxylic acid (307 mg, 2.43 mmol). The crude residue was purified by silica gel column chromatography (ethyl acetate) to give 4-[(4-fluorophenyl)-[4-[(1R)-1-[(1-methylpyrazole-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (1.26 g, 2.43 mmol). [M+H]+ = 519.2.
[0517] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-methyl-pyridine Preparation of azole-4-carboxamide
[0518] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]methylene]piperidin-1-carboxylic acid tert-butyl ester (1.26 g, 2.43 mmol) and a solution of hydrogen chloride in dichloromethane (0.3 M) was prepared according to modified General Method 1.
[0519] Step C: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-1- Preparation of methyl-pyrazole-4-carboxamide
[0520] N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-methyl-pyrazole-4-carboxamide (250 mg, 0.508 mmol) was prepared using a tetrahydrofuran solution (0.05 M) of N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-1-methyl-pyrazole-4-carboxamide (167 mg, 0.386 mmol) according to General Method 8. The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-1-methyl-pyrazole-4-carboxamide (167 mg, 0.386 mmol).
[0521] Step D: Preparation of Example 49
[0522] According to General Method 7, Example 49 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-1-methyl-pyrazole-4-carboxamide (167 mg, 0.386 mmol) and hydrogen chloride (0.772 mmol) to obtain Example 49 (160 mg, 0.316 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm10.48(br s, 1H), 8.36(d, 1H), 8.15(s, 1H), 7.87(s, 1H), 7.33(m, 2H), 7.16(m,4H), 7.07(m, 2H), 5.1(quin, 1H), 3.84(s, 3H), 3.42(br d, 2H), 3.01(m, 2H),2.74(d, 3H), 2.51(m, 4H), 1.42(d, 3H)| [M+H]+=433.2410.
[0523] Example 50: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]benzene [Ethyl]-5-isopropoxy-nicotinamide; hydrochloride
[0524] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl Preparation of 5-isopropoxy-nicotinamide
[0525] N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide was prepared in acetonitrile using intermediate 6 (85.0 mg, 0.179 mmol, 1.0 eq.) and 2-bromoethanol (24.6 mg, 10.0 µL, 0.197 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to give N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide (48.0 mg, 0.0927 mmol).
[0526] Step B: Preparation of Example 50
[0527] According to General Method 7, Example 50 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]-5-isopropoxy-nicotinamide (48.0 mg, 0.0927 mmol) and hydrogen chloride (0.185 mmol) to obtain Example 50 (47.0 mg, 0.0795 mmol). 1H NMR(400 MHz, dmso-d6) δppm 10.02(m, 1H), 9.02(m, 1H), 8.66(d, 1H), 8.44(d, 1H), 7.86(br s, 1H), 7.43(m, 1H), 7.38(d, 1H), 7.18(s, 1H), 7.16(m, 4H), 7.09(s, 1H), 5.18(m, 1H), 4.8(m, 2H), 3.76(m, 2H), 3.53(m, 2H), 3.15(m, 2H), 3.03(m, 2H), 2.51(br s, 4H),1.49(d, 3H), 1.3(dd, 6H). [M+H]+=518.2825.
[0528] Example 51: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl] [Methyl]phenyl]ethyl]nicotinamide; hydrochloride
[0529] Step A: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl Preparation of [B-]phenyl]ethyl]nicotinamide
[0530] 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]nicotinamide was prepared in acetonitrile using intermediate 7 (85.0 mg, 0.184 mmol, 1.0 eq.) and 2-bromoethanol (25.4 mg, 0.0100 mL, 0.203 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to give 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]nicotinamide (58.0 mg, 0.115 mmol).
[0531] Step B: Preparation of Example 51
[0532] According to General Method 7, Example 51 was prepared using 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]nicotinamide (48.0 mg, 0.0953 mmol) and hydrogen chloride (0.190 mmol), yielding Example 51 (48.0 mg, 0.0832 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm10.17(m, 1H), 9.07(m, 1H), 8.7(m, 1H), 8.44(m, 1H), 7.87(br s, 1H), 7.38(m,2H), 7.16(m, 4H), 7.1(m, 2H), 5.2(m, 1H), 4.18(m, 2H), 3.75(m, 2H), 3.53(m,2H), 3.16(m, 2H), 3.03(m, 2H), 2.57(m, 4H), 1.49(d, 3H), 1.36(t, 3H)| [M+H]+=504.2665
[0533] Example 52: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-2-methoxy pyrimidine-4-carboxamide
[0534] Step A: 4-[(4-fluorophenyl)-[4-[(1R)-1-[(2-methoxypyrimidin-4-carbonyl)amino]ethyl]phenyl] Preparation of tert-butyl methylenepiperidine-1-carboxylate
[0535] According to the modified general method 2A, 4-[(4-fluorophenyl)-[4-[(1R)-1-[(2-methoxypyrimidin-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in dichloromethane using 2-methoxypyrimidin-4-carboxylic acid (50.0 mg, 0.324 mmol) and intermediate 2 (146 mg, 0.356 mmol, 1.1 eq.) to give crude 4-[(4-fluorophenyl)-[4-[(1R)-1-[(2-methoxypyrimidin-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (177 mg, 0.323 mmol) which was used in the next step without further purification, considering quantitative yield.
[0536] Step B: Preparation of Example 52
[0537] Example 52 was prepared according to General Method 1 using crude tert-butyl 4-[(4-fluorophenyl)-[4-[(1R)-1-[(2-methoxypyrimidin-4-carbonyl)amino]ethyl]phenyl]methylene]piperidine-1-carboxylate (177 mg, 0.323 mmol) and a dichloromethane solution of hydrogen chloride (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give Example 52 (62.0 mg, 0.446 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.04(d, 1H),8.82(d, 1H), 7.59(d, 1H), 7.35(d, 2H), 7.1(m, 4H), 7.04(d, 2H), 5.16(quin,1H), 4.02(s, 3H), 2.71(m, 4H), 2.25(m, 1H), 2.13(q, 4H), 1.52(d, 3H)| [M+H]+=447.2194
[0538] Example 53: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl] [Phenyl]ethyl]-5-isopropoxy-nicotinamide; hydrochloride
[0539] Example 53 was prepared in acetonitrile using intermediate 6 (85.0 mg, 0.179 mmol, 1.0 eq.) and 1-bromo-2-methoxy-ethane (27.4 mg, 0.197 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) and then mixed with a dioxane solution of 4 N hydrogen chloride (2.0 eq.) to give Example 53 (58.0 mg, 0.115 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.28(br s, 1H),9.05(d, 1H), 8.66(d, 1H), 8.44(d, 1H), 7.87(m, 1H), 7.38(m, 2H), 7.17(m, 4H),7.1(m, 2H), 5.18(quin, 1H), 4.81(quin, 1H), 3.7(m, 2H), 3.5(m, 2H), 3.3(s,3H), 3.27(br d, 2H), 3.04(m, 2H), 2.52(m, 4H), 1.49(d, 3H), 1.3(dd, 6H)| [M+H]+=532.2983
[0540] Example 54: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]benzene [Ethyl]-1-methylpyrazole-4-carboxamide; hydrochloride
[0541] Example 54 was prepared according to General Method 11 using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-methyl-pyrazole-4-carboxamide (150 mg, 0.305 mmol), potassium carbonate (90.8 mg, 0.915 mmol, 3.0 eq.), and 2-bromoethanol (42.0 mg, 0.335 mmol, 1.0 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) and then mixed with a dioxane solution of hydrogen chloride (2.0 eq.) to give Example 54 (110 mg, 0.237 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.26(br s, 1H),8.37(d, 1H), 7.88(s, 1H), 7.33(m, 2H), 7.16(d, 4H), 7.08(m, 2H), 5.1(quin,1H), 4.5(m, 2H), 3.84(s, 3H), 3.76(br t, 2H), 3.52(m, 2H), 3.51(s, 1H), 3.14(m, 2H), 3.05(m, 2H), 2.6(m, 4H), 1.43(d, 3H)| [M+H]+=463.2498
[0542] Example 55: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl] [Phenyl]ethyl]-1-methylpyrazole-4-carboxamide; hydrochloride
[0543] Example 55 was prepared according to General Method 11 using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-methyl-pyrazole-4-carboxamide (150 mg, 0.305 mmol), potassium carbonate (90.8 mg, 0.915 mmol, 3.0 eq.), and 1-bromo-2-methoxy-ethane (46.7 mg, 0.335 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) and then mixed with a dioxane solution of 4 N hydrogen chloride (2.0 eq.) to give Example 55 (110 mg, 0.237 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.5(brs, 1H), 8.38(d, 1H), 8.16(s, 1H), 7.88(s, 1H), 7.33(m, 2H), 7.16(m, 4H), 7.07(m, 2H), 5.1(quin, 1H), 3.84(s, 3H), 3.7(t, 2H), 3.5(br d, 2H), 3.29(s, 3H),3.26(br d, 2H), 3.04(m, 2H), 2.53(m, 4H), 1.43(d, 3H)| [M+H]+=477.2665
[0544] Example 56: 5-ethoxy-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidine] [Subunit]methyl]phenyl]ethyl]nicotinamide; hydrochloride
[0545] Example 56 was prepared according to General Method 11 using intermediate 7 (85.0 mg, 0.184 mmol), potassium carbonate (20.2 mg, 0.203 mmol, 1.1 eq.), and 1-bromo-2-methoxy-ethane (28.3 mg, 0.203 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) and then mixed with a dioxane solution of 4 N hydrogen chloride (2.0 eq.) to give Example 56 (60.0 mg, 0.115 mmol). 1H NMR(400 MHz, dmso-d6) δppm 10.31(br s, 1H), 9.07(d, 1H), 8.69(d, 1H), 8.46(d, 1H), 7.88(s, 1H), 7.38(d, 2H), 7.15(m, 6H), 5.18(quin, 1H), 4.19(q, 2H), 3.72(m, 2H), 3.51(m, 2H),3.29(s, 3H), 3.27(br d, 2H), 3.04(m, 2H), 2.52(br s, 4H), 1.49(d, 3H), 1.36(t, 3H). [M+H]+=518.2779
[0546] Example 57: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl ]-5-tetrahydropyran-4-yloxy-nicotinamide
[0547] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydropyran-4-yloxynicotinyl)amino]ethyl] Preparation of tert-butyl phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0548] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydropyran-4-yloxynicotinamide)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (630 mg, 1.49 mmol) and sodium 5-tetrahydropyran-4-yloxynicotinamide (365 mg, 1.49 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydropyran-4-yloxynicotinamide)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (593 mg, 0.945 mmol). [M+H]+=629.4.
[0549] Step B: Preparation of Example 57
[0550] Example 57 was prepared according to a modified general method 1 using 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydropyran-4-yloxynicotinanoyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (314 mg, 0.500 mmol) and a dichloromethane solution of hydrogen chloride (0.3 M). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain Example 57 (229 mg, 0.434 mmol). 1H NMR(500 MHz, dmso-d6) δ ppm 8.98(d, 1H), 8.67(br s, 1H), 8.41(t, 1H), 7.76(br s, 1H), 7.35(d,2H), 7.14(m, 2H), 7.13(m, 2H), 7.07(d, 2H), 5.2(m, 1H), 5.17(m, 1H), 3.9(m,1H), 3.85(m, 2H), 3.83(m, 2H), 3.83(m, 2H), 3.78(m, 1H), 3.08(m, 4H), 2.27(m,1H), 2(m, 1H), 1.48(m, 3H). [M+H]+ = 528.2627
[0551] Example 58: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-methoxyethyl)-2-azaspiro[3.3]hept- [6-methylene]methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide
[0552] Example 58 was prepared according to General Method 11 using Example 57 (70.0 mg, 0.132 mmol), potassium carbonate (14.5 mg, 0.145 mmol, 1.1 eq.), and 1-bromo-2-methoxy-ethane (20.3 mg, 0.145 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 58 (25.0 mg, 0.0426 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.65(d, 1H), 8.46(d,1H), 7.8(dd, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.17(quin, 1H), 4.75(tt, 1H), 3.86(m, 2H), 3.5(m, 2H), 3.28(m, 6H), 3.2(s, 3H), 2.98(br d, 4H),2.58(m, 2H), 1.99(m, 2H), 1.61(m, 2H), 1.49(d, 3H)| [M+H]+=586.3095
[0553] Example 59: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-isopropyl-4-piperidinyl)methyl]phenyl]ethyl ]-5-tetrahydropyran-4-yloxy-nicotinamide
[0554] Example 59 was prepared according to General Method 11 using Intermediate 8 (100 mg, 0.193 mmol), potassium carbonate (21.1 mg, 0.213 mmol, 1.1 eq.), and 2-iodopropane (36.3 mg, 0.213 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to obtain Example 59 (80.0 mg, 0.143 mmol). 1HNMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.64(d, 1H), 8.45(d, 1H), 7.79(m,1H), 7.33(d, 2H), 7.12(m, 4H), 7.06(d, 2H), 5.16(quin, 1H), 4.75(tt, 1H),3.85(m, 2H), 3.49(m, 2H), 2.7(m, 1H), 2.49(br s, 4H), 2.24(br s, 4H), 1.99(brd, 2H), 1.61(m, 2H), 1.48(d, 3H), 0.97(br s, 6H)| [M+H]+=558.3123
[0555] Example 60: N-[(1R)-1-[4-[(1-ethyl-4-piperidinyl)-(4-fluorophenyl)methyl]phenyl]ethyl ]-5-tetrahydropyran-4-yloxy-nicotinamide
[0556] Example 60 was prepared according to General Method 11 using Intermediate 8 (100 mg, 0.193 mmol), potassium carbonate (21.1 mg, 0.213 mmol, 1.1 eq.), and iodoethane (33.3 mg, 0.213 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 60 (20.0 mg, 0.0367 mmol). 1HNMR(400 MHz, dmso-d6) δ ppm 8.93(d, 1H), 8.64(d, 1H), 8.45(d, 1H), 7.79(m,1H), 7.33(d, 2H), 7.09(m, 6H), 5.16(quin, 1H), 4.74(tt, 1H), 3.85(m, 2H),3.49(m, 2H), 2.29(m, 10H), 1.98(br d, 2H), 1.61(m, 2H), 1.48(d, 3H), 0.98(t,3H)| [M+H]+=544.2969
[0557] Example 61: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-1-(tri- Fluoromethyl)pyrazole-4-carboxamide; hydrochloride
[0558] Example 61 was prepared according to General Method 7 using Intermediate 2 (139 mg, 0.294 mmol) and hydrogen chloride (0.367 mL, 0.735 mmol) to obtain Example 61 (156 mg, 0.285 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 9.02 (s, 1H), 8.97 (br s, 2H), 8.78 (d, 1H), 8.33 (s, 1H), 7.35 (d, 2H), 7.17 (d, 4H), 7.1 (d, 2H), 5.12 (quin, 1H), 3.11 (m, 4H), 2.43 (m, 4H), 1.45 (d, 3H) | [M+H]+=473.1955
[0559] Example 62: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl 5-(1,1-diketothiocyclohexane-4-yl)oxy-nicotinamide
[0560] Step A: Preparation of methyl 5-(1,1-diketothiocyclohexane-4-yl)oxynicotinic acid
[0561] According to General Method 10, methyl 5-(1,1-diketothiocyclohexane-4-yl)oxynicotinic acid was prepared using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.26 mmol) and 1,1-dioxothiocyclohexane-4-ol (0.449 mL, 3.26 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give methyl 5-(1,1-diketothiocyclohexane-4-yl)oxynicotinic acid (931 mg, 3.26 mmol). [M+H]+=286.1.
[0562] Step B: Preparation of sodium 5-(1,1-diketothiocyclohexane-4-yl)oxynicotinate
[0563] Sodium 5-(1,1-diketothiocyclohexane-4-yl)oxynicotinic acid was prepared using methyl 5-(1,1-diketothiocyclohexane-4-yl)oxynicotinic acid (931 mg, 3.26 mmol) to obtain sodium 5-(1,1-diketothiocyclohexane-4-yl)oxynicotinic acid (950 mg, 3.23 mmol). [M+H]+=272.1.
[0564] Step C: 6-[[4-[(1R)-1-[[5-(1,1-diketothiacyclohexane-4-yl)oxynicotinyl]amino]eth Preparation of tert-butyl heptane-2-carboxylate [3,3]-phenyl]-(4-fluorophenyl)methylene]-2-azaspiro[3,3]-heptane-2-carboxylate
[0565] According to general method 2B, 6-[[4-[(1R)-1-[[5-(1,1-diketothiacyclohexane-4-yl)oxynicotinic acid sodium salt (347 mg, 1.18 mmol, 1.0 eq.)]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (500 mg, 1.18 mmol) and sodium 5-(1,1-diketothiacyclohexane-4-yl)oxynicotinic acid sodium salt (347 mg, 1.18 mmol, 1.0 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain tert-butyl 6-[[4-[(1R)-1-[[5-(1,1-diketothiacyclohexane-4-yl)oxynicotinanoyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate (331 mg, 0.489 mmol). [M+H]+=576.2.
[0566] Step D: Preparation of Example 62
[0567] Example 62 was prepared according to General Method 1 using tert-butyl 6-[[4-[(1R)-1-[[5-(1,1-diketothiacyclohexane-4-yl)oxynicotinyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]-2-azaspiro[3.3]heptane-2-carboxylate (331 mg, 0.489 mmol) and a dichloromethane solution of hydrogen chloride (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 62 (150 mg, 0.260 mmol). 1H NMR(400 / 500 MHz,dmso-d6) δ ppm 8.96(d, 1H), 8.68(s, 1H), 8.53(m, 1H), 7.86(br s, 1H), 7.35(d,2H), 7.14(m, 2H), 7.12(m, 2H), 7.07(d, 2H), 5.18(quin, 1H), 4.89(m, 1H), 3.86(br s, 1H), 3.5(br s, 3H), 3.2(m, 4H), 3.05(m, 1H), 2.99(m, 3H), 2.24(m, 4H),1.48(d, 3H)| [M+H]+=576.2326
[0568] Example 63: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl 2,2,2-trifluoroacetic acid]-3-morpholino-benzamide;
[0569] Step A: Preparation of 3-morpholinobenzoic acid
[0570] 3-Morpholine benzoic acid was prepared using methyl 3-morpholinobenzoate (500 mg, 2.25 mmol) according to general method 9A, yielding 3-morpholinobenzoic acid (400 mg, 1.93 mmol). [M+H]+=208.1.
[0571] Step B: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-morpholinobenzoyl)amino]ethyl]phenyl]methylene Preparation of tert-butyl heptane-2-carboxylate [3.3]-2-azaspiro[3.3]-2-carboxylate
[0572] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-morpholinobenzoyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (500 mg, 1.18 mmol) and 3-morpholinobenzoic acid (245 mg, 1.18 mmol, 1.0 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-morpholinobenzoyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (720 mg, 1.17 mmol). [M+H]+ = 612.3.
[0573] Step C: Preparation of Example 63
[0574] Example 63 was prepared according to General Method 1 using tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-morpholinobenzoyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (700 mg, 1.14 mmol) and a dichloromethane solution of trifluoroacetic acid (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 63 (400 mg, 0.639 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.71(d,1H), 8.55(br s, 2H), 7.4(d, 1H), 7.33(m, 4H), 7.12(m, 7H), 5.17(quin, 1H),4.03(br t, 4H), 3.75(br s, 4H), 3.15(m, 8H), 1.48(d, 3H)| [M+H]+=512.2695
[0575] Example 64: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl 5-Isobutoxy-nicotinamide
[0576] Step A: Preparation of methyl 5-isobutoxynicotinic acid
[0577] 5-Isobutoxynicotinic acid methyl ester was prepared according to general method 10 using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.26 mmol) and 2-methylprop-1-ol (0.301 mL, 3.26 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 5-isobutoxynicotinic acid methyl ester (680 mg, 3.24 mmol). [M+H]+=210.1.
[0578] Step B: Preparation of sodium 5-isobutoxynicotinic acid
[0579] Sodium 5-isobutoxynicotinic acid was prepared using methyl 5-isobutoxynicotinic acid (683 mg, 3.26 mmol) according to General Method 9A, yielding sodium 5-isobutoxynicotinic acid (700 mg, 3.22 mmol). [M+H]+=196.1.
[0580] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isobutoxynicotinyl)amino]ethyl]phenyl]methylene Preparation of tert-butyl heptane-2-carboxylate [3.3]-2-azaspiro[3.3]-2-carboxylate
[0581] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isobutoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (500 mg, 1.18 mmol) and sodium 5-isobutoxynicotinic acid (257 mg, 1.18 mmol, 1.0 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isobutoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (368 mg, 0.613 mmol). [M+H]+=600.1.
[0582] Step D: Preparation of Example 64
[0583] Example 64 was prepared according to General Method 1 using tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-isobutoxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (368 mg, 0.613 mmol) and a dichloromethane solution of trifluoroacetic acid (0.3 M). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give Example 64 (400 mg, 0.320 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d,1H), 8.64(d, 1H), 8.42(d, 1H), 7.77(dd, 1H), 7.35(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.18(quin, 1H), 3.88(d, 2H), 3.67(m, 4H), 2.97(br d, 4H), 2.05(m,1H), 1.49(d, 3H), 1(d, 6H)| [M+H]+=500.2691
[0584] Example 65: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[B]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide
[0585] Example 65 was prepared using Example 57 (229 mg, 0.434 mmol) in a 5:1 dichloromethane / methanol mixture according to General Method 8. The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to give Example 65 (95.0 mg, 0.175 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.65(d,1H), 8.46(d, 1H), 7.79(dd, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.17(quin, 1H), 4.75(tt, 1H), 3.85(m, 2H), 3.5(m, 2H), 3.14(s, 4H), 2.95(br d,4H), 2.15(s, 3H), 1.99(br d, 2H), 1.61(m, 2H), 1.49(d, 3H)
[0586] Example 66: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hepta-6-imide] [Methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide
[0587] Example 66 was prepared according to General Method 11 using Example 57 (120 mg, 0.227 mmol), potassium carbonate (24.8 mg, 0.250 mmol, 1.1 eq.), and 2-bromoethanol (31.3 mg, 0.250 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (water / acetonitrile / ammonium bicarbonate) to obtain Example 66 (20.0 mg, 0.0349 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.65(d, 1H), 8.46(d, 1H),7.79(dd, 1H), 7.34(d, 2H), 7.11(m, 6H), 5.17(t, 1H), 4.75(tt, 1H), 4.31(br s,1H), 3.86(m, 2H), 3.5(br d, 2H), 3.26(br s, 2H), 3.16(s, 4H), 2.95(br d, 4H),2.38(m, 2H), 1.99(br d, 2H), 1.61(m, 2H), 1.49(d, 3H)| [M+H]+=572.2912
[0588] Example 67: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [3,3]hepta-2-yloxy-nicotinamide
[0589] Step A: Preparation of methyl 5-spiro[3.3]hept-2-yloxynicotinic acid
[0590] 5-Spiro[3.3]hepta-2-yloxynicotinic acid methyl ester was prepared according to general method 10 using methyl 5-hydroxypyridine-3-carboxylate (350 mg, 2.28 mmol) and spiro[3.3]hepta-2-ol (0.232 mL, 2.28 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain 5-spiro[3.3]hepta-2-yloxynicotinic acid methyl ester (514 mg, 2.07 mmol). [M+H]+=248.1.
[0591] Step B: Preparation of sodium 5-spiro[3.3]hept-2-yloxynicotinate
[0592] Sodium 5-spiro[3.3]hepta-2-yloxynicotinate was prepared from methyl 5-spiro[3.3]hepta-2-yloxynicotinate (514 mg, 2.08 mmol) according to General Method 9A, yielding sodium 5-spiro[3.3]hepta-2-yloxynicotinate (530 mg, 2.08 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+ = 234.1.
[0593] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-spiro[3.3]hept-2-yloxynicotinyl)amino]ethyl Preparation of tert-butyl heptane-2-carboxylate [3,3]-phenyl]methylene]-2-azaspiro[3,3]-heptane-2-carboxylate
[0594] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-spiro[3.3]hept-2-yloxynicotinic acid sodium salt)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (500 mg, 1.18 mmol) and 5-spiro[3.3]hept-2-yloxynicotinic acid sodium salt (302 mg, 1.18 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-spiro[3.3]hept-2-yloxynicotinic acid sodium salt)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (400 mg, 0.627 mmol). [M+H]+=638.5.
[0595] Step D: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 5-spiro[3.3]hept-2-yloxy-nicotinamide
[0596] According to General Method 1, N-[(1R)-1-[4-[2-azaspirospirospirospiro-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]phenyl]methylene]-2-azaspirospirospiro-2-carboxylic acid tert-butyl ester (400 mg, 0.627 mmol) was prepared using a dichloromethane solution (0.3 M) of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-spiro[3.3]hept-2-yloxy-nicotinamide]]ethyl]-5-spiro[3.3]hept-2-yloxy-nicotinamide] was prepared using trifluoroacetic acid. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[2-azaspiro[3.3]hepta-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-spiro[3.3]hepta-2-yloxy-nicotinamide (140 mg, 0.260 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 8.95(d, 1H), 8.64(d, 1H), 8.32(d, 1H), 7.61(dd, 1H), 7.34(d,2H), 7.13(m, 4H), 7.07(d, 2H), 5.17(m, 1H), 4.74(quin, 1H), 3.5(s, 4H), 2.98(m, 4H), 2.59(m, 2H), 2.02(m, 6H), 1.82(m, 2H), 1.49(d, 3H)| [M+H]+=538.2835
[0597] Step E: Preparation of Example 67
[0598] Example 67 was prepared in tetrahydrofuran using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-spiro[3.3]hept-2-yloxy-nicotinamide (90.0 mg, 0.167 mmol) according to General Method 8. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 67 (30.0 mg, 0.0544 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.94(d, 1H), 8.64(d, 1H),8.32(d, 1H), 7.61(dd, 1H), 7.34(d, 2H), 7.11(m, 6H), 5.17(t, 1H), 4.74(quin,1H), 3.13(s, 4H), 2.95(br d, 4H), 2.59(m, 2H), 2.15(s, 3H), 2.02(m, 6H), 1.82(m, 2H), 1.48(d, 3H)| [M+H]+=552.3035
[0599] Example 68: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-isopropyl-2-azaspiro[3.3]hept-6-ylidene) [Methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide
[0600] Example 68 was prepared according to General Method 11 using Example 57 (100 mg, 0.189 mmol), potassium carbonate (20.7 mg, 0.208 mmol, 1.1 eq.), and 2-iodopropane (35.4 mg, 0.208 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 68 (70 mg, 0.123 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.65(d, 1H), 8.46(d, 1H),7.79(dd, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.17(t, 1H), 4.75(tt,1H), 3.85(m, 2H), 3.5(m, 2H), 3.09(s, 4H), 2.94(br d, 4H), 2.14(quin, 1H),1.99(br d, 2H), 1.61(m, 2H), 1.49(d, 3H), 0.8(d, 6H)| [M+H]+=570.3116
[0601] Example 69: N-[(1R)-1-[4-[(2-ethyl-2-azaspiro[3.3]hept-6-ylidene)-(4-fluorophenyl)methyl [[B]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide
[0602] Example 69 was prepared according to General Method 11 using Example 57 (150 mg, 0.284 mmol), potassium carbonate (31.0 mg, 0.313 mmol, 1.1 eq.), and bromoethane (34.1 mg, 0.313 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 69 (50.0 mg, 0.0899 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.65(d, 1H), 8.46(d, 1H),7.79(dd, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.17(t, 1H), 4.75(m,1H), 3.86(m, 2H), 3.5(m, 2H), 3.12(s, 4H), 2.95(br d, 4H), 2.32(q, 2H), 1.99(br d, 2H), 1.61(m, 2H), 1.49(d, 3H), 0.83(t, 3H)
[0603] Example 70: 5-(1,1-diketothiocyclohexane-4-yl)oxy-N-[(1R)-1-[4-[(4-fluorophenyl)- (2-Methyl-2-azaspiro[3.3]hepta-6-ylidene)methyl]phenyl]ethyl]nicotinamide
[0604] Example 70 was prepared in tetrahydrofuran using Example 62 (94.0 mg, 0.163 mmol) according to General Method 8. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 70 (60.0 mg, 0.102 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.68(d, 1H), 8.53(d,1H), 7.86(m, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.18(quin, 1H), 4.89(br d, 1H), 3.21(m, 4H), 3.14(s, 4H), 2.95(br d, 4H), 2.23(br d, 4H), 2.16(s,3H), 1.49(d, 3H)| [M+H]+=590.2493
[0605] Example 71: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-3-morpholino-benzamide; 2,2,2-trifluoroacetic acid
[0606] Example 71 was prepared in tetrahydrofuran using Example 63 (150 mg, 0.240 mmol) according to General Method 8. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to obtain Example 71 (100 mg, 0.156 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.63(br s, 1H), 8.71(d, 1H), 7.4(s, 1H),7.33(m, 4H), 7.12(m, 7H), 5.17(t, 1H), 4.29(m, 2H), 4.01(m, 2H), 3.75(m, 4H),3.15(m, 8H), 2.79(d, 3H), 1.48(d, 3H)| [M+H]+=526.2875
[0607] Example 72: N-[(1R)-1-[4-[[2-(2,2-difluoroethyl)-2-azaspiro[3.3]hepta-6-ylidene]-(4- [Fluorophenyl]methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide; 2,2,2-trifluoroacetic acid
[0608] Example 72 was prepared according to General Method 11 using Example 57 (150 mg, 0.284 mmol), N,N-diisopropylamine (91.9 mg, 0.711 mmol, 2.5 eq.), and 1,1-difluoro-2-iodoethane (60.0 mg, 0.313 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 72 (80 mg, 0.113 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 10.52(m, 1H), 8.96(d, 1H),8.65(d, 1H), 8.47(d, 1H), 7.8(m, 1H), 7.36(d, 2H), 7.17(m, 4H), 7.08(br d,2H), 6.35(br t, 1H), 5.17(t, 1H), 4.75(tt, 1H), 4.29(br s, 4H), 3.86(m, 2H),3.77(m, 2H), 3.64(br s, 12H), 3.49(m, 2H), 3.15(br s, 5H), 1.99(br d, 2H),1.61(m, 2H), 1.49(d, 3H)| [M+H]+=592.2793
[0609] Example 73: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-5-isobutoxy-nicotinamide
[0610] Example 73 was prepared in tetrahydrofuran using Example 64 (100 mg, 0.200 mmol) according to General Method 8. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 73 (75.0 mg, 0.146 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.64(d, 1H), 8.42(d,1H), 7.76(dd, 1H), 7.34(d, 2H), 7.11(m, 6H), 5.18(t, 1H), 3.88(d, 2H), 3.21(br s, 4H), 2.96(br d, 4H), 2.2(s, 3H), 2.05(dt, 1H), 1.49(d, 3H), 1(d, 6H)|[M+H]+=514.2871
[0611] Example 74: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl [3R]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0612] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3R)-tetrahydrofuran-3-yl]oxynicotinyl]amino] Preparation of tert-butyl heptane-2-carboxylate [3,3]-ethyl[phenyl]methylene]-2-azaspiro[3,3]heptane-2-carboxylate
[0613] According to general method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid sodium salt (547 mg, 2.37 mmol)]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (1 g, 2.37 mmol) and sodium 5-[(3R)-tetrahydrofuran-3-yl]oxynicotinic acid sodium salt (547 mg, 2.37 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / ethyl acetate) to obtain tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3R)-tetrahydrofuran-3-yl]oxynicotinanoyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid (1.00 g, 1.63 mmol). [M+H]+=614.4.
[0614] Step B: Preparation of Example 74
[0615] Example 74 was prepared according to a modified general method 1 using a dichloromethane solution (0.3 M) of 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-[(3R)-tetrahydrofuran-3-yl]oxynicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (274 mg, 0.447 mmol) and trifluoroacetic acid (0.223 mL, 0.893 mmol, 2.0 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to obtain Example 74 (198 mg, 0.386 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.67(d, 1H), 8.41(d,1H), 7.75(dd, 1H), 7.35(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(m, 2H), 3.84(m, 4H), 3.5(s, 4H), 2.97(br d, 4H), 2.26(m, 1H), 1.99(m, 1H), 1.49(d, 3H)|[M+H]+ = 514.2503
[0616] Example 75: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hept-6-propane] [3R]-Tetrahydrofuran-3-yl]oxy-nicotinamide
[0617] Example 75 was prepared according to General Method 11 using Example 74 (110 mg, 0.214 mmol), potassium carbonate (32.6 mg, 0.236 mmol, 1.1 eq.), and 2-bromoethanol (29.4 mg, 0.236 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 75 (20.0 mg, 0.0359 mmol). 1HNMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(d, 1H), 8.41(d, 1H), 7.75(dd,1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(m, 2H), 4.31(t, 1H), 3.84(m,4H), 3.29(m, 2H), 3.16(s, 4H), 2.95(br d, 4H), 2.38(t, 2H), 2.26(m, 1H), 1.98(m, 1H), 1.49(d, 3H)| [M+H]+=558.2768
[0618] Example 76: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hepta-6-imide] [3S]-Tetrahydrofuran-3-yl]oxy-nicotinamide
[0619] Example 76 was prepared according to General Method 11 using Example 15 (90.0 mg, 0.175 mmol), potassium carbonate (26.6 mg, 0.193 mmol, 1.1 eq.), and 2-iodoethanol (33.2 mg, 0.193 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 76 (40.0 mg, 0.0717 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(d, 1H), 8.41(d, 1H),7.75(dd, 1H), 7.34(d, 2H), 7.11(m, 6H), 5.19(m, 2H), 4.32(t, 1H), 3.84(m,4H), 3.29(br s, 2H), 3.18(s, 4H), 2.95(br d, 4H), 2.4(m, 2H), 2.26(m, 1H),1.99(m, 1H), 1.49(d, 3H)| [M+H]+=558.2770
[0620] Example 77: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(3,3,3-trifluoropropyl)-2-azaspiro[3.3]] [Hept-6-ylidene]methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0621] Example 77 was prepared according to General Method 11 using Example 74 (110 mg, 0.214 mmol), potassium carbonate (32.6 mg, 0.236 mmol, 1.1 eq.), and 1,1,1-trifluoro-3-iodopropane (52.8 mg, 0.236 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 77 (45.0 mg, 0.0738 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(m, 1H), 8.66(d, 1H), 8.41(d,1H), 7.75(dd, 1H), 7.35(m, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(m, 2H), 3.83(m, 4H), 3.17(s, 4H), 2.95(m, 4H), 2.52(br s, 2H), 2.25(m, 3H), 1.98(m, 1H),1.49(d, 3H)| [M+H]+=610.2682
[0622] Example 78: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(3,3,3-trifluoropropyl)-2-azaspiro[3.3]] [Hept-6-ylidene]methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0623] Example 78 was prepared according to General Method 11 using Example 15 (80.0 mg, 0.156 mmol), potassium carbonate (23.68 mg, 0.171 mmol, 1.1 eq.), and 1,1,1-trifluoro-3-iodopropane (38.4 mg, 0.171 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 78 (52.0 mg, 0.0853 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(m, 1H), 8.66(d, 1H),8.41(d, 1H), 7.75(dd, 1H), 7.35(m, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(m,2H), 3.83(m, 4H), 3.17(s, 4H), 2.95(m, 4H), 2.52(br s, 2H), 2.25(m, 3H), 1.98(m, 1H), 1.49(d, 3H)| [M+H]+=610.2683
[0624] Example 79: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl 2,2,2-trifluoroacetic acid
[0625] Step A: Preparation of methyl 5-morpholinonicotinic acid
[0626] 5-Methyl morpholinonicotinate was prepared in toluene using methyl 5-bromopyridine-3-carboxylate (1.00 g, 4.63 mmol) and morpholine (0.607 mL, 6.94 mmol, 1.5 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give methyl 5-morpholinonicotinate (1.00 g, 4.50 mmol). [M+H]+ = 223.1.
[0627] Step B: Preparation of sodium 5-morpholinonicotinic acid
[0628] Sodium 5-morpholinonicotinate was prepared using methyl 5-morpholinonicotinate (1.00 g, 4.50 mmol) according to General Method 9A, yielding sodium 5-morpholinonicotinate (1.05 g, 4.56 mmol). [M+H]+=209.1.
[0629] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-morpholinonicotinyl)amino]ethyl]phenyl]methylene]- Preparation of tert-butyl 2-azaspiro[3.3]heptane-2-carboxylate
[0630] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-morpholinonicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (500 mg, 1.18 mmol) and sodium 5-morpholinonicotinic acid (272 mg, 1.18 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-morpholinonicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (414 mg, 0.676 mmol). [M+H]+=613.4.
[0631] Step D: Preparation of Example 79
[0632] Example 79 was prepared according to General Method 1 using a solution of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-morpholinonicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (414 mg, 0.677 mmol) in dichloromethane (0.3 M) and trifluoroacetic acid. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 79 (150 mg, 0.239 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d,1H), 8.55(br s, 2H), 8.5(d, 1H), 8.45(d, 1H), 7.75(s, 1H), 7.36(d, 2H), 7.15(m, 4H), 7.08(d, 2H), 5.18(m, 1H), 4.03(br t, 4H), 3.77(br d, 4H), 3.25(m,4H), 3.14(br d, 4H), 1.49(d, 3H)| [M+H]+=513.2668
[0633] Example 80: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-ethanolyl-2-azaspiro[3.3]hept-6-imide] [(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0634] Example 80 was prepared according to General Method 11 using Example 74 (150 mg, 0.292 mmol), potassium carbonate (36.33 mg, 0.263 mmol, 0.9 eq.), and 2-bromoacetamide (44.3 mg, 0.321 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 80 (45.0 mg, 0.0787 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(d, 1H), 8.42(d, 1H),7.75(m, 1H), 7.35(d, 2H), 7.15(d, 4H), 7.09(d, 2H), 5.19(m, 2H), 4.82(t, 1H),4.08(m, 4H), 3.85(m, 6H), 3.09(br d, 4H), 2.26(m, 1H), 1.98(m, 1H), 1.49(d,3H)| [M+H]+ = 572.2564
[0635] Example 81: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-methoxyethyl)-2-azaspiro[3.3]hepta- [6-methylene]methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0636] Example 81 was prepared according to General Method 11 using Example 74 (100 mg, 0.195 mmol), potassium carbonate (24.2 mg, 0.175 mmol, 0.90 eq.), and 1-bromo-2-methoxy-ethane (29.8 mg, 0.214 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 81 (80.0 mg, 0.140 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(d, 1H), 8.41(d, 1H),7.75(dd, 1H), 7.34(d, 2H), 7.11(m, 6H), 5.19(m, 2H), 3.84(m, 4H), 3.22(m,1H), 3.19(m, 8H), 2.95(br d, 4H), 2.46(m, 2H), 2.26(m, 1H), 1.99(br dd, 1H),1.49(d, 3H)| [M+H]+=572.2918
[0637] Example 82: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl 1,2-methylmorpholino-4-carboxamide; hydrochloride
[0638] Step A: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-2-methyl-morpho Preparation of porphyrin-4-carboxamide
[0639] According to General Method 7, N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-2-methyl-morpholine-4-carboxamide (89.0 mg, 0.203 mol) and hydrogen chloride (0.407 mmol) were used to prepare N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-2-methyl-morpholine-4-carboxamide (75.6 mg, 0.159 mol). 1H NMR(400 MHz, dmso-d6) δ ppm 9(m, 2H), 7.28(m, 2H),7.17(m, 4H), 7.07(m, 2H), 6.78(d, 1H), 4.83(quin, 1H), 3.85(br d, 3H), 3.36(m, 2H), 3.11(br s, 4H), 2.7(m, 1H), 2.35(m, 5H), 1.34(d, 3H), 1.06(dd, 3H). [M+H]+=438.2554
[0640] Step B: N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-2- Preparation of methyl-morpholine-4-carboxamide
[0641] N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-2-methyl-morpholine-4-carboxamide (40.3 mg, 0.0850 mmol) and 37 wt.% formaldehyde aqueous solution (213 mg, 0.195 mL, 2.55 mmol) in a 5:1 dichloromethane / methanol mixture were prepared according to modified General Method 8. After the reaction was complete, the mixture was quenched with saturated sodium bicarbonate and dissolved in dichloromethane. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-2-methyl-morpholine-4-carboxamide (38.4 mg, 0.0850 mmol). Considering the quantitative yield, it was used in the next step without further purification.
[0642] Step C: Preparation of Example 82
[0643] According to General Method 7, Example 82 was prepared using N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperidinyl)methyl]phenyl]ethyl]-2-methyl-morpholine-4-carboxamide (38.0 mg, 0.0850 mol) and hydrogen chloride (0.213 mmol), yielding Example 82 (37.5 mg, 0.0768 mol). 1H NMR(400 MHz, dmso-d6) δ ppm10.51(br s, 1H), 7.29(m, 2H), 7.17(m, 4H), 7.06(m, 2H), 6.78(d, 1H), 4.83(m,1H), 3.82(m, 3H), 3.38(m, 4H), 3(br d, 2H), 2.74(d, 3H), 2.69(m, 1H), 2.51(m,4H), 2.38(m, 1H), 1.35(d, 3H), 1.06(dd, 3H)| [M+H]+=452.2680
[0644] Example 83: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-methoxyethyl)-2-azaspiro[3.3]hept- [6-methylene]methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0645] Example 83 was prepared according to General Method 11 using Example 15 (170 mg, 0.331 mmol), potassium carbonate (41.2 mg, 0.298 mmol, 0.90 eq.), and 1-bromo-2-methoxy-ethane (50.6 mg, 0.364 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 83 (70.0 mg, 0.122 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(d, 1H), 8.41(d, 1H),7.75(m, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(m, 2H), 3.84(m, 4H),3.24(t, 2H), 3.19(s, 3H), 3.16(s, 4H), 2.95(br d, 4H), 2.46(m, 2H), 2.27(m,1H), 1.99(m, 1H), 1.49(d, 3H)| [M+H]+=572.2923
[0646] Example 84: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl] [Phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0647] Example 84 was prepared according to General Method 11 using N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide (209 mg, 0.417 mmol), potassium carbonate (46.1 mg, 0.333 mmol, 0.80 eq.), and 1-bromo-2-methoxy-ethane (63.7 mg, 0.458 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 84 (150 mg, 0.268 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.94(d, 1H), 8.66(d, 1H), 8.41(d,1H), 7.75(m, 1H), 7.33(d, 2H), 7.11(m, 4H), 7.05(d, 2H), 5.18(m, 2H), 3.84(m,4H), 3.41(m, 2H), 3.21(s, 3H), 2.46(m, 6H), 2.23(m, 5H), 1.98(m, 1H), 1.48(d,3H)| [M+H]+=560.2892
[0648] Example 85: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)-4-piperidinyl]methyl]benzene [[ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide]
[0649] Example 85 was prepared according to General Method 11 using intermediate 8 (176 mg, 0.341 mmol), potassium carbonate (42.5 mg, 0.307 mmol, 0.9 eq.), and 2-bromoethanol (46.9 mg, 0.376 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 85 (110 mg, 0.197 mmol). 1HNMR(400 MHz, dmso-d6) δ ppm 8.93(d, 1H), 8.64(d, 1H), 8.45(d, 1H), 7.79(dd,1H), 7.33(d, 2H), 7.11(m, 4H), 7.05(d, 2H), 5.16(quin, 1H), 4.74(tt, 1H),4.36(t, 1H), 3.85(m, 2H), 3.49(m, 4H), 2.45(br s, 4H), 2.39(t, 2H), 2.23(m,4H), 1.99(br d, 2H), 1.61(m, 2H), 1.48(d, 3H)| [M+H]+=560.2925
[0650] Example 86: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl 1-(2,2,2-trifluoroethyl)pyrazole-4-carboxamide
[0651] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino] Preparation of tert-butyl ethyl[ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0652] According to general method 2C, 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic acid (105 mg, 0.514 mmol)]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared using a dichloromethane solution (0.15 M) of intermediate 3 (239 mg, 0.565 mmol, 1.1 eq.) and 1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (307 mg) was obtained. (mg, 0.514 mmol), considering quantitative yield.
[0653] Step B: Preparation of Example 86
[0654] Example 86 was prepared according to General Method 1 using a solution of crude 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (307 mg, 0.513 mmol) in dichloromethane (0.3 M) and trifluoroacetic acid. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 86 (108 mg, 0.217 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.53(d, 1H), 8.33(s, 1H), 8.03(s, 1H), 7.31(d, 2H), 7.13(m, 4H),7.07(s, 2H), 5.19(d, 2H), 5.1(m, 1H), 3.49(br s, 4H), 2.96(br d, 4H), 1.44(d,3H)| [M+H]+=499.2086
[0655] Example 87: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [3,5]non-8-ylmethyl]nicotinamide; 2,2,2-trifluoroacetic acid
[0656] Step A: Preparation of methyl 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinic acid
[0657] Methyl 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinate was prepared at room temperature using methyl 5-(bromomethyl)pyridine-3-carboxylate (500 mg, 2.17 mmol), potassium carbonate (474 mg, 3.26 mmol, 1.5 eq.), and 2-oxa-8-azaspiro[3.5]nonane (304 mg, 2.39 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give methyl 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinate (517 mg, 1.87 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.99(d, 1H), 8.74(d, 1H), 8.21(t, 1H), 4.23(d, 2H), 4.16(d, 2H), 3.9(s, 3H), 3.61(s, 2H), 2.49(m, 2H), 2.3(m, 2H), 1.63(br s, 2H), 1.44(quin, 2H). [M+H]+=277.1.
[0658] Step B: Preparation of sodium 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinate
[0659] Sodium 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinate was prepared using methyl 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinate (610 mg, 2.21 mmol) to obtain sodium 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinate (627 mg, 2.21 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+ = 263.1.
[0660] Step C: Preparation of Example 87
[0661] Example 87 was prepared in N,N-dimethylformamide using intermediate 4 (150 mg, 0.446 mmol) and sodium 5-(2-oxa-8-azaspiro[3.5]non-8-ylmethyl)nicotinate (127 mg, 0.446 mmol) according to general method 2B. The crude residue was dissolved in methanol, eluted with PoraPak RxnCX, and purified by reversed-phase column chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 87 (75.0 mg, 0.108 mmol). [M+H]+=581.3264
[0662] Example 88: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl ]3-isopropyl-isooxazolo[5,4-b]pyridine-5-carboxamide
[0663] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-isopropylisoxazolo[5,4-b]pyridine-5-carbonyl) Preparation of tert-butyl [amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0664] According to the modified general method 2C, a 0.15 M solution of intermediate 3 (225 mg, 0.532 mmol, 1.1 eq.) and 3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid (105 mg, 0.484 mmol) in dichloromethane was used. 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-isopropylisoxazolo[5,4-b]pyridine-5-carbonyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared to yield crude 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-isopropylisoxazolo[5,4-b]pyridine-5-carbonyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (295 mg, 0.484 mmol), considering quantitative yield.
[0665] Step B: Preparation of Example 88
[0666] Example 88 was prepared according to General Method 1 using a solution of crude 6-[(4-fluorophenyl)-[4-[(1R)-1-[(3-isopropylisoxazolo[5,4-b]pyridine-5-carbonyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (295 mg, 0.483 mmol) in dichloromethane (0.3 M) and trifluoroacetic acid. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 88 (61.4 mg, 0.117 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 9.12(m, 2H), 8.93(d, 1H), 7.38(d, 2H), 7.12(m, 6H), 5.24(quin,1H), 3.85(m, 1H), 3.49(m, 5H), 2.97(br d, 4H), 1.54(d, 3H), 1.45(d, 6H). [M+H]+=511.2503.
[0667] Example 89: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl] [Phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide
[0668] Example 89 was prepared according to General Method 11 using intermediate 8 (100 mg, 0.194 mmol), potassium carbonate (21.1 mg, 0.213 mmol, 1.1 eq.), and 1-bromo-2-methoxy-ethane (29.6 mg, 0.213 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 89 (25.0 mg, 0.0436 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.93(d, 1H), 8.64(d, 1H), 8.45(d, 1H),7.78(s, 1H), 7.33(d, 2H), 7.09(m, 6H), 5.16(t, 1H), 4.74(tt, 1H), 3.85(m,2H), 3.49(br t, 2H), 3.41(t, 2H), 3.21(s, 3H), 2.44(m, 6H), 2.22(m, 4H), 1.99(m, 2H), 1.61(m, 2H), 1.48(d, 3H)| [M+H]+=574.3068
[0669] Example 90: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl] [Phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0670] Step A: Preparation of 4-[bromo-(4-fluorophenyl)methylene]piperidine
[0671] According to General Method 1, 4-[bromo-(4-fluorophenyl)methylene]piperidine was prepared using a solution of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-spiro[3.3]hept-2-yloxynicotinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (5.00 g, 13.5 mmol) in dichloromethane (0.3 M) and hydrogen chloride to give crude N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-spiro[3.3]hept-2-yloxynicotinamide (3.60 g, 13 mmol), which was used in the next step without further purification. [M+H]+=272.0.
[0672] Step B: Preparation of 4-[bromo-(4-fluorophenyl)methylene]-1-(2-methoxyethyl)piperidine
[0673] According to General Method 11, 4-[bromo-(4-fluorophenyl)methylene]-1-(2-methoxyethyl)piperidine was prepared using 4-[bromo-(4-fluorophenyl)methylene]piperidine (1.90 g, 7.03 mmol), potassium carbonate (0.780 g, 5.64 mmol, 0.80 eq.), and 1-bromo-2-methoxy-ethane (1.10 g, 7.73 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give 4-[bromo-(4-fluorophenyl)methylene]-1-(2-methoxyethyl)piperidine (2.12 g, 6.46 mmol). [M+H]+ = 330.0.
[0674] Step C: 2-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]benzene Preparation of [ethyl]isoindoline-1,3-quinone
[0675] According to general method 4A, 2-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)piperidine]methyl]phenyl]ethyl]isoindoline-1,3-quinone was prepared using 4-[bromo-(4-fluorophenyl)methylene]-1-(2-methoxyethyl)piperidine (2.12 g, 6.46 mmol) and 2-[(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl))phenyl]ethyl]isoindoline-1,3-dione (2.92 g, 7.75 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to give 2-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]isoindoline-1,3-quinone (2.86 g, 5.74 mmol). [M+H]+=499.2.
[0676] Step D: [(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]phenyl] Preparation of ethylamine
[0677] According to General Method 3, [(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinylidene]methyl]phenyl]ethyl]isoindoline-1,3-quinone (2.86 g, 2.50 mmol) and hydrazine (2.37 mL, 28.7 mmol) were used to prepare [(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinylidene]methyl]phenyl]ethyl]amine. The crude residue was purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain [(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinylidene]methyl]phenyl]ethyl]amine (1.40 g, 0.235 mmol). [M+H]+ = 369.1.
[0678] Step E: Preparation of Example 90: Example 90 was prepared in N,N-dimethylformamide using [(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]amine (250 mg, 0.678 mmol) and sodium 5-[(3S)-tetrahydrofuran-3-yl]oxynicotinate (157 mg, 0.678 mmol). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 90 (150 mg, 0.268 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 8.94(d, 1H), 8.66(d, 1H), 8.41(d, 1H), 7.75(m, 1H), 7.33(d,2H), 7.09(m, 6H), 5.18(m, 2H), 3.84(m, 4H), 3.41(t, 2H), 3.21(s, 3H), 2.45(m,6H), 2.24(m, 5H), 1.99(m, 1H), 1.48(d, 3H)| [M+H]+=560.2915
[0679] Example 91: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl 1-(trifluoromethyl)pyrazole-4-carboxamide; 2,2,2-trifluoroacetic acid
[0680] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(trifluoromethyl)pyrazole-4-carbonyl]amino]ethyl]benzene Preparation of tert-butyl heptane-2-carboxylate [3.3]methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0681] According to the modified general method 2C, 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(trifluoromethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared using a dichloromethane solution (0.15 M) of intermediate 3 (401 mg, 0.948 mmol, 1.1 eq.) and 1-(trifluoromethyl)pyrazole-4-carboxylic acid (160 mg, 0.862 mmol) to give crude 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(trifluoromethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (504 mg, 0.862 mmol), considering quantitative yield.
[0682] Step B: Preparation of Example 91
[0683] Example 91 was prepared according to General Method 1 using a solution of crude 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(trifluoromethyl)pyrazole-4-carbonyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (504 mg, 0.860 mmol) in dichloromethane (0.3 M) and trifluoroacetic acid. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 91 (153 mg, 0.316 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.98(s, 1H), 8.72(d, 1H), 8.56(m, 2H), 8.33(s, 1H), 7.34(d, 2H),7.15(m, 4H), 7.07(d, 2H), 5.12(m, 1H), 4.04(s, 4H), 3.14(br d, 4H), 1.46(d,3H)| [M+H]+=485.1958
[0684] Example 92: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)] [Methyl]phenyl]ethyl]pyridine-3-carboxamide diastereomeric 1
[0685] Step A: Preparation of the racemic mixture of 5-(3,3-difluorocyclopentoxy)nicotinic acid methyl ester
[0686] 5-(3,3-difluorocyclopentoxy)nicotinic acid methyl ester was prepared according to General Method 10 using methyl 5-hydroxypyridine-3-carboxylate (630 mg, 4.11 mmol) and 3,3-difluorocyclopentanol (502 mg, 4.11 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give the racemic 5-(3,3-difluorocyclopentoxy)nicotinic acid methyl ester (517 mg, 2.01 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.71 (d, 1H), 8.52 (d, 1H), 7.75 (dd, 1H), 5.18 (m, 1H), 3.9 (m, 3H), 2.69 (m, 1H), 2.14 (m, 5H). [M+H]+=258.1.
[0687] Step B: Preparation of methyl 5-(3,3-difluorocyclopentoxy)pyridine-3-carboxylate enantiomer 1
[0688] According to General Method 13, methyl 5-(3,3-difluorocyclopentoxy)nicotinic acid ester enantiomer 1 was prepared by reverse-phase reaction (ethanol / acetonitrile / diethylamine) using a racemic mixture of 5-(3,3-difluorocyclopentoxy)nicotinic acid ester (500 mg, 1.94 mmol) to obtain methyl 5-(3,3-difluorocyclopentoxy)nicotinic acid ester enantiomer 1 (132 mg, 0.513 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.71 (d, 1H), 8.52 (d, 1H), 7.75 (dd, 1H), 5.18 (m, 1H), 3.9 (m, 3H), 2.69 (m, 1H), 2.14 (m, 5H). [M+H]+=258.1.
[0689] Step C: Preparation of enantiomer 1 of sodium 5-(3,3-difluorocyclopentoxy)nicotinate
[0690] According to General Method 9A, sodium 5-(3,3-difluorocyclopentoxy)nicotinic acid enantiomer 1 was prepared using methyl 5-[(1S)-3,3-difluorocyclopentoxy]nicotinic acid enantiomer 1 (132 mg, 0.513 mmol), yielding sodium 5-(3,3-difluorocyclopentoxy)nicotinic acid enantiomer 1 (627 mg, 0.513 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+ = 244.0.
[0691] Step D: 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridine-3-carbonyl]amino]ethyl]benzene Preparation of diastereomeric 1 of tert-butyl [4-fluorophenyl]methylene [piperidine-1-carboxylate]
[0692] According to general method 2B, the diastereomer 1 of 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridine-3-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (210 mg, 0.512 mmol) and sodium 5-(3,3-difluorocyclopentoxy)nicotinic acid enantiomer 1 (136 mg, 0.512 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give diastereomer 1 of 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridin-3-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (285 mg, 0.448 mmol). [M+H]+=636.1.
[0693] Step E: Preparation of Example 92
[0694] Example 92 was prepared according to General Method 1 using a solution of 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridin-3-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylate tert-butyl diastereomer 1 (285 mg, 0.448 mmol) in dichloromethane (0.3 M) and hydrogen chloride. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 92 (145 mg, 0.271 mmol). 1H NMR(400 MHz, dmso-d6)δ ppm 8.94(m, 1H), 8.66(m, 1H), 8.4(m, 1H), 7.73(m, 1H), 7.33(m, 2H), 7.1(s,4H), 7.04(m, 2H), 5.15(m, 2H), 2.74(m, 4H), 2.64(m, 1H), 2.17(m, 9H), 1.48(d,3H)| [M+H]+=536.2505
[0695] Example 93: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)] [Methyl]phenyl]ethyl]pyridine-3-carboxamide diastereomeric 2
[0696] Step A: Preparation of enantiomer 2 of methyl 5-(3,3-difluorocyclopentoxy)pyridine-3-carboxylate
[0697] According to General Method 13, methyl 5-(3,3-difluorocyclopentoxy)nicotinic acid ester enantiomer 2 was prepared by reverse-phase reaction (ethanol / acetonitrile / diethylamine) using a racemic mixture of 5-(3,3-difluorocyclopentoxy)nicotinic acid ester (500 mg, 1.94 mmol) to obtain methyl 5-(3,3-difluorocyclopentoxy)nicotinic acid ester enantiomer 2 (136 mg, 0.529 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.71 (d, 1H), 8.52 (d, 1H), 7.75 (dd, 1H), 5.18 (m, 1H), 3.9 (m, 3H), 2.69 (m, 1H), 2.14 (m, 5H). rt [M+H]+=258.1.
[0698] Step B: Preparation of enantiomer 2 of sodium 5-(3,3-difluorocyclopentoxy)nicotinic acid
[0699] According to General Method 9A, sodium 5-(3,3-difluorocyclopentoxy)nicotinic acid enantiomer 2 was prepared from methyl 5-[(1R)-3,3-difluorocyclopentoxy]nicotinic acid enantiomer 2 (137 mg, 0.533 mmol) to obtain sodium 5-(3,3-difluorocyclopentoxy)nicotinic acid enantiomer 2 (141 mg, 0.533 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+=244.0.
[0700] Step C: 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridine-3-carbonyl]amino]ethyl]benzene Preparation of diastereomer 2 of tert-butyl [4-fluorophenyl]methylene [piperidine-1-carboxylate]
[0701] According to general method 2B, the diastereomer 2 of 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridine-3-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 2 (220 mg, 0.536 mmol) and sodium 5-(3,3-difluorocyclopentoxy)nicotinic acid enantiomer 2 (142 mg, 0.536 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give diastereomer 2 of 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridin-3-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylic acid tert-butyl ester (280 mg, 0.441 mmol). [M+H]+=636.1.
[0702] Step D: Preparation of Example 93
[0703] Example 93 was prepared according to General Method 1 using a solution of 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)pyridin-3-carbonyl]amino]ethyl]phenyl]-(4-fluorophenyl)methylene]piperidine-1-carboxylate tert-butyl diastereomer 2 (280 mg, 0.441 mmol) in dichloromethane (0.3 M) and hydrogen chloride. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 93 (135 mg, 0.252 mmol). 1H NMR(400 MHz, dmso-d6)δ ppm 8.94(m, 1H), 8.66(m, 1H), 8.4(m, 1H), 7.73(m, 1H), 7.33(m, 2H), 7.1(s,4H), 7.04(m, 2H), 5.15(m, 2H), 2.74(m, 4H), 2.64(m, 1H), 2.17(m, 9H), 1.48(d,3H)|[M+H]+=536.2509
[0704] Example 94: N-[(1R)-1-[4-[(2-ethyl-2-azaspiro[3.3]hept-6-ylidene)-(4-fluorophenyl)methyl [3R]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide
[0705] Example 94 was prepared according to General Method 11 using Example 74 (200 mg, 0.389 mmol), potassium carbonate (43.1 mg, 0.312 mmol, 0.80 eq.), and iodoethane (66.8 mg, 0.428 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 94 (105 mg, 0.194 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(m, 1H), 8.67(d, 1H), 8.41(d, 1H), 7.76(dd, 1H),7.33(s, 2H), 7.13(m, 4H), 7.07(m, 2H), 5.17(m, 2H), 3.83(m, 4H), 3.14(s, 4H),2.96(m, 4H), 2.36(m, 2H), 2.23(m, 1H), 2.01(m, 1H), 1.49(d, 3H), 0.84(m, 3H)|[M+H]+=542.2805
[0706] Example 95: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperyl)] [Pyridyl]methyl]phenyl]ethyl]nicotinamide diastereomer 1
[0707] According to the modified general method 8, Example 95 was prepared in tetrahydrofuran using Example 92 (118 mg, 0.220 mmol). The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to obtain Example 95 (95.0 mg, 0.173 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.94(d, 1H), 8.66(d, 1H), 8.4(d,1H), 7.75(dd, 1H), 7.33(d, 2H), 7.12(m, 4H), 7.05(m, 2H), 5.14(m, 2H), 2.69(m, 1H), 2.29(m, 12H), 2.16(s, 3H), 1.97(m, 1H), 1.49(d, 3H). [M+H]+=550.2670
[0708] Example 96: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(1-methyl-4-piperyl)] [Pyridyl]methyl]phenyl]ethyl]nicotinamide diastereomer 2
[0709] Example 96 was prepared in tetrahydrofuran using the modified general method 8, with the sample from Example 93 (108 mg, 0.202 mmol). The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to obtain Example 96 (70.0 mg, 0.127 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.94(d, 1H), 8.66(d, 1H), 8.4(d,1H), 7.75(dd, 1H), 7.33(d, 2H), 7.12(m, 4H), 7.05(m, 2H), 5.14(m, 2H), 2.69(m, 1H), 2.29(m, 12H), 2.16(s, 3H), 1.97(m, 1H), 1.49(d, 3H). [M+H]+=550.2671
[0710] Example 97: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxamide
[0711] Example 97 was prepared using a modified general method 8, in a 5:1 dichloromethane / methanol mixture, with 60.0 mg (0.120 mmol) of Example 86 and 37 wt.% aqueous formaldehyde solution (301 mg, 0.276 mL, 3.61 mmol). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxamide (40.9 mg, 0.0798 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.51(d, 1H), 8.33(s,1H), 8.03(s, 1H), 7.31(d, 2H), 7.12(m, 4H), 7.05(d, 2H), 5.2(q, 2H), 5.11(m,1H), 3.13(s, 4H), 2.94(m, 4H), 2.15(s, 3H), 1.44(d, 3H)| [M+H]+=513.2266
[0712] Example 98: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-3-isopropyl-isooxazolo[5,4-b]pyridine-5-carboxamide
[0713] Example 98 was prepared according to modified General Method 8 using Example 88 (36.0 mg, 0.0705 mmol) and 37 wt.% aqueous formaldehyde solution (176 mg, 0.162 mL, 2.12 mmol) in a 5:1 dichloromethane / methanol mixture. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 98 (22.3 mg, 0.0425 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.12(m, 2H), 8.93(m, 1H), 7.38(m, 2H),7.14(m, 4H), 7.08(m, 2H), 5.19(m, 1H), 3.5(m, 1H), 3.14(s, 4H), 2.95(m, 4H),2.15(s, 3H), 1.53(d, 3H), 1.45(d, 6H)| [M+H]+=525.2656
[0714] Example 99: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-methoxyethyl)-2-azaspiro[3.3]hepta- [6-methylene]methyl]phenyl]ethyl]-1-(trifluoromethyl)pyrazole-4-carboxamide; 2,2,2-trifluoroacetic acid
[0715] Step A: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 1-(trifluoromethyl)pyrazole-4-carboxamide
[0716] According to General Method 1, N-[(1R)-1-[4-[2-azaspiro[3.3]heptane-6-yenyl-(4-fluorophenyl)methyl]phenyl]ethyl]-1-(trifluoromethyl)pyrazole-4-carboxylate was prepared using a 0.3 M solution of crude 6-[(4-fluorophenyl)-[4-[(1R)-1-[[1-(trifluoromethyl)pyrazole-4-carbonyl]amino]ethyl]-1-(trifluoromethyl)pyrazole-4-carboxamide] in dichloromethane and trifluoroacetic acid. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-1-(trifluoromethyl)pyrazole-4-carboxamide (153 mg, 0.316 mmol).
[0717] Step B: Preparation of Example 99
[0718] Example 99 was prepared according to General Method 11 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-1-(trifluoromethyl)pyrazole-4-carboxamide (50 mg, 0.103 mmol), potassium carbonate (12.8 mg, 0.093 mmol, 0.90 eq.), and 1-bromo-2-methoxy-ethane (16.4 mg, 0.114 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to obtain Example 99 (29.2 mg, 0.0538 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.83(m, 1H), 8.98(s, 1H),8.71(d, 1H), 8.33(s, 1H), 7.34(d, 2H), 7.16(br d, 4H), 7.05(m, 2H), 5.1(m,1H), 4.17(m, 4H), 3.49(m, 2H), 3.33(m, 2H), 3.27(s, 3H), 3.13(m, 4H), 1.46(d,3H)| [M+H]+=543.2370
[0719] Example 100: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl] [Ethyl]-5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinamide
[0720] Step A: Preparation of methyl 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinic acid
[0721] According to General Method 12, methyl 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinic acid was prepared in 1,4-dioxane using methyl 5-bromopyridine-3-carboxylate (0.500 g, 2.31 mmol) and 4-oxa-7-azaspiro[2.5]octane hydrogen chloride (1:1) (416 mg, 2.78 mmol, 1.2 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to give methyl 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinic acid (323 mg, 1.17 mmol). 1HNMR(400 MHz, dmso-d6) δ ppm 8.54(m, 1H), 8.5(m, 1H), 7.65(m, 1H), 3.87(s,3H), 3.8(m, 2H), 3.31(s, 4H), 3.24(s, 2H), 0.7(m, 4H). [M+H]+=249.0.
[0722] Step B: Preparation of sodium 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinate
[0723] Sodium 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinate was prepared using methyl 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinate (320 mg, 1.29 mmol) to give sodium 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinate (330 mg, 1.29 mmol, considering quantitative yield). This compound was used in the next step without further purification. [M+H]+ = 235.0.
[0724] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(4-oxa-7-azaspiro[2.5]octane-7-yl) nicotine Preparation of tert-butyl 2-azellaspiro[3.3]heptane-2-carboxylate
[0725] According to general method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinic acid sodium salt (182 mg, 0.710 mmol)]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (300 mg, 0.710 mmol) and 5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester. The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid (289 mg, 0.452 mmol). [M+H]+=639.3.
[0726] Step D: Preparation of Example 100
[0727] Example 100 was prepared in solvent-free conditions using tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (289 mg, 0.452 mmol) and trifluoroacetic acid (0.693 mL, 9.05 mmol, 20 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 100 (137 mg, 0.254 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.88(d, 1H), 8.47(d, 1H), 8.41(d,1H), 7.63(s, 1H), 7.34(d, 2H), 7.11(m, 6H), 5.18(t, 1H), 3.82(m, 2H), 3.49(m,4H), 3.36(m, 2H), 3.22(m, 3H), 2.98(m, 4H), 1.49(d, 3H), 0.7(m, 4H)| [M+H]+=539.2812.
[0728] Example 101: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[2,5]octane-7-yl]nicotinamide]
[0729] Example 101 was prepared in tetrahydrofuran using the modified general method 8, with the sample from Example 100 (100 mg, 0.186 mmol). The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to obtain Example 101 (83.0 mg, 0.150 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.87(d, 1H), 8.47(d, 1H), 8.41(d,1H), 7.63(m, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.06(d, 2H), 5.18(t, 1H), 3.82(m,2H), 3.29(m, 2H), 3.22(s, 2H), 3.17(s, 4H), 2.95(br d, 4H), 2.17(s, 3H), 1.49(d, 3H), 0.7(m, 4H)| [M+H]+=553.2969
[0730] Example 102: N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]-3-(6- Keto-1-methyl-3-pyridyl)-4-methylbenzamide; 2,2,2-trifluoroacetic acid
[0731] Step A: Preparation of 3-(6-keto-1-methyl-3-pyridyl)-4-methylbenzoic acid
[0732] According to modified General Method 4B, 3-(6-keto-1-methyl-3-pyridinyl)-4-methylbenzoic acid was prepared using 5-bromo-1-methylpyridin-2(1H)-one (500 mg, 2.66 mmol), potassium phosphate (1.41 g, 6.65 mmol), and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl))benzoic acid (383 mg, 2.127 mmol) to give 3-(6-keto-1-methyl-3-pyridinyl)-4-methylbenzoic acid (330 mg, 1.36 mmol). [M+H]+=240.0.
[0733] Step B: 4-[(4-fluorophenyl)-[4-[(1R)-1-[[3-(6-keto-1-methyl-3-pyridyl)-4-methyl-benzene] Preparation of tert-butyl formyl[formyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylate
[0734] To a stirred solution of (R)-4-((4-(1-aminoethyl)phenyl)(4-fluorophenyl)methylene)piperidin-1-carboxylic acid tert-butyl ester (320 mg, 0.779 mmol) and 4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzoic acid (284 mg, 1.17 mmol) in dichloromethane (10.0 mL), N,N-diisopropylethylamine (302 mg, 2.34 mmol) was added, and the solution was cooled to 0 °C. A solution of 50 wt.% propylphosphonic anhydride in ethyl acetate (372 mg, 1.17 mmol) was added, and the mixture was stirred at room temperature until the reaction was complete. The mixture was partitioned between ethyl acetate and water. The layers were separated, and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give (R)-4-((4-fluorophenyl)(4-(1-(4-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzoyl)ethyl)phenyl)methylene)piperidin-1-carboxylic acid tert-butyl ester (320 mg, 0.503 mmol). LCMS: 636.6 [M+H]+
[0735] Step C: Preparation of Example 102
[0736] Example 102 was prepared according to General Method 1 using a solution of 4-[(4-fluorophenyl)-[4-[(1R)-1-[[3-(6-keto-1-methyl-3-pyridyl)-4-methyl-benzoyl]amino]ethyl]phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.315 mmol) in dichloromethane (0.3 M) and trifluoroacetic acid (1.0 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to obtain Example 102 (35.0 mg, 0.065 mmol). 1H-NMR(400MHz, DMSO-d6): δ 8.77(d, J = 8.00 Hz, 1H), 8.65(s, 2H), 7.80-7.76(m, 3H),7.52(dd, J = 2.80, 9.40 Hz, 1H), 7.39-7.35(m, 3H), 7.17(d, J = 7.20 Hz, 4H), 7.17(d, J = 7.20 Hz, 2H), 6.47(d, J = 9.20 Hz, 1H), 5.18(t, J = 7.20 Hz, 1H), 3.49(s, 3H), 3.13(s, 4H), 2.44-2.39(m, 4H), 2.31(s, 3H), 1.47(d, J = 6.80 Hz, 3H). [M+H]+=536.3.
[0737] Example 103: 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)-N-[(1R)-1-[4-[(4-fluoro phenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]benzamide
[0738] Step A: Preparation of methyl 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate
[0739] According to General Method 12, methyl 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate was prepared in 1,4-dioxane using methyl 3-bromobenzoate (477 mg, 2.22 mmol) and 1,4-thiazacyclohexane 1,1-dioxide (300 mg, 2.21 mmol, 1.0 eq.). The crude residue was purified by silica gel column chromatography (ethyl acetate / cyclohexane) to give methyl 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate (285 mg, 1.06 mmol). 1H NMR (400 MHz, dmso-d6) δ ppm 7.52(m, 1H), 7.42(m, 1H), 7.38(m, 1H), 7.32(d, 1H), 3.84(s, 3H), 3.81(m, 4H), 3.15(m, 4H). [M+H]+=270.0.
[0740] Step B: Preparation of 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate
[0741] 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate was prepared from methyl 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate (285 mg, 1.06 mmol) according to General Method 9A, yielding 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate (360 mg, 1.30 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 7.51 (d, 1H), 7.35 (d, 1H), 7.13 (t, 1H), 6.93 (dd, 1H), 3.7 (s, 4H), 3.3 (m, 4H). [M+H]+ = 255.4.
[0742] Step C: Preparation of Example 103
[0743] Example 103 was prepared in N,N-dimethylformamide using intermediate 4 (170 mg, 0.377 mmol) and 3-(1,1-diketo-1,4-thiazacyclohexane-4-yl)benzoate (105 mg, 0.377 mmol) according to general method 2B. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 103 (45.0 mg, 0.078 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.71(d, 1H), 7.44(s, 1H), 7.33(m,5H), 7.18(br d, 1H), 7.13(m, 4H), 7.06(d, 1H), 5.18(t, 1H), 3.81(m, 4H), 3.15(m, 4H), 3.13(s, 4H), 2.94(br d, 4H), 2.15(s, 3H), 1.49(d, 3H)| [M+H]+=574.2529
[0744] Example 104: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxy)] [Ethyl]-4-piperidinyl]methyl]phenyl]ethyl]pyridine-3-carboxamide; 2,2,2-trifluoroacetic acid diastereomer 1
[0745] Step A: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl] Preparation of [phenyl]ethyl]nicotinamide diastereomer 1
[0746] According to General Method 1, 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 1 was prepared under solvent-free conditions using 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)nicotinyl]amino]ethyl]nicotinamide diastereomer 1 (250 mg, 0.393 mmol) and trifluoroacetic acid (0.602 mL, 7.87 mmol, 20 eq.). The crude residue was dissolved in methanol and eluted with a PoraPak RxnCX to give 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 1 (192 mg, 0.359 mmol). [M+H]+ = 536.1.
[0747] Step B: Preparation of Example 104
[0748] Example 104 was prepared according to General Method 11 using 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 1 (95.0 mg, 0.177 mmol), potassium carbonate (22.1 mg, 0.160 mmol, 0.90 eq.), and 1-bromo-2-methoxy-ethane (27.1 mg, 0.195 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 104 (92.0 mg, 0.130 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.57(m, 1H), 8.97(d,1H), 8.67(d, 1H), 8.42(d, 1H), 7.77(t, 1H), 7.38(d, 2H), 7.17(m, 4H), 7.1(d,2H), 5.17(quin, 1H), 5.13(m, 1H), 3.64(t, 2H), 3.51 / 3.05(2m, 4H), 3.3(m+s,5H), 2.68(m, 1H), 2.5(m, 4H), 2.28(m, 4H), 1.96(m, 1H), 1.48(d, 3H)| [M+H]+=594.2932
[0749] Example 105: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)] [4-piperidinyl]methyl]phenyl]ethyl]pyridine-3-carboxamide diastereomeric 1
[0750] Example 105 was prepared according to General Method 11 using 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 1 (95 mg, 0.177 mmol), potassium carbonate (22.1 mg, 0.160 mmol, 0.90 eq.), and 2-bromoethanol (24.4 mg, 0.195 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 105 (65.0 mg, 0.112 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.94(d, 1H), 8.66(d, 1H), 8.4(d,1H), 7.75(dd, 1H), 7.33(d, 2H), 7.11(m, 4H), 7.05(d, 2H), 5.15(m, 2H), 4.35(t, 1H), 3.48(m, 2H), 2.68(m, 1H), 2.45(br d, 4H), 2.38(t, 2H), 2.26(m, 8H),1.97(br dd, 1H), 1.48(d, 3H)|[M+H]+=580.2777
[0751] Example 106: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxy)] [Ethyl]-4-piperidinyl]methyl]phenyl]ethyl]pyridine-3-carboxamide diastereomeric 2
[0752] Step A: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl] Preparation of 2 diastereomers of phenyl[ethyl]nicotinamide
[0753] According to General Method 1, 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 2 was prepared under solvent-free conditions using 4-[[4-[(1R)-1-[[5-(3,3-difluorocyclopentoxy)nicotinyl]amino]ethyl]nicotinamide diastereomer 2 (380 mg, 0.598 mmol) and trifluoroacetic acid (0.96 mL, 12.0 mmol, 20 eq.). The crude residue was dissolved in methanol and eluted with a PoraPak RxnCX to give 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 2 (290 mg, 0.541 mmol). [M+H]+ = 536.1.
[0754] Step B: Preparation of Example 106
[0755] Example 106 was prepared according to General Method 11 using 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 2 (140 mg, 0.261 mmol), potassium carbonate (32.5 mg, 0.235 mmol, 0.90 eq.), and 1-bromo-2-methoxy-ethane (40 mg, 0.288 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 106 (37.0 mg, 0.0623 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.95(d, 1H), 8.67(d,1H), 8.4(d, 1H), 7.75(t, 1H), 7.33(d, 2H), 7.11(m, 4H), 7.05(d, 2H), 5.17(quin, 1H), 5.13(m, 1H), 3.42(t, 2H), 3.22(s, 3H), 2.67(m, 1H), 2.46(t+m,7H), 2.22(m, 8H), 1.96(m, 1H), 1.48(d, 3H)| [M+H]+=594.2934
[0756] Example 107: 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-hydroxyethyl)] [4-piperidinyl]methyl]phenyl]ethyl]pyridine-3-carboxamide diastereomeric 2
[0757] Example 107 was prepared according to General Method 11 using 5-(3,3-difluorocyclopentoxy)-N-[(1R)-1-[4-[(4-fluorophenyl)-(4-piperidinyl)methyl]phenyl]ethyl]nicotinamide diastereomer 2 (140 mg, 0.261 mmol), potassium carbonate (32.5 mg, 0.235 mmol, 0.90 eq.), and 2-bromoethanol (35.9 mg, 0.288 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 107 (96.0 mg, 0.166 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.94(d, 1H), 8.67(d, 1H), 8.4(d,1H), 7.75(m, 1H), 7.33(d, 2H), 7.09(m, 6H), 7.08(s, 1H), 5.16(m, 2H), 4.35(brs, 1H), 3.48(br d, 2H), 2.68(qd, 1H), 2.4(m, 6H), 2.25(m, 8H), 1.48(d, 3H)|[M+H]+=580.2777
[0758] Example 108: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[ ...][[[[[[[[[[[[][[[[[[[[[[][[[[[[[[[][[[[[[[][[[[[[[[[][[[[[[][[[[[[[]
[0759] Step A: Preparation of methyl 5-(3,6-dihydro-2H-pyran-4-yl)nicotinic acid
[0760] Methyl 5-(3,6-dihydro-2H-pyran-4-yl)nicotinic acid was prepared according to General Method 4B using methyl 5-bromopyridin-3-carboxylate (500 mg, 2.31 mmol) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentane (584 mg, 2.78 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give methyl 5-(3,6-dihydro-2H-pyran-4-yl)nicotinic acid (446 mg, 2.03 mmol). [M+H]+ = 220.0.
[0761] Step B: Preparation of methyl 5-tetrahydropyran-4-ylnicotinic acid ester
[0762] According to modified general method 14, methyl 5-tetrahydropyran-4-ylnicotinate was prepared using methyl 5-(3,6-dihydro-2H-pyran-4-yl)nicotinate (446 mg, 2.03 mmol) to obtain crude methyl 5-tetrahydropyran-4-ylnicotinate (415 mg, 1.86 mmol), which was used in the next step without further purification. [M+H]+=222.0.
[0763] Step C: Preparation of sodium 5-tetrahydropyran-4-ylnicotinate
[0764] Sodium 5-tetrahydropyran-4-ylnicotinate was prepared from methyl 5-tetrahydropyran-4-ylnicotinate (415 mg, 1.88 mmol) according to General Method 9A, yielding sodium 5-tetrahydropyran-4-ylnicotinate (429 mg, 1.88 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+=208.0.
[0765] Step D: Preparation of Example 108
[0766] Example 108 was prepared in N,N-dimethylformamide using intermediate 4 (250 mg, 0.743 mmol) and sodium 5-tetrahydropyran-4-ylnicotinate (170 mg, 0.743 mmol) according to general method 2B. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 108 (60.0 mg, 0.114 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 8.95(d, 1H), 8.89(d, 1H), 8.63(d, 1H), 8.13(t, 1H), 7.35(d,2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(t, 1H), 3.97(m, 2H), 3.45(m, 2H), 3.13(s,4H), 2.95(br d, 5H), 2.15(s, 3H), 1.74(m, 4H), 1.5(d, 3H)| [M+H]+=526.2861
[0767] Example 109: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl] [Ethyl]-5-(3-pyridyl)nicotinamide; 2,2,2-trifluoroacetic acid
[0768] Step A: Preparation of methyl 5-(3-pyridyl)nicotinic acid
[0769] 5-(3-pyridyl)nicotinic acid methyl ester was prepared according to General Method 4B using methyl 5-bromopyridin-3-carboxylate (500 mg, 2.31 mmol) and 3-pyridylboronic acid (341 mg, 2.78 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 5-(3-pyridyl)nicotinic acid methyl ester (495 mg, 2.31 mmol). [M+H]+ = 215.0.
[0770] Step B: Preparation of sodium 5-(3-pyridyl)nicotinic acid
[0771] Sodium 5-(3-pyridyl)nicotinate was prepared from methyl 5-(3-pyridyl)nicotinate (495 mg, 2.31 mmol) according to General Method 9A, yielding sodium 5-(3-pyridyl)nicotinate (513 mg, 2.31 mmol), considering quantitative yield. This compound was used in the next step without further purification. [M+H]+=201.1.
[0772] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(3-pyridyl)nicotinyl]amino]ethyl]phenyl] Preparation of tert-butyl [methyl]-2-azaspiro[3.3]heptane-2-carboxylate
[0773] According to General Method 2B, 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(3-pyridyl)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using intermediate 3 (500 mg, 1.18 mmol) and sodium 5-(3-pyridyl)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid. The crude residue was purified by silica gel column chromatography (ethyl acetate / methanol) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(3-pyridyl)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (473 mg, 0.782 mmol). [M+H]+=605.2.
[0774] Step D: Preparation of Example 109
[0775] Example 109 was prepared in solvent-free conditions using tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[[5-(3-pyridyl)nicotinyl]amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate (470 mg, 0.777 mmol) and trifluoroacetic acid (1.19 mL, 15.5 mmol, 20 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 109 (295 mg, 0.477 mmol). 1H NMR(400MHz, dmso-d6) δ ppm 9.09(m, 4H), 8.69(dd, 1H), 8.59(t, 1H), 8.55(br s, 2H),8.29(dt, 1H), 7.61(dd, 1H), 7.39(d, 2H), 7.15(m, 4H), 7.09(d, 2H), 5.22(m,1H), 4.03(br t, 4H), 3.14(br d, 4H), 1.52(d, 3H)| [M+H]+=505.2394
[0776] Example 110: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-methoxyethyl)-2-azaspiro[3.3]] [Hept-6-ylidene]methyl]phenyl]ethyl]-5-morpholino-nicotinamide; 2,2,2-trifluoroacetic acid
[0777] Step A: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 5-morpholino-nicotinamide
[0778] N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]morpholino-nicotinamide was prepared under solvent-free conditions using 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-morpholinonicotinyl)amino]ethyl]phenyl]ethyl]morpholino-nicotinamide. The crude residue was dissolved in methanol and eluted with a PoraPak RxnCX elution apparatus to obtain N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-morpholino-nicotinamide (233 mg, 0.455 mmol). [M+H]+=513.1.
[0779] Step B: Preparation of Example 110
[0780] Example 110 was prepared according to General Method 11 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-morpholino-nicotinamide (110 mg, 0.215 mmol), potassium carbonate (26.7 mg, 0.193 mmol, 0.90 eq.), and 1-bromo-2-methoxy-ethane (32.8 mg, 0.236 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 110 (65.0 mg, 0.0945 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.8(br s, 1H), 8.94(br d, 1H), 8.49(t,1H), 8.45(d, 1H), 7.74(s, 1H), 7.36(dd, 2H), 7.13(m, 6H), 5.18(m, 1H), 4.2(m,4H), 3.77(br d, 4H), 3.65(m, 1H), 3.49(m, 2H), 3.32(br s, 2H), 3.27(s, 3H),3.25(m, 4H), 3.13(m, 4H), 1.49(dd, 3H)| [M+H]+=571.3073
[0781] Example 111: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hepta-6- [methylene]methyl]phenyl]ethyl]-5-morpholino-nicotinamide; 2,2,2-trifluoroacetic acid
[0782] Example 111 was prepared according to General Method 11 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-morpholino-nicotinamide (110 mg, 0.215 mmol), potassium carbonate (26.7 mg, 0.193 mmol, 0.90 eq.), and 2-bromoethanol (29.5 mg, 0.236 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 111 (25.0 mg, 0.0373 mmol). 1HNMR(400 MHz, dmso-d6) δ ppm 9.74(br s, 1H), 8.94(br d, 1H), 8.47(m, 2H), 7.75(s, 1H), 7.36(dd, 2H), 7.13(m, 6H), 5.18(br dd, 2H), 4.22(m, 4H), 3.77(br s,4H), 3.57(m, 2H), 3.21(m, 11H), 1.49(dd, 3H)| [M+H]+=557.2919.
[0783] Example 112: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [By]phenyl]ethyl]-5-(3-pyridyl)nicotinamide
[0784] Example 112 was prepared in tetrahydrofuran using the modified general method 8, with the sample from Example 109 (150 mg, 0.243 mmol). The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to obtain Example 112 (105 mg, 0.203 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.1(d, 1H), 9.08(s, 1H), 9.06(d,1H), 9.04(d, 1H), 8.67(dd, 1H), 8.58(t, 1H), 8.24(dt, 1H), 7.57(ddd, 1H),7.38(d, 2H), 7.13(m, 4H), 7.08(d, 2H), 5.23(quin, 1H), 3.15(s, 4H), 2.95(brd, 4H), 2.16(s, 3H), 1.52(d, 3H)| [M+H]+=519.2549
[0785] Example 113: 5-(2,5-dihydrofuran-3-yl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2- [3.3]hepta-6-ylidene]methyl]phenyl]ethyl]nicotinamide
[0786] Step A: Preparation of methyl 5-(2,5-dihydrofuran-3-yl)nicotinic acid
[0787] Methyl 5-(2,5-dihydrofuran-3-yl)nicotinic acid was prepared according to General Method 4B using methyl 5-bromopyridin-3-carboxylate (1.00 g, 4.63 mmol) and 2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentane (1.09 g, 5.55 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give methyl 5-(2,5-dihydrofuran-3-yl)nicotinic acid (929 mg, 4.53 mmol).
[0788] Step B: Preparation of sodium 5-(2,5-dihydrofuran-3-yl)nicotinic acid
[0789] Sodium 5-(2,5-dihydrofuran-3-yl)nicotinate was prepared using methyl 5-(2,5-dihydrofuran-3-yl)nicotinate (200 mg, 0.975 mmol) according to general method 9A, yielding sodium 5-(2,5-dihydrofuran-3-yl)nicotinate (207 mg, 0.971 mmol).
[0790] Step C: Preparation of Example 113
[0791] Example 113 was prepared in N,N-dimethylformamide using sodium 5-(2,5-dihydrofuran-3-yl)nicotinate (190 mg, 0.892 mmol) and intermediate 4 (300 mg, 0.892 mmol) according to general method 2B. The crude residue was dissolved in methanol, eluted with PoraPak RxnCX, and purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 113 (70 mg, 0.137 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.02(d, 1H), 8.94(d,1H), 8.79(d, 1H), 8.21(t, 1H), 7.35(d, 2H), 7.11(m, 6H), 6.75(s, 1H), 5.2(t,1H), 4.97(td, 2H), 4.77(m, 2H), 3.13(s, 4H), 2.95(br d, 4H), 2.15(s, 3H), 1.5(d, 3H)| [M+H]+=510.2548
[0792] Example 114: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[ ...][[[[[[[[[[[[][[[[[[[[[[][[[[[[[[[][[[[[[[][[[[[[[[[][[[[[][[[[[[[][
[0793] Step A: Preparation of methyl 5-tetrahydrofuran-3-ylnicotinic acid ester
[0794] 5-Tetrahydrofuran-3-ylnicotinic acid methyl ester was prepared using 5-(2,5-dihydrofuran-3-yl)nicotinic acid methyl ester (929 mg, 4.53 mmol) according to General Method 14. The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain 5-tetrahydrofuran-3-ylnicotinic acid methyl ester (500 mg, 2.41 mmol). 1H NMR(400 MHz, dmso-d6) δppm 8.95(m, 1H), 8.77(m, 1H), 8.16(m, 1H), 4.05(m, 1H), 3.97(m, 1H), 3.89(s,3H), 3.81(m, 1H), 3.63(m, 1H), 3.54(m, 1H), 2.37(m, 1H), 1.95(m, 1H). [M+H]+=208.0.
[0795] Step B: Preparation of enantiomer 1 of methyl 5-tetrahydrofuran-3-ylnicotinic acid ester
[0796] According to general method 13, methyl 5-tetrahydrofuran-3-ylnicotinic acid ester enantiomer 1 was prepared by SFC (carbon dioxide / ethanol / diethylamine) using methyl 5-tetrahydrofuran-3-ylnicotinic acid ester (500 mg, 2.41 mmol) to obtain methyl 5-tetrahydrofuran-3-ylnicotinic acid ester enantiomer 1 (175 mg, 0.844 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm8.95(m, 1H), 8.77(m, 1H), 8.16(m, 1H), 4.05(m, 1H), 3.97(m, 1H), 3.89(s, 3H),3.81(m, 1H), 3.63(m, 1H), 3.54(m, 1H), 2.37(m, 1H), 1.95(m, 1H). [M+H]+=208.0.
[0797] Step C: Preparation of sodium 5-tetrahydrofuran-3-ylnicotinate enantiomer 1
[0798] According to general method 9A, sodium 5-tetrahydrofuran-3-ylnicotinic acid enantiomer 1 was prepared using methyl 5-tetrahydrofuran-3-ylnicotinic acid (175 mg, 0.845 mmol) to obtain sodium 5-tetrahydrofuran-3-ylnicotinic acid enantiomer 1 (181 mg, 0.841 mmol).
[0799] Step D: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinyl)amino]ethyl]benzene Preparation of diastereomeric 1 of tert-butyl heptane-2-carboxylate [3.3]methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0800] According to general method 2B, the diastereomer 1 of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinamide)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using sodium 5-tetrahydrofuran-3-ylnicotinamide)enantioic acid sodium ester 1 (178 mg, 0.828 mmol) and intermediate 3 (350 mg, 0.828 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain tert-butyl 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinanoyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylate diastereomer 1 (307 mg, 0.514 mmol).
[0801] Step E: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 5-tetrahydrofuran-3-yl-nicotinamide diastereomer 1
[0802] According to General Method 1, N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomer 1 was prepared under solvent-free conditions using 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinamide)amino]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide. The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to give N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomer 1 (198 mg, 0.398 mmol).
[0803] Step F: Preparation of Example 114
[0804] Example 114 was prepared according to modified General Method 8 using a tetrahydrofuran solution (0.02 M) of N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomeric 1 (90.0 mg, 0.181 mmol). The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to give Example 114 (73.0 mg, 0.143 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.98(m,1H), 8.89(m, 1H), 8.64(m, 1H), 8.1(m, 1H), 7.34(m, 2H), 7.13(m, 4H), 7.07(m,2H), 5.17(m, 1H), 4.06(m, 1H), 3.98(m, 1H), 3.81(m, 1H), 3.62(m, 1H), 3.49(m,1H), 3.13(s, 4H), 2.95(m, 4H), 2.36(m, 1H), 2.15(s, 3H), 1.95(m, 1H), 1.49(m, 3H) | [M+H]+=512.2714
[0805] Example 115: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[ ...][[[[[[[[[[[[[][[[[[[[[[[][[[[[[[[[][[[[[[[][[[[[[[[[][[[[[[][[[[[[[
[0806] Step A: Preparation of enantiomer 2 of methyl 5-tetrahydrofuran-3-ylnicotinic acid ester
[0807] According to general method 13, methyl 5-tetrahydrofuran-3-ylnicotinic acid ester enantiomer 2 was prepared by SFC (carbon dioxide / ethanol / diethylamine) using methyl 5-tetrahydrofuran-3-ylnicotinic acid ester (500 mg, 2.41 mmol) to obtain methyl 5-tetrahydrofuran-3-ylnicotinic acid ester enantiomer 2 (182 mg, 0.876 mmol). 1H NMR(400 MHz, dmso-d6) δppm 8.95(m, 1H), 8.77(m, 1H), 8.16(m, 1H), 4.05(m, 1H), 3.97(m, 1H), 3.89(s,3H), 3.81(m, 1H), 3.63(m, 1H), 3.54(m, 1H), 2.37(m, 1H), 1.95(m, 1H). [M+H]+=208.0.
[0808] Step B: Preparation of sodium 5-tetrahydrofuran-3-ylnicotinate enantiomer 2
[0809] According to general method 9A, sodium 5-tetrahydrofuran-3-ylnicotinic acid enantiomer 2 was prepared using methyl 5-tetrahydrofuran-3-ylnicotinic acid ester enantiomer 2 (182 mg, 0.878 mmol) to obtain sodium 5-tetrahydrofuran-3-ylnicotinic acid enantiomer 2 (188 mg, 0.874 mmol).
[0810] Step C: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinyl)amino]ethyl]benzene Preparation of diastereomeric 2 of tert-butyl heptane-2-carboxylate [3.3]methylene]-2-azaspiro[3.3]heptane-2-carboxylate
[0811] According to general method 2B, the diastereomer 2 of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinamide)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in N,N-dimethylformamide using sodium 5-tetrahydrofuran-3-ylnicotinamide)enantioic acid sodium salt 2 (178 mg, 0.828 mmol) and intermediate 3 (350 mg, 0.828 mmol). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to obtain 2 diastereomers of 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinanoyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (356 mg, 0.596 mmol).
[0812] Step D: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 5-tetrahydrofuran-3-yl-nicotinamide diastereomer 2
[0813] According to General Method 1, N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomer 2 was prepared under solvent-free conditions using 6-[(4-fluorophenyl)-[4-[(1R)-1-[(5-tetrahydrofuran-3-ylnicotinamide)amino]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide]ethyl]heptan-6-yl-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide. The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to give N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomer 2 (207 mg, 0.416 mmol).
[0814] Step E: Preparation of Example 115
[0815] Example 115 was prepared according to modified General Method 8 using a tetrahydrofuran solution (0.02 M) of N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomeric 2 (100 mg, 0.201 mmol). The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to obtain Example 115 (85.0 mg, 0.166 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.98(m,1H), 8.89(m, 1H), 8.64(m, 1H), 8.1(m, 1H), 7.34(m, 2H), 7.13(m, 4H), 7.07(m,2H), 5.17(m, 1H), 4.06(m, 1H), 3.98(m, 1H), 3.81(m, 1H), 3.62(m, 1H), 3.49(m,1H), 3.13(s, 4H), 2.95(m, 4H), 2.36(m, 1H), 2.15(s, 3H), 1.95(m, 1H), 1.49(m, 3H) | [M+H]+=512.2695
[0816] Example 116: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hepta-6- [methylene]methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide; 2,2,2-trifluoroacetic acid diastereomer 1
[0817] Example 116 was prepared according to General Method 11 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomer 1 (100 mg, 0.201 mmol), potassium carbonate (25.0 mg, 0.181 mmol, 0.90 eq.), and 2-bromoethanol (27.6 mg, 0.221 mmol, 1.1 eq.). The crude residue was dissolved in methanol, eluted with PoraPak RxnCX, and purified by reversed-phase chromatography (water / acetonitrile / trifluoroacetic acid) to obtain Example 116 (49.0 mg, 0.0747 mmol). 1H NMR(400 MHz, dmso-d6)δ ppm 9.74(m, 1H), 9(dd, 1H), 8.9(t, 1H), 8.64(d, 1H), 8.12(d, 1H), 7.37(m,2H), 7.16(m, 4H), 7.08(t, 2H), 5.19(td, 2H), 4.22(m, 2H), 4.14(m, 2H), 4.06(t, 1H), 3.98(m, 1H), 3.82(q, 1H), 3.62(m, 1H), 3.56(m, 2H), 3.5(m, 1H), 3.17(m, 6H), 2.36(m, 1H), 1.97(qd, 1H), 1.5(dd, 3H). [M+H]+=542.2796
[0818] Example 117: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hepta-6- [methylene]methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide; 2,2,2-trifluoroacetic acid diastereomer 2
[0819] Example 117 was prepared according to General Method 11 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-tetrahydrofuran-3-yl-nicotinamide diastereomer 2 (100 mg, 0.201 mmol), potassium carbonate (25.0 mg, 0.181 mmol, 0.90 eq.), and 2-bromoethanol (27.6 mg, 0.221 mmol, 1.1 eq.). The crude residue was dissolved in methanol, eluted with PoraPak RxnCX, and purified by reversed-phase chromatography (water / acetonitrile / trifluoroacetic acid) to obtain Example 117 (27.0 mg, 0.0412 mmol). 1H NMR(400 MHz, dmso-d6)δ ppm 9.73(m, 1H), 8.99(dd, 1H), 8.91(m, 1H), 8.64(d, 1H), 8.12(d, 1H), 7.37(m, 2H), 7.15(m, 4H), 7.08(m, 2H), 5.19(td, 1H), 4.22(m, 2H), 4.13(m, 2H),4.06(t, 1H), 3.98(td, 1H), 3.82(q, 1H), 3.62(m, 1H), 3.56(m, 2H), 3.5(m, 1H),3.17(m, 6H), 2.36(m, 1H), 1.98(m, 1H), 1.51(m, 3H). [M+H]+=542.2797
[0820] Example 118: N-[(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl] [[B]phenyl]ethyl]-1-(oxetane-3-ylmethyl)pyrazole-4-carboxamide
[0821] Step A: Preparation of ethyl 1-(oxetane-3-ylmethyl)pyrazole-4-carboxylate
[0822] according toModified General Method 11 prepared 1-(oxetane-3-ylmethyl)pyrazole-4-carboxylate ethyl ester using 1H-pyrazole-4-carboxylate (300 mg, 2.14 mmol), cesium carbonate (698 mg, 2.14 mmol), and 3-(bromomethyl)oxetane (404 mg, 2.57 mmol, 1.2 eq.) to obtain 1-(oxetane-3-ylmethyl)pyrazole-4-carboxylate ethyl ester (425 mg, 2.02 mmol), which was used in the next step without further purification. 1H NMR(400 MHz, dmso-d6)δ ppm 8.37(s, 1H), 7.85(s, 1H), 4.62(dd, 2H), 4.45(d, 2H), 4.4(t, 2H), 4.21(q, 2H), 3.41(m, 1H), 1.26(t, 3H).
[0823] Step B: Preparation of 1-(oxetane-3-ylmethyl)pyrazole-4-carboxylic acid
[0824] 1-(oxetane-3-ylmethyl)pyrazole-4-carboxylic acid was prepared according to General Method 9 B using ethyl 1-(oxetane-3-ylmethyl)pyrazole-4-carboxylic acid (425 mg, 2.02 mmol) to give 1-(oxetane-3-ylmethyl)pyrazole-4-carboxylic acid (307 mg, 1.69 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 12.35 (br s, 1H), 8.28 (s, 1H), 7.79 (s, 1H), 4.63 (dd, 2H), 4.44 (d, 2H), 4.4 (t, 2H), 3.41 (m, 1H).
[0825] Step C: Preparation of Example 118
[0826] Example 118 was prepared in dichloromethane using 1-(oxetane-3-ylmethyl)pyrazol-4-carboxylic acid (100 mg, 0.521 mmol) and [(1R)-1-[4-[(4-fluorophenyl)-[1-(2-methoxyethyl)-4-piperidinyl]methyl]phenyl]ethyl]amine (211 mg, 0.574 mmol, 1.1 eq.). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 118 (153 mg, 0.288 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 8.33(d, 1H), 8.19(s, 1H), 7.9(s, 1H), 7.29(d, 2H), 7.1(m, 4H),7.03(d, 2H), 5.1(s, 1H), 4.62(m, 2H), 4.4(m, 4H), 3.41(m, 3H), 3.21(s, 3H), 2.46(m, 6H), 2.22(m, 4H), 1.42(d, 3H). [M+H]+=533.2927
[0827] Example 119: 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)-N-[(1R)-1-[4-[(4-fluoro phenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; 2,2,2-trifluoroacetic acid
[0828] Step A: Preparation of methyl 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinic acid
[0829] According to General Method 12, methyl 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinic acid was prepared in 1,4-dioxane using methyl 5-bromopyridine-3-carboxylate (320 mg, 1.48 mmol) and 1,4-thiazacyclohexane 1,1-dioxide (200 mg, 1.48 mmol). The crude residue was purified by silica gel chromatography (cyclohexane / ethyl acetate) to give methyl 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinic acid (226 mg, 0.835 mmol). 1H NMR (400 MHz, dmso-d6) δ ppm 8.62(m, 1H), 8.53(d, 1H), 7.79(m, 1H), 3.9(br d,4H), 3.88(s, 3H), 3.17(m, 4H). [M+H]+=271.8.
[0830] Step B: Preparation of 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinate
[0831] 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinate was prepared using methyl 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinate (225 mg, 0.832 mmol) to give 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinate (326 mg, 1.17 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.45 (d, 1H), 8.25 (d, 1H), 7.7 (dd, 1H), 3.77 (m, 4H), 3.15 (m, 4H). [M+H]+ = 257.0.
[0832] Step C: Preparation of Example 119
[0833] Example 119 was prepared in N,N-dimethylformamide using general method 2C, with 5-(1,1-diketo-1,4-thiazacyclohexane-4-yl)nicotinate (99.0 mg, 0.210 mmol, 1.1 eq.) and intermediate 4 (65.0 mg, 0.190 mmol). The crude product was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to give Example 119 (42.0 mg, 0.0610 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.59(br s, 1H), 8.91(d, 1H),8.52(d, 1H), 8.49(s, 1H), 7.77(br s, 1H), 7.36(d, 2H), 7.13(m, 6H), 5.19(brt, 1H), 4.3(br d, 2H), 4.01(m, 2H), 3.89(br s, 4H), 3.19(m, 4H), 3.14(br d,4H), 2.8(d, 3H), 1.5(d, 3H)| [M+H]+=575.2433
[0834] Example 120: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [3R]-6-[(3R)-tetrahydrofuran-3-yl]oxy-pyrazinamide
[0835] Step A: Preparation of 6-[(3R)-tetrahydrofuran-3-yl]oxypyrazine
[0836] according toModified General Method 15A was used to prepare 6-[(3R)-tetrahydrofuran-3-yl]oxypyrazine using (3R)-tetrahydrofuran-3-ol (229 mg, 2.61 mmol) and methyl 6-chloropyrazine-2-carboxylate (150 mg, 0.951 mmol). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give 6-[(3R)-tetrahydrofuran-3-yl]oxypyrazine (93.0 mg, 0.208 mmol). [M+H]+ = 210.9.
[0837] Step B: Preparation of Example 120
[0838] Example 120 was prepared in N,N-dimethylformamide using general method 2B, with 6-[(3R)-tetrahydrofuran-3-yl]oxypyrazine (86.4 mg, 0.193 mmol) and intermediate 4 (65.0 mg, 0.193 mmol). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 120 (22.0 mg, 0.0416 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.8(d, 1H), 8.71(s, 1H), 8.49(s, 1H), 7.37(d,2H), 7.13(m, 4H), 7.07(d, 2H), 5.88(br dd, 1H), 5.22(m, 1H), 3.97(dd, 1H),3.83(m, 3H), 3.13(s, 4H), 2.95(br d, 4H), 2.32(m, 1H), 2.15(s, 3H), 2.06(m,1H), 1.55(d, 3H)| [M+H]+=529.2566
[0839] Example 121: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [4,5]decane-2-yl]nicotinamide
[0840] Step A: Preparation of methyl 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinic acid
[0841] according toModified General Method 12 was used to prepare methyl 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinic acid in 1,4-dioxane using methyl 5-bromopyridin-3-carboxylate (300 mg, 1.39 mmol), BINAP (2,2′-bis(diphenylphosphine)-1,1′-binaphthyl; 86.5 mg, 0.139 mmol, 0.10 eq.) and 7-oxa-2-azaspiro[4.5]decane; hydrochloride (0.296 mg, 1.39 mmol, 1.2 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give methyl 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinic acid (383 mg, 1.39 mmol).
[0842] Step B: Preparation of sodium 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinate
[0843] Sodium 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinate was prepared from methyl 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinate (383 mg, 1.39 mmol) to give sodium 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinate (394 mg, 1.39 mmol), considering quantitative yield. This compound was used in the next step without further purification.
[0844] Step C: Preparation of Example 121
[0845] Example 121 was prepared in N,N-dimethylformamide using sodium 5-(7-oxa-2-azaspiro[4.5]decane-2-yl)nicotinate (169 mg, 0.594 mmol) and intermediate 4 (200 mg, 0.594 mmol) according to general method 2B. The crude residue was dissolved in methanol, eluted with PoraPak RxnCX, and purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 121 (100 mg, 0.172 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.84(d,1H), 8.31(d, 1H), 8.03(d, 1H), 7.33(d, 2H), 7.26(m, 1H), 7.13(m, 4H), 7.06(d,2H), 5.18(quin, 1H), 3.62(m, 1H), 3.54(m, 1H), 3.38(m, 5H), 3.13(s, 4H), 3.07(m, 1H), 2.95(br d, 4H), 2.15(s, 3H), 1.93(dt, 1H), 1.76(m, 1H), 1.63(m, 4H),1.49(m, 3H)| [M+H]+=581.3256
[0846] Example 122: 5-[4-(1-fluorocyclopropanecarbonyl)piperazinyl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2- Methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide
[0847] Step A: Preparation of tert-butyl 4-(5-methoxycarbonyl-3-pyridyl)piperazine-1-carboxylate
[0848] according to Modified General Method 12 was used to prepare 4-(5-methoxycarbonyl-3-pyridyl)piperazine-1-carboxylate in 1,4-dioxane using methyl 5-bromopyridinyl-3-carboxylate (1.00 g, 4.63 mmol), BINAP (288 mg, 0.463 mmol, 0.10 eq.), and tert-butyl piperazine-1-carboxylate (1.03 g, 5.55 mmol, 1.2 eq.). The crude residue was purified by silica gel column chromatography (n-heptane / ethyl acetate) to give 4-(5-methoxycarbonyl-3-pyridyl)piperazine-1-carboxylate (1.33 g, 3.72 mmol).
[0849] Step B: Preparation of sodium 5-(4-tert-butoxycarbonylpiperazinyl)nicotinic acid
[0850] Sodium 5-(4-tert-butoxycarbonylpiperazinyl)nicotinate was prepared using tert-butyl 4-(5-methoxycarbonyl-3-pyridyl)piperazin-1-carboxylate (500 mg, 1.56 mmol) to give sodium 5-(4-tert-butoxycarbonylpiperazinyl)nicotinate (512 mg, 1.56 mmol), considering quantitative yield. This compound was used in the next step without further purification.
[0851] Step C: 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl Preparation of tert-butyl [phenyl]ethyl]carbamoyl]-3-pyridyl]piperazine-1-carboxylate
[0852] According to general method 2B, sodium 5-(4-tert-butoxycarbonylpiperazinyl)nicotinate (489 mg, 1.49 mmol) and intermediate 4 (500 mg, 1.49 mmol) were prepared in N,N-dimethylformamide using sodium 5-(4-tert-butoxycarbonylpiperazinyl)nicotinate (489 mg, 1.49 mmol) and intermediate 4 (500 mg, 1.49 mmol). 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]-3-pyridyl]piperazin-1-carboxylic acid tert-butyl ester. The crude product was dissolved in methanol, eluted with PoraPak RxnCX, and purified by silica gel column chromatography (dichloromethane / methanol / ammonia) to obtain 4-[5-[[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]-3-pyridyl]piperazine-1-carboxylic acid tert-butyl ester (453 mg, 0.724 mmol).
[0853] Step D: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]benzene Preparation of [ethyl]-5-piperazinyl-nicotinamide
[0854] N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]carbamoyl]-3-pyridyl]piperazin-1-carboxylic acid tert-butyl ester (453 mg, 0.724 mmol) was prepared in solvent-free conditions in 2,2,2-trifluoroacetic acid (1.65 g, 14.5 mmol, 20 eq.). The crude residue was dissolved in methanol and eluted with PoraPak RxnCX to obtain N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-piperazinyl-nicotinamide (283 mg, 0.744 mmol).
[0855] Step E: Preparation of Example 122
[0856] Example 122 was prepared in N,N-dimethylformamide using 1-fluorocyclopropanecarboxylic acid (27.7 mg, 0.266 mmol) and N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-piperazinyl-nicotinamide (140 mg, 0.266 mmol). The crude residue was dissolved in methanol, eluted with PoraPak RxnCX, and purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 122 (62.0 mg, 0.101 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.9(d, 1H), 8.5(d, 1H), 8.46(d, 1H), 7.72(dd, 1H), 7.34(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.19(quin, 1H),3.76(br s, 4H), 3.34(br s, 4H), 3.15(s, 4H), 2.95(br d, 4H), 2.16(s, 3H),1.49(d, 3H), 1.25(m, 4H)| [M+H]+=612.3141.
[0857] Example 123: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [3R]-2-[(3R)-tetrahydrofuran-3-yl]oxy-isonicotinamide
[0858] Step A: Preparation of 2-[(3R)-tetrahydrofuran-3-yl]oxyisonicotinic acid
[0859] 2-[(3R)-tetrahydrofuran-3-yl]oxyisonicotinic acid was prepared according to general method 15A using (3R)-tetrahydrofuran-3-yl alcohol (252 mg, 2.86 mmol) and 2-chloropyridin-4-carboxylic acid (150 mg, 0.952 mmol) to give 2-[(3R)-tetrahydrofuran-3-yl]oxyisonicotinic acid (200 mg, 0.956 mmol). [M+H]+=210.0.
[0860] Step B: Preparation of Example 123
[0861] Example 123 was prepared in N,N-dimethylformamide using general method 2B, with 2-[(3R)-tetrahydrofuran-3-yl]oxyisonicotinic acid (200 mg, 0.287 mmol) and intermediate 4 (96.5 mg, 0.287 mmol). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 123 (23.3 mg, 0.0442 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9(d, 1H), 8.27(d, 1H), 7.36(dd, 1H), 7.33(d,2H), 7.26(s, 1H), 7.13(m, 4H), 7.06(d, 2H), 5.54(dd, 1H), 5.14(t, 1H), 3.92(dd, 1H), 3.8(m, 3H), 3.13(s, 4H), 2.94(br d, 4H), 2.23(m, 1H), 2.15(s, 3H),2.01(m, 1H), 1.46(d, 3H)| [M+H]+=528.2654
[0862] Example 124: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [[4-(oxocyclobutane-3-carbonyl)piperazinyl]nicotinamide; 2,2,2-trifluoroacetic acid]
[0863] Example 124 was prepared in N,N-dimethylformamide using oxetane-3-carboxylic acid (71.9 mg, 0.704 mmol) and N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-piperazinyl-nicotinamide (370 mg, 0.704 mmol). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to give Example 124 (75.0 mg, 0.104 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 9.61(m, 1H), 8.93(d, 1H), 8.49(d, 1H), 8.45(d, 1H), 7.74(br s,1H), 7.36(d, 2H), 7.13(m, 6H), 5.18(br t, 1H), 4.7(m, 4H), 4.29(m, 2H), 4.18(m, 1H), 4.01(br dd, 2H), 3.65(m, 2H), 3.29(m, 6H), 3.16(br dd, 4H), 2.8(d,3H), 1.49(d,3H). [M+H]+=610.3179
[0864] Example 125: 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)-N-[(1R)-1-[4-[(4-fluorobenzene)] [2-methyl-2-azaspiro[3.3]hept-6-ylidene]methyl]phenyl]ethyl]nicotinamide
[0865] Step A: Preparation of methyl 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinic acid
[0866] 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinic acid methyl ester was prepared according to General Method 4B using methyl 5-bromopyridin-3-carboxylate (250 mg, 1.16 mmol) and 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl))-3,6-dihydro-2H-pyridin-1-yl]acetone (349 mg, 1.39 mmol). The crude residue was purified by silica gel column chromatography (ethyl acetate / methanol) to give 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinic acid methyl ester (300 mg, 1.15 mmol).
[0867] Step B: Preparation of sodium 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate
[0868] Sodium 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate was prepared from methyl 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate (300 mg, 1.15 mmol) according to General Method 9A, yielding sodium 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate (309 mg, 1.15 mmol), considering quantitative yield. This compound was used in the next step without further purification.
[0869] Step C: Preparation of Example 125
[0870] Example 125 was prepared in N,N-dimethylformamide using sodium 5-(1-acetyl-3,6-dihydro-2H-pyridin-4-yl)nicotinate (159 mg, 0.594 mmol) and intermediate 4 (350 mg, 0.594 mmol) according to general method 2B. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 125 (62.0 mg, 0.110 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.01(d, 1H), 8.92(s, 1H), 8.8(dd, 1H),8.24(m, 1H), 7.36(d, 2H), 7.12(m, 6H), 6.39(br dd, 1H), 5.2(quin, 1H), 4.16(br dd, 2H), 3.67(m, 2H), 3.47(br s, 4H), 3.02(br d, 4H), 2.62(m, 1H), 2.54(m, 1H), 2.36(s, 3H), 2.07(d, 3H), 1.5(d, 3H)| [M+H]+=565.2970
[0871] Example 126: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hepta-6- [methylene]methyl]phenyl]ethyl]-1-(trifluoromethyl)pyrazole-4-carboxamide
[0872] According to General Method 11, Example 126 was prepared using Example 91 (73.0 mg, 0.122 mmol), potassium carbonate (15.2 mg, 0.110 mmol, 0.90 eq.), and 2-bromoethanol (0.0951 mL, 0.134 mmol, 1.1 eq.), and was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to obtain Example 126 (20.3 mg, 0.0354 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.98(s, 1H), 8.7(d, 1H), 8.32(s, 1H), 7.33(d,2H), 7.14(m, 4H), 7.07(d, 2H), 5.13(quin, 1H), 4.71(m, 1H), 3.66(m, 4H), 3.42(br d, 2H), 3.04(br d, 4H), 2.76(m, 2H), 1.46(d, 3H)| [M+H]+=529.2220
[0873] Example 127: 3-(4,4-difluoropiperidinyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-aza-] Spiro[3.3]hepta-6-ylidene]methyl]phenyl]ethyl]benzamide
[0874] Step A: Preparation of methyl 3-(4,4-difluoropiperidinyl)benzoate
[0875] 3-(4,4-difluoropiperidinyl)benzoate was prepared in 1,4-dioxane using methyl 3-bromobenzoate (136 mg, 0.635 mmol) and 4,4-difluoropiperidinyl hydrochloride (100 mg, 0.635 mmol). The crude product was purified by silica gel column chromatography (dichloromethane / ethanol) to give methyl 3-(4,4-difluoropiperidinyl)benzoate (113 mg, 0.443 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 7.51(s, 1H), 7.38(q, 2H),7.3(m, 1H), 3.84(s, 3H), 3.38(m, 4H), 2.06(m, 4H)| [M+H]+=256.5.
[0876] Step B: Preparation of 3-(4,4-difluoropiperidinyl)benzoate
[0877] 3-(4,4-difluoropiperidinyl)benzoate was prepared from methyl 3-(4,4-difluoropiperidinyl)benzoate (193 mg, 0.756 mmol) according to general method 9A, yielding 3-(4,4-difluoropiperidinyl)benzoate (225 mg, 0.855 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 7.5 (dd, 1H), 7.32 (d, 1H), 7.1 (t, 1H), 6.9 (m, 1H), 3.32 (m, 2H), 3.28 (br d, 2H), 2.05 (m, 4H)| [M+H]+=243.2.
[0878] Step C: Preparation of Example 127
[0879] Example 127 was prepared in N,N-dimethylformamide using 3-(4,4-difluoropiperidinyl)benzoate (111 mg, 0.253 mmol) and intermediate 4 (85.0 mg, 0.253 mmol) according to general method 2C. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 127 (18.5 mg, 0.0331 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.71(d, 1H), 7.45(s, 1H), 7.33(m, 3H), 7.3(m, 1H),7.16(m, 1H), 7.13(m, 4H), 7.06(d, 2H), 5.18(quin, 1H), 3.37(m, 4H), 3.13(s,4H), 2.94(br d, 4H), 2.15(s, 3H), 2.07(ddd, 4H), 1.48(d, 3H)| [M+H]+=560.2881
[0880] Example 128: N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl [3R]-3-[(3R)-tetrahydrofuran-3-yl]oxy-benzamide
[0881] Step A: Preparation of methyl 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate
[0882] Methyl 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate was prepared according to General Method 10 using methyl 3-hydroxybenzoate (500 mg, 3.29 mmol) and (3S)-tetrahydrofuran-3-ol (0.262 mL, 3.29 mmol). The crude residue was purified by silica gel column chromatography (dichloromethane / ethyl acetate) to give methyl 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate (619 mg, 2.79 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 7.55(d, 1H), 7.45(t, 1H), 7.42(br d, 1H), 7.22(dd, 1H), 5.11(br dd, 1H), 3.89(m, 1H), 3.85(s,3H), 3.81(m, 2H), 3.76(m, 1H), 2.23(m, 1H), 1.97(m, 1H). [M+H]+=269.3.
[0883] Step B: Preparation of 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate
[0884] 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate was prepared from methyl 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate (619 mg, 2.78 mmol) according to General Method 9A, yielding 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate (700 mg, 3.04 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 7.46 (d, 1H), 7.41 (m, 1H), 7.17 (t, 1H), 6.83 (dd, 1H), 5 (br dd, 1H), 3.89 (dd, 1H), 3.79 (m, 2H), 3.74 (m, 1H), 2.19 (m, 1H), 1.96 (m, 1H). [M+H]+=190.8.
[0885] Step C: Preparation of Example 128
[0886] Example 128 was prepared in N,N-dimethylformamide using 3-[(3R)-tetrahydrofuran-3-yl]oxybenzoate (123.0 mg, 0.2675 mmol) and intermediate 4 (90.0 mg, 0.2675 mmol) according to general method 2C. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 128 (31.8 mg, 0.0604 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.76(d, 1H), 7.48(d, 1H), 7.42(m,1H), 7.38(t, 1H), 7.33(d, 2H), 7.12(m, 5H), 7.06(d, 2H), 5.16(quin, 1H), 5.09(br dd, 1H), 3.9(m, 1H), 3.81(m, 2H), 3.75(m, 1H), 3.13(s, 4H), 2.94(br d,4H), 2.23(m, 1H), 2.15(s, 3H), 1.96(m, 1H), 1.47(d, 3H)| [M+H]+=527.2703
[0887] Example 129: 5-[(4,4-dimethyloxetane-2-yl)methoxy]-N-[(1R)-1-[4-[(4-fluoro phenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide diastereomeric 2
[0888] Step A: Preparation of enantiomer 2 of methyl 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinic acid
[0889] 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinic acid methyl ester was prepared according to General Method 10 using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.27 mmol) and (4,4-dimethyloxetane-2-yl)methanol (0.344 mL, 3.27 mmol). The crude residue was purified by silica gel column chromatography (methyl tert-butyl ether / ethyl acetate). The two enantiomers were separated by chiral SFC (carbon dioxide / ethanol) to give 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinic acid methyl ester enantiomer 2 (195 mg, 0.774 mmol). 1H NMR(400 MHz, dmso-d6) δppm 8.7(d, 1H), 8.57(d, 1H), 7.82(dd, 1H), 4.82(m, 1H), 4.24(m, 2H), 3.89(s,3H), 2.38(m, 2H), 1.41(s, 3H), 1.35(s, 3H). [M+H]+=253.4.
[0890] Step B: Preparation of 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate enantiomer 2
[0891] According to General Method 9A, 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate enantiomer 2 was prepared using 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate enantiomer 2 (194 mg, 0.772 mmol), yielding 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate enantiomer 2 (204 mg, 0.785 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.57 (d, 1H), 8.19 (d, 1H), 7.68 (dd, 1H), 4.8 (m, 1H), 4.12 (m, 2H), 2.38 (m, 2H), 1.36 (m, 6H). [M+H]+=239.2.
[0892] Step C: Preparation of Example 129
[0893] Example 129 was prepared in N,N-dimethylformamide using enantiomer 2 (61.65 mg, 0.238 mmol) of 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate and intermediate 4 (80.0 mg, 0.238 mmol) according to general method 2C. The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 129 (28.8 mg, 0.0518 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(d,1H), 8.45(d, 1H), 7.81(m, 1H), 7.35(d, 2H), 7.13(m, 4H), 7.07(d, 2H), 5.18(quin, 1H), 4.82(m, 1H), 4.21(d, 2H), 3.13(s, 4H), 2.95(br d, 4H), 2.38(m,2H), 2.15(s, 3H), 1.49(d, 3H), 1.38(m, 6H)| [M+H]+=556.2966.
[0894] Example 130: 5-[(4,4-dimethyloxetane-2-yl)methoxy]-N-[(1R)-1-[4-[(4-fluoro phenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide diastereomeric 1
[0895] Step A: Preparation of enantiomer 1 of methyl 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinic acid
[0896] Enantiomer 1 of 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinic acid methyl ester was prepared according to General Method 10 using methyl 5-hydroxypyridine-3-carboxylate (500 mg, 3.27 mmol) and (4,4-dimethyloxetane-2-yl)methanol (0.344 mL, 3.27 mmol). The crude residue was purified by silica gel column chromatography (methyl tert-butyl ether / ethyl acetate). The two enantiomers were separated by chiral SFC (carbon dioxide / ethanol) to give 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinic acid methyl ester enantiomer 1 (183 mg, 0.728 mmol). 1H NMR(400 MHz,dmso-d6) δ ppm 8.7(d, 1H), 8.57(d, 1H), 7.82(dd, 1H), 4.82(m, 1H), 4.24(m,2H), 3.89(s, 3H), 2.38(m, 2H), 1.41(s, 3H), 1.35(s, 3H). [M+H]+=253.3.
[0897] Step B: Preparation of 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate enantiomer 1
[0898] According to General Method 9A, 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate enantiomer 1 was prepared using methyl 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate enantiomer 1 (183 mg, 0.728 mmol) to give 5-[(4,4-dimethyloxetane-2-yl)methoxy]nicotinate (201 mg, 0.775 mmol). ¹H NMR (400 MHz, dmso-d6) δ ppm 8.57 (d, 1H), 8.19 (d, 1H), 7.68 (dd, 1H), 4.8 (m, 1H), 4.12 (m, 2H), 2.38 (m, 2H), 1.36 (m, 6H). [M+H]+=239.2.
[0899] Step C: Preparation of Example 130
[0900] Example 130 was prepared in N,N-dimethylformamide using sodium 5-[(4,4-dimethyloxetane-2-yl)methoxy]pyridine-3-carboxylate (1+) (1:1) (61.7 mg, 0.238 mmol, 1.0 eq.) and intermediate 4 (80.0 mg, 0.238 mmol). The crude residue was purified by reversed-phase chromatography (acetonitrile / water / ammonium bicarbonate) to give Example 130 (30.2 mg, 0.0543 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 8.96(d, 1H), 8.66(s, 1H), 8.45(d, 1H), 7.81(br s, 1H), 7.35(d, 2H), 7.13(m, 4H),7.07(d, 2H), 5.18(m, 1H), 4.82(m, 1H), 4.22(m, 2H), 3.14(s, 4H), 2.95(br d,4H), 2.38(m, 2H), 2.15(s, 3H), 1.49(d, 3H), 1.39(m, 6H)| [M+H]+=556.2965
[0901] Example 131: N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(2-hydroxyethyl)-2-azaspiro[3.3]hepta-6- [methylene]methyl]phenyl]ethyl]-3-isopropyl-isoxazolo[5,4-b]pyridine-5-carboxamide
[0902] Step A: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]- Preparation of 3-isopropyl-isoxazolo[5,4-b]pyridine-5-carboxamide; 2,2,2-trifluoroacetic acid
[0903] N-[(1R)-1-[4-[2-azaspiro[3.3]heptane-6-yenyl-(4-fluorophenyl)methyl]phenyl]ethyl]-3-isopropyl-isoxazo[5,4-b]pyridine-5-carboxylic acid tert-butyl ester (450 mg, 0.737 mmol) was prepared in solvent-free conditions in 2,2,2-trifluoroacetic acid (1.68 g, 14.7 mmol, 20 eq.) using 6-[(4-fluorophenyl)-[4-[2-azaspiro[3.3]heptane-6-yenyl-(4-fluorophenyl)methyl]phenyl]ethyl]-3-isopropyl-isoxazo[5,4-b]pyridine-5-carboxamide;2,2,2-trifluoroacetic acid. The residue was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to obtain N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-3-isopropyl-isooxazolo[5,4-b]pyridine-5-carboxamide; 2,2,2-trifluoroacetic acid (154.5 mg, 0.284 mmol).
[0904] Step B: Preparation of Example 131
[0905] Example 131 was prepared according to General Method 11 using N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-3-isopropyl-isoxazolo[5,4-b]pyridine-5-carboxamide; 2,2,2-trifluoroacetic acid (155 mg, 0.209 mmol), potassium carbonate (54.9 mg, 0.397 mmol, 1.9 eq.), and 2-bromoethanol (0.0163 mL, 0.230 mmol, 1.1 eq.). The crude residue was purified by SFC chromatography (carbon dioxide / methanol / diethylamine) to obtain Example 131 (48.8 mg, 0.0880 mmol). 1H NMR(400 MHz, dmso-d6) δ ppm 9.12(m, 2H), 8.93(d, 1H), 7.38(d, 2H), 7.12(m, 6H), 5.24(t, 1H), 4.33(br t, 1H),3.48(m, 1H), 3.28(br s, 2H), 3.19(s, 4H), 2.96(br d, 4H), 2.41(m, 2H), 1.53(d, 3H), 1.45(d, 6H)| [M+H]+=555.2763
[0906] Example 132: N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl] [Ethyl]-4-methoxy-pyridineamide; 2,2,2-trifluoroacetic acid
[0907] Step A: 6-[(4-fluorophenyl)-[4-[(1R)-1-[(4-methoxypyridinyl)amino]ethyl]phenyl] Preparation of tert-butyl [methyl]-2-azaspiro[3.3]heptane-2-carboxylate
[0908] According to modified general method 2C, 6-[(4-fluorophenyl)-[4-[(1R)-1-[(4-methoxypyridinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester was prepared in dichloromethane using 4-methoxypyridinyl-2-carboxylic acid (200 mg, 1.24 mmol) and intermediate 3 (577 mg, 1.36 mmol, 1.1 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to give 6-[(4-fluorophenyl)-[4-[(1R)-1-[(4-methoxypyridinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (601 mg, 1.08 mmol).
[0909] Step B: Preparation of Example 132
[0910] Example 132 was prepared according to General Method 1 using 6-[(4-fluorophenyl)-[4-[(1R)-1-[(4-methoxypyridinyl)amino]ethyl]phenyl]methylene]-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (601 mg, 1.08 mmol) in solvent-free conditions in 2,2,2-trifluoroacetic acid (2.46 g, 21.6 mmol, 20 eq.). The residue was purified by reversed-phase chromatography (acetonitrile / water / trifluoroacetic acid) to give Example 132 (358 mg, 0.522 mmol). 1H NMR(400MHz, dmso-d6) δ ppm 8.99(d, 1H), 8.56(br s, 2H), 8.47(d, 1H), 7.53(d, 1H),7.38(d, 2H), 7.15(m, 5H), 7.06(d, 2H), 5.16(quin, 1H), 4.03(br t, 4H), 3.9(s,3H), 3.14(br d, 4H), 1.52(d, 3H)| [M+H]+=458.2221.
[0911] Example 133: 5-(4-acetylpiperazinyl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-aza-] Spiro[3.3]hepta-6-ylidene]methyl]phenyl]ethyl]nicotinamide
[0912] Step A: Preparation of methyl 5-(4-acetylpiperazinyl)nicotinic acid
[0913] 5-(4-acetylpiperazinyl)nicotinic acid methyl ester was prepared in 1,4-dioxane using methyl 5-bromopyridine-3-carboxylate (1.00 g, 4.63 mmol), BINAP (288 mg, 0.463 mmol, 0.10 eq.), and 1-piperazin-1-yl ethyl ketone (712 mg, 5.55 mmol, 1.2 eq.). The crude residue was purified by silica gel column chromatography (dichloromethane / methanol) to give 5-(4-acetylpiperazinyl)nicotinic acid methyl ester (1.18 g, 4.03 mmol).
[0914] Step B: Preparation of sodium 5-(4-acetylpiperazinyl)nicotinic acid
[0915] Sodium 5-(4-acetylpiperazinyl)nicotinate was prepared using methyl 5-(4-acetylp...
Claims
1. Compounds of formula (I): in: Ring A represents a heterocyclic alkyl group. R1 represents a hydrogen atom or a halogen atom. R2 represents a hydrogen atom, a halogen atom, a cyano group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkoxy group, a straight-chain or branched amino(C1-C6) alkyl group, -CH(CH2-OH)CH2-Cl, or , R3 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a straight-chain or branched di(C1-C6) alkyl phosphoryl group, a cycloalkyl group, an aryl group, or a heterocyclic alkyl group. R4 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy(C1-C6) alkyl group, a straight-chain or branched hydroxy(C1-C6) alkyl group, -CO-CH2-OH, a cycloalkyl group, a heterocyclic alkyl group, or... , , , R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, or a group selected from the following: and R6 represents a hydrogen atom, a halogen atom, or a straight-chain or branched (C1-C6) alkyl group. W represents a bond, an oxygen atom, -CO-, -O-CH2-, or -CH2-. Cy1 represents aryl or heteroaryl. Cy2 represents aryl, heteroaryl, or heterocyclic alkyl. Cy3 represents cycloalkyl, heterocycloalkyl, or heteroaryl. Their enantiomers and diastereomers, and their addition salts with pharmaceutically acceptable acids or bases.
2. Compounds of formula (I): in: Ring A represents a heterocyclic alkyl group. R1 represents a hydrogen atom or a halogen atom. R2 represents a halogen atom, a cyano group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkoxy group, a straight-chain or branched amino(C1-C6) alkyl group, -CH(CH2-OH)CH2-Cl, or , R3 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy group, a cycloalkyl group, an aryl group, or a heterocyclic alkyl group. R4 represents a hydrogen atom, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, a straight-chain or branched (C1-C6) alkoxy(C1-C6) alkyl group, a straight-chain or branched hydroxy(C1-C6) alkyl group, -CO-CH2-OH, a cycloalkyl group, or... , R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a straight-chain or branched (C1-C6) alkyl group, a straight-chain or branched halo(C1-C6) alkyl group, or a group selected from the following: and R6 represents a hydrogen atom, a halogen atom, or a straight-chain or branched (C1-C6) alkyl group. W represents a bond, an oxygen atom, -CO-, -O-CH2-, or -CH2-. Cy1 represents aryl or heteroaryl. Cy2 represents aryl, heteroaryl, or heterocyclic alkyl. Cy3 represents cycloalkyl, heterocycloalkyl, or heteroaryl. Their enantiomers and diastereomers, and their addition salts with pharmaceutically acceptable acids or bases.
3. The compound according to claim 1 or 2, wherein it is a compound of formula (Ia): R1, R2, R3, R4, Cy1, Cy2 and A are defined as in claim 1.
4. The compound according to claim 1 or 2, wherein ring A represents a heterocyclic alkyl group selected from: and , R4 is defined as in claim 1.
5. The compound according to claim 1 or 2, wherein ring A represents a heterocyclic alkyl group selected from: and , R4 is defined as in claim 1.
6. The compound according to claim 1 or 2, wherein it is a compound of formula (Ib): R1, R2, R3, R4, Cy1, and Cy2 are defined as in claim 1.
7. The compound according to claim 1 or 2, wherein R1 represents a hydrogen atom, a chlorine atom, or a fluorine atom.
8. The compound according to claim 1 or 2, wherein R1 represents a hydrogen atom or a fluorine atom.
9. The compound according to claim 1 or 2, wherein R2 represents a bromine atom, cyano group, methyl group, ethyl group, isopropyl group, isobutyl group, tert-butyl group, methoxy group, ethoxy group, isopropoxy group, isobutoxy group, trifluoromethyl group, difluoromethyl group, 2,2,2-trifluoroethyl group, trifluoromethoxy group, 2,2-difluoroethoxy group, -CH2-NH2 group, -CH(CH2-OH)CH2-Cl group, or... .
10. The compound according to claim 1 or 2, wherein R3 represents a hydrogen atom, methyl, methoxy, cyclopropyl, phenyl, diethylphosphoryl or dihydrofuranyl.
11. The compound according to claim 1 or 2, wherein R3 represents a hydrogen atom, methyl, methoxy, cyclopropyl, phenyl, or dihydrofuranyl.
12. The compound according to claim 1 or 2, wherein R4 represents a hydrogen atom, methyl, ethyl, isopropyl, 2-fluoroethyl, 2,2-difluoroethyl, 3,3,3-trifluoropropyl, methoxyethyl, hydroxyethyl, -CO-CH2-OH, cyclobutyl, tetrahydrofuranyl, oxetaneyl, or , or .
13. The compound according to claim 1 or 2, wherein R4 represents a hydrogen atom, methyl, ethyl, isopropyl, 2,2-difluoroethyl, 3,3,3-trifluoropropyl, methoxyethyl, hydroxyethyl, -CO-CH2-OH, cyclobutyl, or .
14. The compound according to claim 1 or 2, wherein R5 represents a hydrogen atom, a fluorine atom, a hydroxyl group, a methyl group, a fluoromethyl group, a difluoromethyl group, or a group selected from the group consisting of: and .
15. The compound according to claim 1 or 2, wherein R6 represents a hydrogen atom, a fluorine atom, or a methyl group.
16. The compound according to claim 1 or 2, wherein W represents a bond, an oxygen atom, or -O-CH2-.
17. The compound according to claim 1 or 2, wherein Cy1 represents phenyl or pyridyl.
18. The compound according to claim 1 or 2, wherein Cy2 represents phenyl, pyrazolyl, triazolyl, thiophenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridoneyl, quinolinyl, isoquinolinyl, thiophenopyridyl, isoxazolopyridyl, benzoxadiazolyl, or morpholinyl.
19. The compound according to claim 1 or 2, wherein Cy2 represents phenyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridoneyl, quinolinyl, isoquinolinyl, thienopyridyl, isoxazolopyridyl, benzoxadiazolyl, or morpholinyl.
20. The compound according to claim 1 or 2, wherein Cy3 represents cyclopropyl, cyclopentyl, cyclohexyl, spiro[3.3]heptyl, aziridine, oxaziridine, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, morpholinyl, piperidinyl, piperazine, tetrahydropyranyl, tetrahydropyridinyl, dihydropyranyl, dioxothiazinyl, dioxothiacyclohexyl, oxazaspiro[3.3]heptyl, oxazaspiro[2.5]octyl, oxazaspiro[3.5]nonyl, oxazaspiro[4.5]decyl, pyrazolyl, pyridinyl, pyridoneyl, or 4-oxo-1,4λ 5 -Oxyphenoxanecyclohexyl group.
21. The compound according to claim 1 or 2, wherein Cy3 represents cyclopropyl, cyclopentyl, cyclohexyl, spiro[3.3]heptyl, aziroxybutyl, oxaziroxybutyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, morpholinyl, piperidinyl, piperazine, tetrahydropyranyl, tetrahydropyridinyl, dihydropyranyl, dioxothiazinyl, dioxothiacyclohexyl, oxazaspiro[3.3]heptyl, oxazaspiro[2.5]octyl, oxazaspiro[3.5]nonyl, oxazaspiro[4.5]decyl, pyrazolyl, pyridinyl, or pyridoneyl.
22. The compound according to claim 1 or 2, wherein it is a compound of formula (Ic): R2, R3, R4 and Cy2 are defined as in claim 1.
23. The compound according to claim 1 or 2, wherein the compound is: - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-[(3S)-tetrahydrofuran-3-yl]oxy-nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-(oxetane-3-ylmethoxy)nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-tetrahydropyran-4-yloxy-nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-3-isopropyl-isooxazolo[5,4-b]pyridine-5-carboxamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-(4-oxa-7-azaspiro[2.5]octane-7-yl)nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-tetrahydropyran-4-yl-nicotinamide; - 5-(2,5-dihydrofuran-3-yl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-[4-(oxecyclobutane-3-carbonyl)piperazinyl]nicotinamide; - N-[(1R)-1-[4-[2-azaspiro[3.3]hept-6-ylidene-(4-fluorophenyl)methyl]phenyl]ethyl]-5-[4-(oxecyclobutane-3-carbonyl)piperazinyl]nicotinamide; - 5-[4-(cyclobutanecarbonyl)piperazinyl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - 5-[1-(cyclobutanecarbonyl)-3,6-dihydro-2H-pyridin-4-yl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - 2-[1-[1-(fluoromethyl)cyclopropanecarbonyl]-3,6-dihydro-2H-pyridin-4-yl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]pyrimidine-4-carboxamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-[(3R)-tetrahydrofuran-3-yl]oxy-nicotinamide; - 5-(3,6-dihydro-2H-pyran-4-yl)-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-2-[(3R)-tetrahydrofuran-3-yl]oxy-pyrimidine-4-carboxamide; - 5-[4-(cyclopropanecarbonyl)piperazinyl]-N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-2-tetrahydropyran-4-yl-pyrimidin-4-carboxamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-(2-methyl-2-azaspiro[3.3]hept-6-ylidene)methyl]phenyl]ethyl]-5-morpholino-nicotinamide; - N-[(1R)-1-[4-[(4-fluorophenyl)-[2-(oxacyclobutane-3-ylmethyl)-2-azaspiro[3.3]hept-6-ylidene]methyl]phenyl]ethyl]-2-tetrahydropyran-4-yl-pyrimidine-4-carboxamide.
24. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 23, or a combination thereof with an addition salt of a pharmaceutically acceptable acid or base and one or more pharmaceutically acceptable excipients.
25. The pharmaceutical composition according to claim 24, which is used as an SOS1 inhibitor.
26. The pharmaceutical composition of claim 24, for the treatment of cancer, autoimmune diseases and immune system diseases and genetic diseases.
27. The pharmaceutical composition of claim 26, wherein the cancer is selected from pancreatic cancer, lung cancer, colorectal cancer, bile duct cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial carcinoma, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, sarcoma, glioma, and malignant peripheral nerve sheath tumor.
28. The pharmaceutical composition of claim 27, wherein the hereditary disease is selected from neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple freckles, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardiofacial skin syndrome, Legius syndrome, and hereditary gingival fibromatosis.
29. A compound of formula (I) according to any one of claims 1 to 23, or an addition salt thereof with a pharmaceutically acceptable acid or base, used as an SOS1 inhibitor.
30. A compound of formula (I) according to any one of claims 1 to 23, or an addition salt thereof with a pharmaceutically acceptable acid or base, for the treatment of pancreatic cancer, lung cancer, colorectal cancer, bile duct cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial carcinoma, gastric cancer, cervical cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, sarcoma, glioma, malignant peripheral nerve sheath tumor, neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple freckles, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardiofacial skin syndrome, Legius syndrome, and hereditary gingival fibromatosis.
